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  Abstract 
Abstract 
 
Influenza (or flu) is a highly contagious, acute viral respiratory disease that occurs 
seasonally in most parts of the world and is caused by influenza viruses. Influenza 
vaccination is an effective way to reduce the complications and the mortality rate 
following influenza infections. The currently available influenza vaccines are 
manufactured in embryonated chicken eggs, a 40-year old production technology. The 
research in this thesis was aimed at the design, validation and development of a 
production process for a recombinant hemagglutinin (rHA) influenza vaccine for the 
prevention of seasonal influenza. The viral surface protein HA is the key antigen in 
the host response to influenza virus since neutralizing antibodies directed against HA 
can mitigate or prevent infection. The baculovirus-insect cell system was selected for 
the synthesis of rHA molecules. The designed process was used to manufacture 
candidate trivalent rHA vaccines, which were tested in four clinical studies in a total 
of more than 3000 human subjects age 18 - 92 to support licensure of FluBlok under 
the “Accelerated Approval” procedure in the United States (U.S.). These studies 
demonstrated that the purified rHA protein was well tolerated and resulted in a strong 
and long lasting immune response. In addition, the novel vaccine provided cross 
protection against drifted influenza viruses. In response to the emergence of the new 
H1N1 A/California /04/2009 influenza strain, the outlined design was used to produce 
a rHA vaccine candidate and merely 6 weeks later, the first batches of vaccine were 
ready for human clinical testing. There are two especially important advantages to the 
use of this technology from a public health perspective: First, the insect cell-
baculovirus system has demonstrated the potential to facilitate safe and expeditious 
responses to health care emergencies such as the one currently posed by the novel 
H1N1 virus pandemic and secondly, the rHA vaccine does not contain ovalbumin or 
other antigenic proteins that are present in eggs and may therefore be administered to 
people who are egg-allergic. 
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Chapter 1 
General introduction  
 
Influenza Disease 
Influenza (or flu) is a highly contagious, acute viral respiratory disease caused by 
influenza viruses that occurs seasonally in most parts of the world. Epidemics occur 
annually and are the cause of significant morbidity and mortality worldwide [Glezen, 
1982]. The symptoms of the flu are similar to those of the common cold but tend to be 
more severe. Fever, headache, fatigue, muscle weakness and pain, sore throat, dry 
cough, and a runny or stuffy nose are common and may develop rapidly. A number of 
complications, such as the onset of bronchitis and pneumonia, can occur in 
association with influenza and are especially common among the elderly, young 
children, and anyone with a suppressed immune system.  
Influenza affects all age groups and in the United States (U.S.) alone, 25 to 50 
million people contract influenza each year, and an annual average of 36,000 deaths 
in the years 1990 to 1999 [Thompson et al., 2003] and 226,000 hospitalizations from 
1979 to 2001 [Thompson et al., 2004] have been associated with influenza epidemics. 
The majority of the influenza-related serious illness and deaths occur in people over 
age 65, children younger than 2 years and persons of any age who have medical 
conditions that place them at increased risk for influenza [MMWR, 2008].  
Influenza vaccination is the most effective method for preventing influenza 
virus infection and its potential severe complications [LaMontagne et al., 1983; 
Quinnan et al., 1983; Barker and Mullooly, 1980; Patriarca et al., 1985; Nichol et al., 
1994; Nichol et al., 2003]. Antiviral drugs, including amantidines, Tamiflu and 
Relenza are also approved for use in influenza disease. Their use is recommended 
when vaccines are contra-indicated and/or in high risk populations. The disadvantage 
of these antiviral drugs is that they must be used within 24-48 hours after onset of the 
disease and the use is in general cautioned because of the potential side effects 
[MMWR, 2008]. 
 
Influenza Viruses 
Influenza viruses have a segmented genome of linear single-stranded ribonucleic acid 
(RNA) molecules of negative polarity and are classified in the family 
Orthomyxoviridae [Lamb and Krug, 2001]. Influenza viruses are categorized in three 
main types, designated A, B, and C, determined by differences between their matrix 
and nucleoproteins (M and NP). These viruses further differ with respect to host 
range, variability of the surface glycoproteins, genome organization and morphology 
[Lamb and Krug, 2001]. Influenza viruses belonging to type A and B can cause 
epidemic human disease.  
The influenza virus particles, usually spherical or filamentous in shape (Fig. 1), 
are approximately 80-120 nm in diameter. They are surrounded by a lipid-containing 
envelope and contain ten (Influenza A) or nine (Influenza B) structural proteins. The 
three large proteins (PB1, PB2 and PA) represent subunits of the viral polymerase and 
are responsible for RNA transcription and replication of the virus. The M1 protein, 
which contributes about 40% of the viral protein, encloses the particle underneath the 
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lipid envelope and is considered to be important in virion morphogenesis. Two 
distinct surface glycoproteins - hemagglutinin (HA) and neuraminidase (NA) - project 
from the surface. HA, the major glycoprotein is responsible for the attachment of the 
virus to specific cell surface receptors and subsequent fusion between the virus and 
the cell. HA, is interposed irregularly by clusters of NA. The NA of influenza virus 
cleaves the glycoside bond of neuraminic acid, and is involved in the release of newly 
formed virions from the surface of infected cells. The ratio of HA to NA is about 4-
5:1. Overall, HA represents about 25% of viral protein and NA about 5%. The M2 ion 
channel protein is only present on the envelope of influenza A viruses. This protein, 
however, is present in low quantities, at only a few copies per particle.  
 
Figure 1a.  Electron micrograph of influenza virus 
particles. The morphology of the influenza virus is 
somewhat variable, but the virion particles are 
usually spherical or ovoid in shape and 80 to 120 
nm in diameter. On the surface of the virus the HA 
(≈80%) and NA (≈20%) glycoprotein spikes can be 
observed. Picture obtained from 
http://www.wales.nhs.uk/sites3/ 
page.cfm?orgId=719&pid=23110. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1b. Schematic view of an influenza A virus. 
The envelope carries two major glycoproteins, HA 
and NA, and the transmembrane ion channel protein 
M2. The matrix protein M1 underlies the bilayer. 
Within the core of the virus, the single stranded 
negative sense RNA is associated with the six other 
viral proteins expressed from its genome: the 
nucleoprotein (NP), three transcriptases (PB2, PB1, 
and PA) and two nonstructural proteins (NS1 and 
NS2).    
 
 
 
http://en.wikipedia.org/wiki/File:Flu_und_legende_color_c.jpg 
 
 
Influenza A and B virions contain eight (8) RNA segments and the total genome 
length varies between 12000 and 15000 nucleotides (nt) (Fig. 2). The largest genome 
segment is 2300-2500 nt long (note: the three largest segments encoding the 
polymerase proteins (P) are co-migrating in Fig. 2) and the smallest 800-900 nt. Most 
of these viral genome segments code for a single protein.  
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Figure 2. Agarose gel depicting cDNA products derived 
from influenza viral RNA (vRNA) using a universal primer 
(5’-AGCAAAAGCAGG-3’) complementary to the 
conserved 3’ end of influenza RNA segments. The right 
panel indicated which proteins are encoded by the 
respective cDNA fragments. P represents the comigrating 
cDNA fragments for subunits of the viral polymerase (PB1, 
PB2, and PA) encoded on segments 1–3. Segment 4 
encodes HA, the hemagglutinin glycoprotein important for 
viral attachment to cell surface receptors and for fusion of 
the viral envelope to the host cell membrane. Nucleoprotein 
(NP) on segment five encapsulates vRNAs. Neuraminidase 
(NA) glycoprotein encoded on segment 6 is involved in the 
release of newly formed virions from the surface of 
infected cells using its ability to cleave sialic acid residues. 
Segment 7 produces a single transcript for two matrix (M) 
proteins, M1, and M2. M1 plays a structural role to the 
virus particle while M2 is an ion channel with a postulated 
role in virus assembly. Alternative splicing yields the 
nonstructural proteins (NS) of segment 8, NS1 and NS2, 
involved in vRNA processing. 
 
 
 
HA and NA exhibit antigenic variation and their immunologic characterization forms 
the basis for classification of the influenza A virus subtypes. There are at least 16 
different subtypes of the HA antigen, labeled H1 through H16. The first three HA 
serotypes, H1, H2, and H3, are found in human and swine influenza A viruses. Nine 
subtypes of influenza NA have been described of which only N1 and N2 have been 
linked to epidemics in man and swine. Birds are the natural hosts for all influenza 
viruses, whereas H3, H7, N7 and N8 have also been found in horses. H5, H7 and H9 
viruses have been reported in human as well recently [Lamb and Krug, 2001] 
although human-to-human transmission does not appear to be efficient [Web link 1-
1].  
New influenza virus variants result from frequent antigenic changes (i.e. 
antigenic drift) resulting from accumulating point mutations that occur during viral 
replication [Cox NJ and Subbarao, 1999]. New influenza A viruses can also arise as a 
results of re-assortment of viral RNA (vRNA) molecules between viruses strains 
(antigenic shift), resulting in a new subtype of the virus. This re-assortment whereby 
a "new" HA and/or NA is introduced in the circulating viral strains can result in a 
pandemic as discussed in greater detail below. 
 
Influenza Laboratory Surveillance 
The World Health Organization (WHO) and collaborating laboratories are actively 
involved in influenza surveillance. In this process human influenza viruses around the 
globe are isolated and characterized. For example, from September 2007 through May 
2008, the U.S. WHO and collaborating laboratories characterized approximately 
40,000 influenza viruses as influenza A (71%) or influenza B (29%) viruses. Among 
the influenza A viruses, that were subtyped; 26% were influenza A (H1) and the 
majority 74% were influenza A (H3) viruses [Web link 1-2] Antigenic 
characterization of circulating influenza viruses is crucial in determining the annual 
composition of the influenza vaccine. Viruses are characterized to be antigenically 
similar to / or distinct (a “drift” variant) from the vaccine component. This 
characterization is based on ferret serum hemagglutination-inhibition (HAI) antibody 
Base pair Protein
P
HA
NP
NA
M
NS
2341
1565
1466
1027
890
1778
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cross-reactivity (i.e. red blood cells clump together [agglutinate] in the presence of 
hemagglutinin; this process is inhibited in the presence of hemagglutinin antibodies). 
Antigenic variants selected serologically are then tested for antibody cross-reactivity 
in human sera to evaluate the potential cross-protection against the antigenic variants 
provided by the current vaccines and to select vaccine strains for the next season. For 
influenza B viruses, two antigenically distinct lineages represented by 
B/Victoria/02/87 and B/Yamagata/16/88 viruses are currently circulating. In February 
of each year representatives from WHO and the reference laboratories convene in 
Geneva, review and evaluate the available surveillance data and make 
recommendations for the composition of the annual vaccine for the Northern 
hemisphere. Six months later a similar process results in the strain selection for the 
Southern hemisphere. Predictions have been difficult particularly for the B-lineage; 
for example, the selection of the B-variant has been problematic for the past many 
years resulting in a mismatch in the vaccine. As a result an active discussion is 
ongoing in the U.S. to include representative antigens from both lineages in the 
vaccine [Web link 1-3].  
 
Influenza Vaccines 
HA and NA have been recognized as key antigens in the host response to influenza 
virus in both natural infection and vaccination. Neutralizing antibodies that can 
prevent infection are directed against HA. Trivalent inactivated influenza vaccines 
(TIVs) have been developed to stimulate humoral and (to a lesser extent) cellular 
immunity to influenza. Live attenuated influenza virus vaccines (LAIVs) mimic a 
“mild” natural infection and induce high levels of local IgA antibodies in nasal 
washings, and local cellular immunity, but they induce lower serum antibody IgG 
titers than the inactivated vaccines. Inactivated influenza vaccines are immunogenic 
in healthy adults and induce increased levels of HAI antibodies in 70% to 90% of 
recipients [LaMontagne et al., 1983; Quinnan et al., 1983]. In older age groups, the 
vaccines are less effective in preventing infection, but remain effective in preventing 
complications and death following influenza infection [Barker and Mullooly, 1980; 
Patriarca et al., 1985]. Influenza vaccination can reduce hospitalization by about 50% 
and the risk of death in the elderly by about 75% [Nichol et al., 1994]. Recent data 
also suggest that influenza vaccinations play a role in reduction of heart attacks and 
strokes in the elderly [Nichol et al., 2003]. 
The effectiveness of these vaccines is, however, typically much lower during 
those seasons when a suboptimal match between vaccine strains and circulating 
strains is reported. For example, a vaccine efficacy of 50% against culture-confirmed 
influenza and no measurable efficacy in reduction of influenza-like illness was 
observed in a study reported by Bridges et al. (2000) during a year when a poorly 
matched strain was circulating, whereas the vaccine efficacy was 86% against 
laboratory confirmed influenza in the following year when there was a close match 
between the vaccine and circulating strains. Another study by Belongia et al. (2009) 
reported a vaccine efficacy of only 10% (95% Confidence Interval [CI] -36, 40) for 
2004-05, 21% (95% CI -52, 59) for 2005-06 and 52% (95% CI 22, 70) for 2006-07 
when percentages of antigenically matched viruses were only 5% during 2004-05 and 
2005-06 and 91% in 2006-07. The estimate for the 2005-06 influenza season reported 
by Belongia et al. is very similar to the estimate obtained in a randomized, placebo-
controlled trial conducted by GlaxoSmithKline (GSK) during the same influenza 
season (22.3% (95% CI -49.1, 58.5) [GSK, Study number 104438 (2009); 
NCT00197223] reported by Beran et al. (2009). In addition, a study conducted in 
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Canada [Skowronski et al., 2009] reported an overall vaccine efficacy estimate of 
47% (95% CI 18, 65) for the 2006-07 influenza season, with relatively high efficacy 
associated with well-matched strains (e.g., efficacy against A/H1N1 of 92% [95% CI 
40, 91)]) versus a relatively poor efficacy against the B strains (19% [95% CI -112, 
69]) all of which were a lineage-level mismatch to the vaccine. In addition, in the 
study reported by Wang et al. (2009) that compared the effectiveness of LAIV with 
TIV over three influenza seasons from 2004-2007 found that vaccine effectiveness for 
TIV ranged from 28-55% and from 10.7-20.8% for LAIV, depending primarily on the 
degree to which the vaccine strains were antigenically related to circulating wild-type 
strains. Unfortunately, none of these studies provides insight into the molecular, 
cellular and pathological basis of the vaccine failures. 
Currently available licensed vaccines can be produced at low cost and are 
relatively effective in reducing the impact of influenza; therefore, the incentive to 
develop novel influenza vaccines has been relatively limited. The most widely 
available licensed influenza vaccines consist of inactivated whole or chemically split 
subunit preparations from two influenza A subtypes (H1N1 and H3N2) and one 
influenza B subtype. Production of influenza vaccines involves the adaptation of the 
selected variants for high yield in embryonated chicken eggs by serial passage or 
reassortment with other high-yield strains. Selected influenza viruses are grown in 
embryonated chicken eggs by infecting a 12-14 day-old chicken embryo with an 
influenza virus. Influenza virions are purified three days later from the allantoic fluid. 
Whole or split virus preparations are then inactivated for instances by treatment with 
the cross-linking agent formaldehyde [Chiron Vaccines, 2002].  
 
 
Figure 3. Schematic view of the annual manufacturing cycle for influenza vaccines (Figure adapted 
from Datamonitor, 2007) 
 
Whole virion vaccines use the whole inactivated virus particle and, as a consequence, 
elicit more adverse effects [al-Mazrou et al., 1991; Carle et al., 1988]. Split virion 
vaccines are produced by splitting the virus particles by use of detergents or solvents. 
Split vaccines contain the surface antigens HA and NA, the NP and the M1 protein 
[Chiron Vaccines, 2002]. The trivalent inactivated subunit vaccines are further 
purified to remove the internal proteins, leaving mostly HA and NA.  
Distinct roles have been attributed to the humoral response elicited by the 
influenza surface glycoproteins, HA and NA. The antibody against HA generally 
neutralizes viral infectivity, probably by interfering either with the viral attachment to 
host surface receptors or with the fusion between viral and endosomal membranes 
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[Kida et al., 1983; Yoden et al., 1986]. Anti-NA antibody, in contrast, does not 
prevent infection, but can reduce viral replication below a pathogenic threshold so 
that infection can occur without disease, presumably by inhibiting release of progeny 
virus from cells or by aggregating viral particles in the blood and thus preventing 
further spread of the virus [Beutner et al., 1979; Couch et al., 1974; Kilbourne et al., 
1968; Ogra et al., 1997]. As discussed before, conventional vaccines are usually 
effective in preventing illness by preventing infection when the HA in the vaccine is 
antigenically similar to the expected wild-type HA strain [Couch et al., 1974; Couch 
et al., 1971; Kilbourne, 1980; Bridges et al., 2000; Skowronski et al., 2009]. 
Limitations of the currently available influenza vaccines include:  
(i) Reduced efficacy in the elderly. Studies have shown that inactivated 
influenza vaccine is effective in prevention of influenza in young adults, 
achieving levels of protection of 70 to 90% [Meiklejohn et al., 1987; Ruben, 
1987]. Among the elderly, the rate of protection against illness is lower, 
especially for those who are institutionalized [Clements, 1992]. Significant 
antibody responses to a trivalent subvirion influenza vaccine are observed in 
less than 30 percent of vaccinees of 65 years or older [Powers and Belshe, 
1993];  
(ii) Production in eggs. The manufacture of influenza vaccines is limited to 
influenza virus strains that replicate well in eggs and a large supply of eggs is 
required each year. Production is at risk each year because of the need to find 
a suitable virus combination. It would also not be feasible to rapidly increase 
production capacity, for example in the event of a pandemic outbreak – since 
eggs need to be ordered well in advance and the source (chicken) may be 
especially vulnerable to avian influenza viruses. In addition, on average one 
embryonated egg is needed to produce one vaccine dose; 
(iii) Inability to respond to late appearing strains such as A/Sydney/5/97 in the 
late 1990s, or to respond to a potential pandemic strain such as the Hong 
Kong H5N1 virus that appeared in 1997 and killed the chicken embryos. 
Reverse genetics has recently been used to create less pathogenic H5N1 
viruses that can be grown in chicken embryos; however, the efficacy of such 
vaccines remains to be proven [Wood and Robertson, 2004]; 
(iv) Antigenic variation. In response to immune selection, influenza viruses 
undergo antigenic drift through amino acid sequence changes in the 
hemagglutinin, and, to a lesser extent, the neuraminidase molecules. 
Protection with current whole or split influenza vaccines is short-lived, and 
its effectiveness wanes as genetic changes occur in the epidemic strains of 
influenza. Ideally, the vaccine strains should be matched to the influenza 
virus strains causing disease. Changes can occur in the hemagglutinin 
proteins of egg-grown influenza viruses when compared to primary isolates 
from infected individuals [Katz  et al., 1987; Rajakumar et al., 1990;  Wang 
et al., 1989] resulting in a less effective vaccine; 
(v) Adverse Reactions. Less than one-third of those who receive influenza 
vaccines experience some soreness at the vaccination site and 5% - 10% 
experience mild side effects such as headache or low-grade fever. The most 
serious side effect that can occur is an allergic reaction in people who have 
severe allergy to eggs. Therefore, people with egg allergy are advised not to 
take influenza vaccine; and  
(vi) Inability to achieve the objective of vaccination of all people because of 
inadequate production capacity and egg-allergy. 
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Alternative Influenza Vaccines 
Most pharmaceutical vaccine development efforts are aimed at producing influenza 
viruses in cell culture. Solvay [Brands et al., 1999], Novartis, Nobilon and GSK 
[Percheson et al., 1999] are developing vaccines that are manufactured using Madin 
Darby Canine Kidney (MDCK) cells, whereas Baxter has selected African Green 
Monkey Kidney (VERO) cells [Barrett et al., 2009] and Sanofi Pasteur applies a 
human retina cell line (Per.C6) [Becker, 2004]. Production of influenza viruses in cell 
systems has proven to be challenging as demonstrated by the fact that none of these 
manufacturers has been successful in commercializing a cell-based vaccine to date. 
No such products are marketed despite the fact that two companies (Solvay and 
Novartis) have received regulatory approval in Europe.  
A recombinant subunit vaccine based on HA would be a good choice as 
resistance to influenza infection correlates with anti-HA antibody levels in serum 
[Couch and Cate, 1983; Dowdle et al., 1973], the antigenic structure of the HA is of 
primary importance in strain selection for inclusion in the influenza strain each year 
and TIV is standardized to contain 15µg HA of each strain represented in the vaccine. 
Resistance to disease can be correlated with local neutralizing antibody and secretary 
IgA antibody to HA as well as circulating serum IgG anti-HA antibody [Clements et 
al., 1987].  
Progress in recombinant DNA technology has allowed for the rapid cloning of 
influenza virus HA genes. Selection of an appropriate expression system that would 
enable high expression of correctly folded and biologically active HA is, however, 
critical. An influenza vaccine based on rHA could offer the following advantages:  
(i) The influenza rHA antigens could be produced under safe, sterile and 
stringently controlled conditions using a scalable fermentation process;  
(ii) rHA protein could be highly purified and would not contain contaminants 
from eggs, eliminating possible adverse reactions in individuals with 
severe egg allergies;  
(iii) Since the ability to produce at high levels in eggs is no longer a criterion 
the vaccine strains with the best genetic match to the influenza virus 
strains causing disease can be chosen;  
(iv) The procedure of cloning, expression, and manufacture of rHA influenza 
vaccine could be very rapid, allowing for vaccine strain selection later in 
the year when more reliable epidemiological data are available. Health 
officials would be better able to respond in the event of the emergence of 
a new epidemic or pandemic strain of influenza virus; and  
(v) Purification procedures for rHA would not need to include virus 
inactivation or organic extraction procedures, thus avoiding possible 
denaturing effects and additional safety concerns due to residual toxic 
chemicals in the vaccine. 
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Selection of an appropriate expression system for the production of 
hemagglutinin 
The selection of an appropriate expression system for the production of a protein can 
ultimately determine success or failure of a product. Factors such as time to market, 
cost of goods, the characteristics of the product, regulatory challenges and patents are 
all influenced by the expression system that is selected. For example, selecting a 
novel expression system can hugely affect the time that the regulatory authorities will 
need to review a biologics license application (BLA) or the biological function of a 
protein can be affected. Figure 4 below may provide some guidance for selection of a 
particular expression system for a particular protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Qualitative ranking of six commonly used protein expression systems 
Five important considerations for various expression systems are listed below with least 
attractive on the left and most attractive on the right. Bacteria and yeast are expression systems 
of choice for simple proteins since they are well accepted, cost effective protein production 
systems. Mammalian production systems are often systems of choice for the production of 
complex proteins, however development time lines may be long and production costs high. 
The baculovirus expression vector system (BEVS) provides an attractive “in between 
solution”, while the Food and Drug Administration (FDA) to date has not approved a product 
made in BEVS the system is generally considered safe. 
 
HA is a complex large protein requiring multiple post-translational modifications, 
including glycosylation and di-sulfide bond formation (Fig. 5) [Skehel and Wiley, 
2000]. Influenza HA forms trimers and it has been reported that HA forms rosettes, 
which would have a length of twice a trimer [Sato et al., 1983]. Sequence analysis of 
HA genes and serology data have identified the amino acids of the HA protein that are 
necessary for neutralizing the influenza virus [Skehel and Wiley, 2000]. These 
antigenic sites are predominantly located in the membrane-distal ectodomain known 
as HA1. Host cell endoproteases (e.g. bromelain) cleave HA into an active form 
consisting of two disulfide-linked fragments, the amino-terminal HA1 subunit and the 
carboxyterminal HA2 subunit. The HA2 fragment contains the transmembrane 
portion and the membrane fusion peptide, while the HA1 fragment has a number of 
glycosylation sites and the sialic acid receptor binding site, in addition to the antigenic 
determinants of the molecule [Skehel and Wiley, 2000]. Recently however, Sui et al. 
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(2009) identified a neutralizing antibody that bound into the conserved pocket in the 
stem region of the HA2 domain. The antibody further exhibited cross neutralizing 
potential, and it was suggested that this region is resistant to neutralization escape. 
Thus, the HA2 domain may be more important for protection against influenza 
disease than originally thought. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic depicting the primary structure of the HA protein. HA monomers are cleaved by 
host endoproteases into two disulfide-linked fragments, an amino-terminal HA1 fragment and a 
carboxyl terminal HA2 fragment. The HA1 ectodomain has the five antigenic sites (A–E) on the 
surface of its globular headpiece. HA1 also contains many N-linked glycosylation sites (G) and the 
sialic acid receptor binding site. The HA2 fragment has a transmembrane domain and a hydrophobic 
peptide that penetrates the target membrane for viral entry. The considerable conformational change 
required for membrane fusion by the HA2 hydrophobic peptide necessitates the proteolytic cleavage 
event that releases it from the HA1 domain. The pathogenicity of viral strains has been correlated with 
the efficiency of this activation event. 
 
The complexity of the HA protein and the modifications required for its biological 
function warrants the use of a higher eukaryotic expression system such as 
mammalian or insect cell systems. The baculovirus-insect cell expression system is 
such a system [Miller, 1981]. In particular the versatility and speed with which new 
recombinant baculoviruses can be generated make the latter system particularly 
attractive for the production of an influenza vaccine, which requires annual 
adjustments. A single, well characterized insect cell line can be used for the 
production of all influenza proteins, thereby eliminating the time-consuming process 
of preparing and qualifying a new cell line for each new protein as would be the case 
for e.g. a stable HA producing Chinese Hamster Ovary cell line [Knezevic et al., 
2007]. Finally, manufacturing costs are important for vaccines, which usually do not 
carry high-profit margins, and also in this aspect the baculovirus – insect cell system 
is an attractive choice. 
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The baculovirus-insect cell expression system  
The baculovirus-insect cell expression system is well known as tool for the production 
of complex proteins. Its reputation is one of providing quick access to biologically 
active proteins. It also has been extensively explored for the production of viral 
antigens [Oers, van 2006]. Recently, both veterinary and human vaccines 
manufactured using this production system have been commercialized such as 
Intervet’s Porcilis Pesti (Classical swine fever) and CIRCUMVENTTM (Porcine 
circovirus), Boehringer Ingelheim’s Ingelvac® CircoFLEXTM (Porcine circovirus) 
and CervarixTM GSK’s bivalent Human Papilloma Virus (HPV 16/18) vaccine against  
cervical cancer.  
Baculoviruses are insect pathogens and can cause fatal disease in lepidopteran, 
dipteran and hymenopteran larvae. They are primarily used as biocontrol agents of 
insect pests in agriculture and forestry. The name baculovirus is derived from the 
Latin word “baculum” (= rod) describing the shape of a baculovirus particle. These 
particles are present singly (in granuloviruses) or in multiples (in 
nucleopolyhedrosisviruses) in proteinaceous capsules, referred to as granula, 
polyhedra or occlusion bodies. Baculoviruses are characterized by their narrow host 
range [Tinsley and Harrap, 1978] and their inability to replicate in vertebrates 
including man. Baculoviruses are commonly found on green vegetables and, 
therefore, are part of the daily diet of healthy individuals. For example, a typical 
serving of coleslaw contains 112 million polyhedra, each containing multiple 
baculovirus virions [Heimpel et al., 1973]. 
Although baculoviruses are not able to replicate in mammalian cells, the 
baculovirus Autographa californica multiple capsid nucleopolyhedrovirus 
(AcMNPV), the type species of the genus Alphabaculovirus, has .been shown to 
efficiently transduce a variety of mammalian cells [Kost et al., 2005]. The baculovirus 
particles or virions contain a large double-stranded DNA genome, on average, 
depending on the virus species, 130 kilobase pairs in size, which can be easily 
characterized using genomic restriction digests, Southern blotting and sequencing 
techniques. In larvae the baculovirus virions are released from the polyhedra in the 
alkaline environment of the gut and are infecting midgut epithelial cells. After one 
round of replication a budded virus (BV) form is released into the hemolymph to 
initiate a systemic infection of the larvae. The BV is phenotypically different, but 
genetically identical to the occlusion-derived virus (ODV) and can be used to infect 
insect cell cultures. AcMNPV, for example, can be propagated in cell lines derived 
from a.o. the fall armyworm Spodoptera frugiperda (SF) or the cabbage looper 
Trichoplusia ni (T. ni) [Granados, 1994], which both grow well in suspension cultures 
[Jehle et al., 2006].  
Summers and Smith demonstrated in the 1980s that polyhedrin, the major 
capsule protein, was not essential for the propagation of the virus in a cell cultures and 
that its encoding open reading frame could be exchanged for sequences encoding 
proteins of medical importance such as β-interferon [Smith et al., 1983]. This marked 
the beginning of the baculovirus-insect cell expression area and thousands of proteins 
have been produced since using the polyhedrin promoter or later also the p10 
promoter to drive expression. A scheme depicting the baculovirus expression system 
is shown in Figure 6. Insect cells have the capability of performing many of the post-
translational modifications such as glycosylation, disulfide bond formation, 
myristoylation and phosphorylation required for the biological activity of many 
complex proteins [Miller, 1981; Oers, van 2006]. However, complex glycosylation 
rarely occurs. Proteins can usually be produced in the baculovirus-insect cell system 
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in weeks rather than months or years because the virus used to infect the insect cells 
rather than the cell line is modified. After the baculovirus infects the insect cell, the 
cell is transformed into a baculovirus DNA and protein production facility until the 
cell finally dies. In the baculovirus expression system proteins are usually produced 
under the control of the polyhedrin gene promoter, one of the strongest promoters 
known in nature. Insect cell-produced proteins are generally biologically active [Oers, 
van 2006].  
 
Figure 6. Baculovirus expression system. Left panel shows an insect cell infected with wild type 
baculovirus (A). The nucleus contains virions, occluded in polyhedra, mainly consisting of the 
polyhedrin protein. In the middle, the insect cell is infected with a recombinant baculovirus, now 
recombinant protein is expressed instead of polyhedrin (B) and on the right a SDS-PAGE protein 
analysis of cells infected with wild type baculovirus (A) or recombinant virus using the polyhedrin (B) 
or p10 (C) promoter is shown (Figure was adapted from van Oers and Vlak, 2008).  
 
Recombinant baculoviruses that express foreign genes are constructed in various ways 
and means. The ‘classical’ way of engineering baculovirus expression vectors is by 
homologous recombination in insect cells between wild type baculovirus genomic 
DNA and chimeric plasmids containing the open reading frame (ORF) of the gene of 
interest with flanking sequences matching the up and downstream regions of the 
polyhedrin ORF, including the 5’ and 3’untranslated regions. Recombinant viruses 
can be detected by virtue of their distinct plaque morphology; plaques derived from 
viruses containing the polyhedrin gene have a cloudy appearance, and plaques derived 
from recombinant viruses in which the polyhedrin gene has been replaced by a 
foreign gene are clear. The presence of the inserted heterologous DNA in the 
baculovirus genome can easily be verified using genome digests, Southern blotting or 
polymerase chain reaction (PCR) techniques. Later on more sophisticated strategies 
have been used to generate recombinant baculoviruses in insect cells, e.g. by 
linearizing the baculovirus DNA rendering it non-infectious for insect cells except 
when recombination occurs between the linear baculovirus DNA and the chimeric 
plasmid [Kitts and Possee, 1993] 
A general scheme for the construction of a recombinant baculovirus for 
expression of a foreign protein is shown in Figure 7. Coding sequences from a foreign 
gene are inserted into a plasmid known as a baculovirus transfer plasmid using 
standard cloning techniques. The transfer plasmid contains the polyhedrin promoter 
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upstream of a multiple cloning site, coupled to sequences naturally flanking the 
polyhedrin locus in AcMNPV and a portion of the essential gene ORF1629 located 
downstream of the polyhedrin locus. The transfer plasmid is co-transfected with 
baculovirus genomic DNA that has been linearized with an enzyme that removes the 
polyhedrin gene and part of ORF1629, rendering the non-recombined genomic DNA 
non-infectious [Kitts and Possee, 1993]. Homologous recombination between the 
transfer plasmid and the linearized genomic DNA rescues the virus. The efficiency of 
recovery of recombinant viruses versus non-recombinants is nearly 100%. This 
process results in plaques that are nearly homogeneous, eliminating the need for 
multiple rounds of plaque purification. These are undesirable because defective 
particles may be generated rendering the amplified baculovirus unstable [Kool et al., 
1991; Pijlman et al., 2001] and interfering with the replication, and hence protein 
production, of the baculovirus-insect cell system. A further advance in the 
engineering of baculovirus expression vectors has been the generation of so-called 
‘bacmids’ in Escherichia coli [Luckow et al., 1993]. This system (also commercially 
available) allows for the production of recombinants via transposition of recombinant 
plasmids into the AcMNPV genome incorporated into a bacterial artificial 
chromosome (bacmid), allowing for manipulation of the whole AcMNPV genome in 
bacteria [Luckow et al., 1993]. This not only speeds up the cloning process, but 
invariably results in genetically homogeneous baculovirus expression vectors. 
Unfortunately, viruses generated using bacmid tend to be highly unstable during 
scale-up and are therefore not suitable for commercial production purposes [Pijlman 
et al., 2003]. 
 
 
Figure 7. General scheme for construction of a recombinant baculovirus expression 
vector. The generation of a recombinant baculovirus takes approximately 1-2 weeks. 
Scale-up of the virus and characterization adds another 2-4 weeks. 
 
Full-length cDNA Polyhedrin promoter
Transfer plasmid
Processing Signals
Full-length HA gene
PCR-direct cloning
Linearized BV DNA
X X
HA gene
Recombination
BV expression vector2-6 wks
12
  Chapter 1 
  
Pandemic preparedness 
An influenza pandemic is a global epidemic caused by an influenza virus and infects a 
large proportion of the human population. It is commonly believed that a pandemic 
occurs as a result of the earlier described “antigenic shift” when a new influenza virus 
emerges that has not previously, or not for a long period of time, circulated in 
humans. As a result no immunological memory exists in the human population for 
such a virus, or may be limited to older adults in the event the virus circulated 
previously. Three worldwide outbreaks (pandemics) of influenza occurred in the 20th 
century [Kilbourne, 2006]. The 1918 Spanish flu was the most serious one, killing 
somewhere between 20 and 40 million individuals. The causative agent was a H1N1 
virus, a subtype that is today still actively circulating in humans and is included in the 
seasonal influenza vaccine. The other two milder pandemics were the Asian influenza 
in 1957, caused by a H2N2 virus and the Hong Kong influenza in 1968 caused by a 
H3N2 virus, the other subtype that is today still actively circulating in humans and 
included in the seasonal influenza vaccine. Pandemic influenza has become a high 
priority for all public health authorities, especially since the re-occurrence of avian 
H5N1 viruses that are capable of infecting and killing human beings. Reports from 
WHO as of March 2, 2009 indicate that the cumulative number of confirmed human 
cases of avian influenza caused by A/H5N1 is 409 with a case fatality of 56. The good 
news that we have seen a decline in cases since 2006 with 115 cases reported in 2006, 
88 cases in 2007 and only 44 cases reported in 2008. Avian influenza in poultry 
remains, however, widespread. Most human cases of H5N1 are thought to have 
occurred as a result of direct contact with sick or infected poultry. Only in a few 
instances limited, inefficient and unsustained human-to-human transmission was 
suspected [Web link 1-1].  
An effective vaccine will be needed to substantially reduce the impact of an 
influenza pandemic. Current influenza vaccine manufacturing technology is not 
adequate to support vaccine production in the event of an avian influenza outbreak 
and it is clear that new innovative production technology is required.  
In 1997 health officials in Hong Kong were first alarmed by the death of a 
child following infection with a highly pathogenic avian H5N1 influenza strain. This 
virus had previously caused the death of 70-100% of the chickens in infected flocks in 
Hong Kong. Before year-end, six out of eighteen infected people died of the disease 
[Claas et al., 1998]. Fortunately, the efficiency of transmission of this virus between 
humans was low, but the need for better vaccines became obvious [Belshe, 1998]. 
Particularly alarming was that the usual egg-based influenza vaccine manufacturing 
process was incapable of producing a vaccine for this kind of virus because the 
chicken embryos used for production of the vaccine were killed by this highly 
pathogenic virus.  
The baculovirus-insect cell production technology offered a solution in this 
emergency situation. As a case, at Protein Sciences Corporation, the cDNA encoding 
the hemagglutinin gene from the avian H5N1 strain was used to produce a 
recombinant H5 HA (rHA) sub-unit vaccine in insect cells. Within a period of six 
weeks a near-authentic H5 rHA antigen was produced that was first tested in 
chickens. These tests confirmed the immunogenicity of the product and, more 
importantly, showed protection of chickens from a lethal viral challenge [Crawford et 
al., 1999]. Four weeks later 1,700 doses were delivered to the National Institute of 
Health (NIH) for testing in humans and approval was received for compassionate use 
from the Food and Drug Administration (FDA). A clinical study was conducted using 
this material and the results suggested that the H5 rHA produced with the baculovirus 
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– insect cell expression system was able to induce functional antibodies in individuals 
who had no prior exposure to the H5 viruses [Treanor et al., 2001]. Hence this 
expression system was shown to provide a powerful rHA manufacturing technology 
that can potentially provide healthcare solutions in pandemic, biodefense and 
emergency influenza situations.  
Avian influenza has been a problem in the poultry industry for many years. 
Examples include the North American highly pathogenic outbreak in Pennsylvania in 
1983 [Eckroade et al., 1984] and in Central Mexico during 1994 -1995 [Garcia et al., 
1996]. Human cases of avian influenza have only been reported since 1997. Table I 
summarizes the occurrence of human cases and the disease outcome associated with 
concurrent poultry outbreaks in various geographic regions. The fact that human cases 
where first identified in Hong Kong, and subsequently in the US, the Netherlands, and 
Canada, suggests that the availability of improved diagnostic methods in these 
countries enabled the identification of these avian influenza viruses in humans. In 
other words, human infection with avian influenza viruses may have previously or in 
less well equipped countries, gone undiagnosed and may have been more commonly 
associated with outbreaks in poultry. The other important finding presented in Table I, 
is that besides H5N1 a wide variety of avian influenza viruses, including the H7 and 
H9 subtypes, are capable of infecting and causing disease in humans [Web link 1-1].  
 
Table I: Human impact of avian influenza outbreaks in poultry between 
1997 and February 2009.  
Year Strain Impact* Geographic Region 
1997 H5N1 18 (6) Hong Kong 
1999 H9N2 2 Hong Kong 
2002 H7N2 1 US Virginia 
2003 
H5N1 
H7N7 
H9N2 
H7N2 
4 (4) 
89 (1) 
1 
1 
Vietnam/China 
Netherlands 
HongKong 
New York 
2004 – 
FEB09 
H5N1 
H7N3 
H7N2 
H9N2 
409 (256) 
2 
4 
1 
Asia/Africa 
Canada 
U.K. 
HongKong 
*Total number of subjects with disease. In brackets subjects with fatal outcome 
 
When Hong Kong in 1997 suffered from a severe H5N1 outbreak in poultry, 
the authorities undertook the following actions: 1.5 million chickens were culled, 
ducks and geese were removed, two cleaning days per month were introduced in the 
live bird markets and, finally, poultry flocks were vaccinated with an inactivated H5 
vaccine [Webster, 2005]. Unfortunately, the above measures are not followed 
throughout Asia because they are too expensive. Bird culling is the most common and 
widespread approach to eradicate avian influenza in developed countries. Despite the 
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availability of poultry vaccines, countries often elect not to vaccinate their birds 
because of a potential negative impact on the ability to export the birds.  
An influenza pandemic is believed to be imminent and scientists agree that it 
only is a matter of when, where and what will be the causative agent. Recently, most 
attention has been directed to human cases of avian influenza caused by a H5N1 avian 
influenza virus. When Dr. John La Montagne speculated that our strengthened 
surveillance systems to monitor disease spread and modern diagnostics tools would 
allow us to slowly see a disease unfold [Gellin, 2005], he was probably right. 
Currently the avian influenza viruses have not acquired the ability to transmit easily 
from human to human, but as we continue to monitor the disease and the genetic 
composition of the viruses as suggested by the work of Taubenberger et al. (2005) we 
may be able to make useful predictions as to when, where and what the next pandemic 
will be.  
Developing and pre-vaccination with a safe, prophylactic vaccine containing, 
for example, H2, H5, H7 and/or H9 rHA proteins could stimulate a low level immune 
response against these viruses to which many people do not have pre-existing 
antibodies. This is because the viruses, H5, H7 and H9, do not efficiently infect 
humans or, like H2, have not circulated for the past 40 years. Such a vaccine may be 
the most effective proactive response to the threat of a potential pandemic. Various 
studies have suggested that memory against a specific HA subtype can stimulate a 
broad-spectrum immune response and may prevent from severe disease even in 
instance when there is not a close relatedness between strains. For example, a vaccine 
based on 1999 circulating H1N1 virus (A/New Caledonia) was able to cross-protect 
mice against a lethal challenge with the 1918 influenza virus [Tumpey et al., 2004]. 
Also, preliminary data from a recently conducted re-vaccination study also suggest 
that vaccination with recombinant H5 can also prime for booster responses on 
revaccination with or exposure to drifted strains of H5 [Goji et al., 2008]. 
The current reports of human cases caused by a novel swine-origin influenza 
A H1N1 variant in Mexico and the U.S. with high lethality in healthy adults are 
perhaps of greater concern [MMWR, 2009]. On April 29 2009, the WHO raised the 
pandemic influenza phase from 4 to 5. The emergence of this novel H1N1 virus has 
been reported to be the greatest pandemic threat since the emergence of the influenza 
A (H3N2) in 1968 [Novel Swine-Origin Influenza A (H1N1) Virus Investigation 
Team, 2009]. It is unsettling and surprising that an H1N1 virus could cause 
widespread lethal disease in humans, since H1N1 viruses have been actively 
circulating in humans during the past decades, even though immunological memory 
exists within the population.  
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Scope of this thesis 
The main challenge in identifying a suitable manufacturing system for an influenza 
vaccine is that this system has to be sufficiently flexible to deliver the annual updates 
in a timely manner. The final determination for the composition of the influenza 
vaccine is made by the WHO in February and the vaccine needs to be available for 
administration preferably in September but not later than October, leaving only six 
months to complete the production of a vaccine that can have as many as three new 
components each year. In addition, the protein produced has to be immunogenic and 
exhibit the same characteristics as the licensed inactivated influenza vaccine, i.e. it 
has to be safe and able to prevent influenza illness.  
The aim of this thesis is to evaluate whether the baculovirus-insect cell 
production system can be used to produce an influenza vaccine for both seasonal and 
pandemic emergency use. The work described in this thesis forms the basis for a 
biologics license application (BLA) for FluBlok. 
In Chapter 2, the time needed to clone the influenza HA into baculovirus 
vectors is determined and the biochemical properties of rHA produced in the 
baculovirus-insect cell system are compared with those of viral HA. To this aim, 
various methods were developed to assess its biological activity. The greatest 
challenge is, however, to purify different rHA proteins within the short time available. 
A universal purification resin, lentil lectin was initially tried that specifically binds 
glycoproteins produced in insect cells. While this purification process is simple and 
can be implemented readily within the short development time available, it will not be 
suitable for commercialization of an insect cell vaccine. Residual lentil lectin resin 
causes safety concerns since many people are allergic to lectins. Nevertheless, the 
rHA produced using this method was analyzed in clinical studies for its 
immunogenicity.  
In Chapter 3 the focus is on developing a more scalable production process, 
methods to monitor rHA protein production and additional methods to characterize 
the rHA.  
The questions whether rHA alone would be adequate to provide protection 
against influenza infection and whether the differences in glycosylation of rHA 
produced in insect cells compared to rHA synthesized in mammalian cells would 
impact the performance of the vaccine are addressed in Chapter 4.  
Reduction in vaccine effectiveness of the licensed vaccine has been reported 
when the influenza vaccine was not well matched to the circulating strain [MMWR, 
2004; Bridges et al., 2000; Belongia et al., 2009; GSK Study number 104438, 2009; 
Beran et al., 2009; Skowronski et al., 2009; Wang et al., 2009]. To address the 
question whether more antigen can result in cross-protection of the vaccine against 
drifted viruses, ten H3N2 influenza viruses were isolated from six placebo recipients 
and four low dose vaccine recipients and characterized  by sequence analysis in 
Chapter 5.  
Questions and concerns that specifically relate to the safety of a novel cell 
substrate are addressed in Chapter 6. The specific concern regarding the potential 
presence of latent viruses in the cell line is addressed by transmission electron 
microscopy of stressed insect cells. Furthermore, PCR methods are developed for 
various adventitious agents that have been described for insects in general and for a 
specific virus that was described previously for a related insect cell line T. ni High 
Five [Li et al., 2007]. Additionally, fluorescent PCR-based reverse transcriptase 
testing is performed at the end of the production procedure to rule out increased 
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presence of retrovirus-like particles. In addition, the safety and immunogenicity was 
assessed in clinical studies that are used to support licensure of the rHA-based subunit 
vaccines (FluBlok®) in the U.S. The total safety database for FluBlok includes 2497 
subjects 18-49 years and 736 subjects older than 50 years who received the 
commercial formulation of FluBlok. 
In Chapter 7, the general discussion, we assess the importance of this work 
for pandemic preparedness and public health in general. The recent reports of human 
cases in healthy adults of a novel swine influenza H1N1 variant in Mexico, the U.S. 
and its subsequent rapid spread around the globe are of major concern [MMWR, 
2009], and demonstrate the need for a vaccine that can be produced rapidly and in 
large quantities. We further assess how FluBlok can be further improved both from a 
manufacturing (i.e. what can be done to improve production yields) and product 
quality (i.e. how can vaccine performance be improved) stand point. Also a critical 
assessment is provided of how FluBlok compares to other influenza vaccines in 
development (i.e. the baculovirus insect cell expression system versus alternative 
influenza vaccine production systems and the importance of inclusion of other 
influenza antigens [N and/or M])  
 
17
 18
  Chapter 2 
  
Chapter 2 
Production of a recombinant influenza vaccine using the 
baculovirus expression vector system 
 
 
Summary 
 
A method to produce recombinant influenza hemagglutinin (rHA) in the baculovirus-
insect cell system aimed at seasonal vaccine development is described. Recombinant 
full length HA molecules from the three strains recommended by the World Health 
Organization for the 2003-2004 influenza season were cloned, expressed and purified. 
The production process for rHA isolated from the influenza virus A/Panama/2007/99 
is described in detail. This process is adjusted slightly for rHAs derived from the other 
influenza strains. The biological activity of rHA expressed in insect cells was 
confirmed using a variety of methods. For example, a hemagglutinin assay 
demonstrated the ability to agglutinate red blood cells, a trypsin digest assay showed 
that the rHA was resistant to digestion and electron microscopy showed rosette-like 
structures. Therefore, we conclude that the baculovirus-insect cell system can support 
the production of full-length biologically active rHA proteins, which may potentially 
be used in a seasonal influenza vaccine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is modified from: Holtz, KM, Anderson, DK and Cox, MMJ Production of a 
Recombinant Influenza Vaccine Using the Baculovirus Expression Vector System. 
Bioprocessing Journal 2003; 2: 25-32.  
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Introduction 
 
Influenza is a highly contagious, acute viral respiratory disease that occurs seasonally 
in most parts of the world. The infection resides primarily in the respiratory tract 
(nose, throat and bronchi), but causes both local and systemic symptoms including 
fever, chills, cough, headache, myalgia, sore throat, and malaise. Influenza-related 
pneumonia is the main complication of infection. Annual epidemics cause significant 
morbidity and mortality worldwide [Glezen, 1982; MMWR 1993; MMWR 2000]. 
Each year, influenza infections result in an average of 110,000 hospitalizations, 
approximately 20,000 of which result in death [MMWR 2000]. These deaths are 
heavily concentrated (>90%) among persons who are at highest risk for influenza-
related complications - elderly adults (over 65), children under age five, patients with 
pre-existing respiratory or cardiovascular disease, and women in the third trimester of 
pregnancy. Thus, the prevention of influenza virus infection is a major public health 
priority. 
Influenza viruses are enveloped, negative-sense RNA viruses belonging to the 
family Orthomyxoviridae. The RNA genome is segmented into eight fragments that 
code for 10 proteins. The influenza viruses are divided into three types, A, B, and C, 
based on differences in nucleoproteins and matrix proteins. Although all cause disease 
in humans, influenza A also infects a wide variety of avian species and mammals. 
Influenza A causes the most serious respiratory illness in humans, whereas influenza 
C infections are of subclinical importance. The greater pathogenicity of influenza A, 
and to a lesser extent influenza B, has been attributed to the antigenic variability of 
the two major surface glycoproteins important in viral infection and immunity, 
hemagglutinin (HA) and neuraminidase (NA). HA mediates viral attachment by 
binding to sialic acid residues on host cell surface receptors and, following 
endocytosis, fuses the viral envelope to the cell membrane in a pH-dependent process; 
NA cleaves sialic acid residues from HA molecules and cell surface proteins, thus 
releasing budding progeny virions and preventing reinfection of the same cell. 
Differences in the HA and the NA surface antigens distinguish types A and B, as well 
as define subtypes of influenza A. Of the 16 recognized HA subtypes (H1-H16) and 
nine recognized NA subtypes (N1-N9), only three HA subtypes (H1, H2, and H3) and 
two NA subtypes (N1 and N2) are commonly isolated in humans [Zambon, 2001; 
Lamb and Krug, 2001].  
Protection against influenza disease and infection is conferred primarily 
through HA, which stimulates production of anti-HA antibodies. In contrast, the anti-
NA antibody response does not prevent disease but may slow its spread by reducing 
the release of progeny virions [Johansson, 1999]. Sequence analysis of HA genes and 
serology data have identified the amino acids of the HA protein targeted by 
neutralizing antibodies. These antigenic sites are predominantly located in the 
membrane-distal ectodomain known as HA1. Host cell endoproteases cleave HA into 
an active form consisting of two disulfide-linked fragments, the amino-terminal HA1 
subunit and the carboxyterminal HA2 subunit. The HA2 fragment contains the 
transmembrane region and the membrane fusion peptide, while the HA1 fragment has 
a number of glycosylation sites and the sialic acid receptor binding site, in addition to 
the antigenic determinants of the molecule [Skehel and Wiley, 2000].  
The protective efficacy of anti-HA neutralizing antibodies is continually 
challenged by the rapid mutation rate of the influenza genome. Replication errors 
introduced by influenza’s low-fidelity RNA-dependent RNA polymerase can lead to   
amino acid substitutions [Wright and Webster, 2001]. In particular, point mutations 
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introduced to the antigenic sites HA may render preexisting, protective HA antibodies 
ineffective. ‘Antigenic drift’ refers to the progressive generation of molecular variants 
of existing influenza strains through replication and leads to annual epidemics 
[Zambon, 1999]. In contrast, ‘antigenic shifts’ have pandemic potential because novel 
viral strains of unpredictable pathogenicity are generated from the exchange of 
genomic segments from different influenza viruses (genetic reassortment) or from 
interspecies transmission of viruses [Zambon, 1999]. The direct transmission of a 
highly pathogenic avian influenza strain (H5N1) from chickens to humans occurred in 
the Hong Kong bird flu epidemic of 1997 that killed 70–100% of infected stocks and 
caused the death of six out of 18 infected people [Claas et al., 1998]. The low 
transmission efficiency of this viral strain among the human population prevented a 
pandemic, however, the situation did underscore the need for a better vaccine to 
handle potential crises [Belshe, 1998].  
Vaccination of high-risk persons each year before the flu season is the most 
effective measure for reducing the impact of influenza [MMWR, 1993]. The current 
licensed trivalent inactivated vaccine (TIV) consists of three chemically inactivated 
viruses (two A strains, H1 and H3, and one B strain) generated in embryonated hen’s 
eggs [Treanor et al., 1996; Lakey et al., 1996]. These vaccines are immunogenic in 
healthy adults and induce an increase in hemagglutination inhibition (HAI) antibodies 
in 70% to 90% of recipients [Quinnan et al., 1983; LaMontagne et al., 1983]. In older 
age groups, TIV is less effective in preventing infection but can prevent complication 
and death following influenza infection [Barker and Mullooly, 1980; Patriarca et al., 
1985]. Adverse side effects including local soreness, erythema, and induration are 
commonly associated with this vaccine and may contribute to its poor acceptance 
among high-risk groups [Fedson, 1987; Govaert et al., 1993]. In addition to the 
reduced efficacy in the elderly and the side effects, other drawbacks of TIV are 
related to the production process. TIV relies on a yearly supply of pathogen-free eggs 
for vaccine production. Also, the adaptation process typically required for high-yield 
production of the vaccine in eggs causes antigenic deviations in the vaccine strains 
compared to field isolates [Robertson et al., 1987; Katz et al., 1989]. Furthermore, the 
egg-based process is incapable of producing vaccines for highly pathogenic avian 
strains, such as H5N1, because they are lethal to chicken embryos [Wood et al., 2002; 
Wuethrich et al., 2003].  
Several studies have shown that vaccines containing purified recombinant 
influenza HA produced in insect cells using the baculovirus expression vector system 
(BEVS) are safe, well-tolerated, and immunogenic in humans [Powers et al., 1995; 
Treanor et al., 1996; Lakey et al., 1996; Powers et al., 1997; Johansson, 1999; 
Treanor et al., 2001]. Based on randomized, double-blind, controlled clinical studies, 
these recombinant HA vaccines produce fewer side effects and yield enhanced 
immunogenicity at higher doses (up to 135 µg HA) in elderly and healthy adult 
populations when compared to TIV (15 µg HA/strain) [Keitel et al., 1994; Keitel et 
al., 1996]. This production system also permits selection of influenza strains later in 
the season for better genetic matching between circulating strains and vaccine strains, 
and avoids the dependence on an egg supply. The latter was extremely important in 
quickly responding to the outbreak in Hong Kong of the pathogenic H5N1 avian 
strain. Following tests in chickens confirming immunogenicity and protection from a 
lethal viral challenge, 1,700 doses of the BEVS/insect cell-derived H5 HA antigen 
were quickly produced for human clinical testing [Crawford et al., 1999]. The H5 HA 
antigen was able to induce functional antibodies in individuals with no prior exposure 
to the H5 virus, thus demonstrating the utility of this system in a potential pandemic 
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crisis [Treanor et al., 2001]. 
This paper describes the production and purification of recombinant HA 
molecules from the three strains recommended by the World Health Organization 
(WHO) for the 2003-2004 influenza season for use in a trivalent recombinant 
influenza vaccine. Using the antigen isolated from the influenza strain 
A/Panama/2007/99 as a representative example, recombinant HA produced using 
BEVS in insect cells is highly purified, properly folded, and biologically active. 
 
 
Materials and Methods 
 
Influenza vaccine strains and their propagation 
Based on the recommendation of the WHO, the following influenza strains were 
obtained from the U.S. Centers for Disease Control and Prevention (CDC) as vaccine 
strains: A/New Caledonia/20/99 (H1N1, referred to as H1 HA), A/Panama/2007/99 
(H3N2, referred to as H3 HA), and B/Hong Kong/330/2001 (referred to as B HA). 
Viral titers were determined in a standard hemagglutination assay using chicken red 
blood cells (RBCs) [Barrett and Inglis, 1995]. The influenza viral stocks were 
amplified in Madin Darby canine kidney (MDCK) cells (ATCC CCL34) by infection 
at a low multiplicity of infection (0.1 to 0.5). Infection was allowed to proceed at 37° 
C for 48 h while virus production was monitored in the media using the 
hemagglutination assay  [Barrett and Inglis, 1995]. 
 
Cloning HA genes  
Influenza virions for each of the strains were isolated from the MDCK culture and 
viral RNA was purified using the Qiagen RNeasy kit. The purified viral RNA served 
as a template in RT-PCR reactions (Titan One Tube RT-PCR System, Roche) to 
generate cDNA for each of the desired HA molecules (H1, H3, and B). For H3 HA, 
the RT-PCR was performed with primers designed to directly generate a cDNA gene 
fragment with 5’ and 3’ ends compatible for overlap extension (OE) PCR (Fig. 1). In 
OE PCR, the 5’ end of the HA cDNA fragment anneals to the complementary 
sequence found on the 3’ end of a PCR amplified fragment of the transfer plasmid 
pPSC12 (= MGS12 in Smith et al., 1993) containing the polyhedrin promoter and the 
baculovirus chitinase signal sequence. Overlap occurs in the region of the baculovirus 
signal sequence and extension gives a full-length product for amplification in 
subsequent PCR cycles. The final OE product for each HA molecule includes a 
seamless fusion of the baculovirus chitinase signal sequence to the DNA sequence 
encoding the N-terminus of the mature protein and a KpnI restriction site incorporated 
downstream of the stop codon. The OE-PCR products are then digested with KpnI and 
NgoMIV, gel purified, and cloned into the baculovirus transfer vector, pPSC12, 
similarly digested with KpnI and NgoMIV, Candidates for DNA sequencing were 
selected based on restriction digest analysis. The genes for H1 HA and B HA were 
cloned using a similar method. 
 
DNA and amino acid sequence of the H3 HA gene 
The DNA sequence of the cloned H3 HA gene was determined using primers that 
anneal to flanking sequences in the pPSC12 plasmid vector and using internal primers 
spaced roughly every 300 nucleotides. The sequencing reactions were performed by 
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MWG Biotech and the resulting sequence data assembled and analyzed using the  
SeqMan program (Lasergene, DNAstar, Inc.). The sequence of the cloned H3 HA 
gene is identical to the sequence of the HA1 region (N-terminal portion) published for 
this strain. No sequence for the HA2 region (C-terminal portion) is published for this 
HA. To analyze this region, the sequences of the HA clone was compared to known 
sequences of related HA strains from the H3 subtype. A/Panama/2007/99 H3 HA 
differs at only one position (R470K) over this region from its closest match among the 
H3 HA subtypes. Sequence comparison of various published H3 subtypes reveals 
variability in the amino acid sequence at position 470 (often a lysine substitution) 
(unpublished data). Thus, we conclude the Panama clone is correct. 
 
Transfection and isolation of recombinant baculoviruses  
Sf9 insect cells (ATCC CRL1771) were cotransfected with linearized AcMNPV 
baculovirus genomic DNA (PSC internal code AcB729.3) and the recombinant 
baculovirus transfer plasmid for H3 HA using the calcium phosphate precipitation 
method. During this process, the expression cassette was transferred from the transfer 
plasmid into the baculovirus genome via homologous recombination. The 
cotransfected cells were harvested by centrifugation, and the supernatants were used 
to grow isolated plaques on plates containing Sf9 cells. Recombinant plaques having a 
distinctive (clear) morphology were selected to generate virus stocks.  
 
Generation of virus stocks 
The isolated plaques were added to T-25 flasks containing Sf9 insect cells in 5 mls of 
TNM-FH medium with 5% fetal bovine serum (FBS) to generate passage one (P1) 
viral stocks. After incubation for five days at 28° C, the infected cells were harvested 
and removed from the culture medium by low-speed centrifugation. One milliliter of 
the supernatant containing the P1 virus stock was used to inoculate a 50 ml culture of 
expresSF+ (SF+) cells (ATCC CRL12579) in serum-free medium (Protein Sciences 
Fortified Medium, PSFM), at a density of 1.5 × 106 cells/ml, in a 100-ml spinner 
flask. Following incubation for 48 h at 28° C with stirring (100 rpm), the infected 
cells were removed from the culture supernatant (P2) by low-speed centrifugation. 
One milliliter of the P2 virus stocks was used to infect a 3-L spinner flask containing 
500 ml of SF+ cells at a density of 1.5 × 106 cells/ml in serum-free PSFM cell 
medium. After incubating the culture at 28° C on a stir plate (100 rpm) for 72 h, the 
cells were removed by low-speed centrifugation, and the supernatant (P3) was titered 
by plaque assay. 
 
Fermentation and harvesting of recombinant HA 
Cultures of SF+ cells (10L to 45L) in serum-free PSFM medium at a density 1.5 × 106 
cells/ml were infected with P3 virus stock at a multiplicity of infection (MOI) of 1. 
The reactors were maintained at 28° C with a stirring speed of 200 rpm and dissolved 
oxygen (DO2) setting of 60%. The cultures were harvested by low-speed 
centrifugation at 72 hours post infection (hpi) and the supernatants discarded. The cell 
pellets containing membrane-bound HA were further processed. 
 
Isolation of recombinant HA 
The cell pellet was resuspended in 50 mM ethanolamine, 0.3 M NaCl, 0.1% ß-ME pH 
9 followed by centrifugation at 6,000×g for 30 minutes at 4° C. The supernatant 
containing membrane proteins was discarded. The remaining pellet was then washed 
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with 50 mM ethanolamine, 0.1% ß-ME pH 9 and centrifuged as described above. The 
supernatant containing contaminating proteins was discarded. The remaining pellet 
was resuspended in extraction buffer containing 50 mM ethanolamine, 1% Triton X-
100, 0.1% ß-ME pH 9. The resuspension was homogenized for five minutes followed 
by 15 min incubation at 4° C. The extracted cell pellet was centrifuged as before and 
the supernatant containing solubilized HA was stored on ice until further processing.  
 
Chromatography 
A generalized purification strategy for HA proteins produced in insect cells using 
BEVS has been established using a combination of ion exchange chromatography and 
affinity chromatography. The specific protocol used to purify A/Panama/2007/99 H3 
HA was as follows. The H3 HA-containing supernatant was applied to an anion 
exchange (Q Sepharose) column equilibrated in 50 mM ethanolamine, 0.1% Triton X-
100, 0.01% ß-ME pH 9. HA flows through this column while bound proteins elute 
with 0.2 M – 2.0 M NaCl.The Q flow-through (containing HA) is applied to a lentil 
lectin affinity column equilibrated in 0.5 M NaCl, 50 mM ethanolamine, 0.1% Triton 
X-100, 0.01% ß-ME pH 9. Lentil lectin is an affinity matrix that reversibly binds 
polysaccharides and glycoconjugates containing glucose and mannose type sugar 
groups. The column is washed with equilibration buffer containing 0.5 M NaCl to 
prevent non-specific protein interactions. The pH and conductivity of the column 
were adjusted with 20 mM Tris, 0.1% Triton X-100, 0.01% ß-ME pH 7.4 followed by 
HA elution with 0.5 M N-methyl-α-D-mannopyrannoside in 20 mM Tris, 0.1% Triton 
X-100, 0.01% ß-ME pH 7.4. The HA-containing material from the lentil lectin 
column is loaded onto a cation exchange (CM Sepharose) column equilibrated in 20 
mM Tris, 0.1% Triton X-100, 0.01% ß-ME pH 7.4. After loading and washing the 
column with equilibration buffer, 10 mM sodium phosphate, 0.01% Tween-20 pH 7.4 
is used to exchange the detergents and remove ß-ME. The purified HA is then eluted 
with 150 mM NaCl, 10 mM sodium phosphate, 0.01% Tween-20 pH 7.4.  
 
Hemagglutination activity assay 
This method was performed as described by Barrett and Inglis (1995). Briefly, 
chicken RBCs are washed with phosphate buffered saline (PBS) and suspended as a 
0.5% solution in PBS. HA is serially diluted in PBS buffer in wells of the assay plate 
and an equal volume of RBCs is added. The plate is covered, incubated at 2–8° C for 
30 minutes to one hour and then scored for agglutination. Agglutination is observed as 
a uniform cell suspension. In the absence of agglutination, the cells settle out and 
form compact pellets. 
 
Trypsin digest assay 
HA is incubated for 30 minutes at 0° C without or with 50 µg/ml L-(tosylamido-2-
phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin. Denatured samples of HA 
were prepared by boiling the samples for 10 minutes prior to trypsin treatment. 
The TPCK treatment inactivates any remaining chymotrypsin activity of trypsin. 
Modified trypsin cleaves Lys-Pro and Arg-Pro bonds at a much slower rate than 
bonds between other aminoacid residues (Perona, 1995).  
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Results 
 
Three vaccine strains, A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), 
and B/Hong Kong/330/2001 were obtained from the CDC under WHO 
recommendations and used to infect MDCK cells in culture. mRNA purified from the 
virions was used to generate cDNA of the HAs from each strain. Using overlap 
extension PCR (Fig. 1), the HA genes were seamlessly fused to the baculovirus 
chitinase signal sequence behind the polyhedrin promoter and subsequently cloned 
into the PSC transfer plasmid pPSC12. Insect cells were cotransfected with the 
transfer plasmid and linearized AcMNPV baculovirus genomic DNA. The 
supernatants of the cotransfected insect cells were subjected to plaque assay, and 
stocks of selected recombinant baculoviruses were prepared. Virus stocks of the 
recombinant baculoviruses were scaled and used to infect SF+ insect cells in 
bioreactors. Recombinant HA was localized to the insect cell membrane and 
subsequently purified as shown in Figure 2 and 3 below.  
 
Extraction of HA 
The chitinase signal sequence present in the PSC vector directs the HA molecules to 
the secretory pathway for glycosylation. However, the hydrophobic C-terminal 
membrane anchor peptide results in protein docking in the insect cell membrane. A 
general extraction scheme was devised in order to simplify isolation of the three 
recombinant HA products during manufacturing.  The first cell pellet wash containing 
0.3 M NaCl in 50 mM ethanolamine, 0.3 M NaCl, 0.1% ß-ME pH 9 removes 
cytosolic and periphery membrane proteins in the supernatant (Fig. 2). The second 
wash without NaCl removes additional loosely bound proteins and lowers the 
conductivity for detergent extraction with 1% Triton X-100. Extractions carried out at 
pH 9 give improved efficiency relative to extractions performed at pH 7 (not shown). 
Typically, the efficiency of protein extraction is 60% or greater using 1% Triton X-
100 at pH 9. However, the estimated 40% HA remaining bound to the membrane after 
solubilization is not extractable with additional detergent washes and most likely 
represents an improperly folded, inactive population of molecules that have not been 
fully processed. 
  
HA Purification 
Solubilized HA in 1% Triton X-100 flows through the Q-Sepharose anion exchange 
column at pH 9. As shown in Figure 3A, HA is found in the column flow-through and 
column wash while a significant amount of contaminating proteins and nucleic acids 
binds to the resin and elutes with sodium chloride. The Q-flow-through containing 
HA is applied directly onto a lentil lectin affinity column. This resin has a high 
specificity for non-reducing α-mannopyranosyl terminal residues that are typically 
produced in insect cell cultures. The HA binds tightly to the resin while contaminating 
proteins flow through and HA elutes with 0.5 M N-methyl-α-D-mannopyrannoside. 
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Figure 1. Cloning strategy for insertion of the influenza A virus H3 HA coding sequence into a PSC 
baculovirus transfer plasmid. The 5’ end of the RT-PCR generated cDNA HA gene fragment has a 
nucleotide sequence that is complementary to the 3’ end of a pPSC12 gene fragment generated by 
standard PCR. In OE-PCR, the complementary regions of these two fragments anneal and are 
extended. The resulting amplified product is digested and ligated into the pPSC12 vector. The final 
construct contains the H3 HA coding sequence seamlessly fused to the PSC signal sequence 
downstream of the polyhedrin promoter.  
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 Figure 2. General procedure for extracting HA from the insect 
cell membrane. After washing cells in the presence and 
absence of NaCl (0.3M) using ethanolamine buffer, pH 9, to 
remove loosely associated proteins, the membrane proteins are 
solubilized with 1% Triton X-100 in ethanolamine buffer pH 
9. The band corresponding to HA is denoted by the arrow. 
Based on the amino acid sequence, monomeric HA has a 
molecular mass of 64 kDa; however, each trimannose core 
unit added to the protein by insect cells is an additional 
1.8 kDa. Lanes: 1, MW markers; 2, supernatant from 0.3 M 
NaCl wash; 3, pellet following the 0.3 M NaCl wash; 4, 
supernatant from ethanolamine wash; 5, pellet following the 
ethanolamine wash; 6, supernatant after membrane extraction 
with 1% Triton X-100 containing soluble HA; 7, pellet after 
1% Triton X-100 extraction containing insoluble HA.  
 
 
Final purity is achieved with lentil lectin chromatography (Fig. 3B). The highly pure 
HA is subsequently loaded onto a final CM column for concentration and exchanged 
into the final formulation buffer system. As shown in Figure 3B, the lentil lectin 
eluate is subsequently concentrated approximately 10-fold using CM column 
chromatography.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3A. Q column chromatography of Triton X-100 solubilized H3 HA. Solubilized HA is loaded 
directly onto the Q column. HA is collected in the Q flow-through and Q wash with minimal losses. 
Impurities and DNA remain bound to the column and elute with 0.2-2.0 M NaCl. HA is denoted by 
the arrow. Lanes: 1, MW markers; 2, pre-column solubilized H3 HA; 3, flow-through; 4–5, 50 mM 
ethanolamine, 0.1% Triton X-100, 0.01% ß-ME wash; 6–12, 0.2–2 M NaCl elution of bound material. 
Figure 3B. Lentil lectin and CM column chromatography of pooled Q flow-through and Q wash 
containing H3 HA. Lentil lectin chromatography purifies HA to homogeneity while the CM column 
concentrates the material approximately 10-fold and exchanges the detergent for the final formulation 
(10 mM Na phosphate, 0.01% Tween-20, 0.15 M NaCl pH 7.4). Higher MW bands observed above 
and below the 188 kDa MW marker band represent higher molecular weight forms of HA (dimers and 
trimers). Lanes: 1, MW markers; 2, Q flow-through and Q wash combined; 3, lentil lectin eluate; 4, 
CM fraction containing highly concentrated HA. 
 
 
1 2 3 4 5 6 7
188 –
62 –
49 –
38 –
28 –
14 –
6 –
3 –
HA
A B
1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4
HA
trimer
dimer
monomer
188 –
62 –
49 –
38 –
28 –
14 –
6 –
3 –
27
  Production of rHA 
  
HA Characterization 
Based on the migration in SDS-PAGE gel and a comparison with the molecular 
weight markers (MW), the purified monomeric form of HA has a calculated 
molecular mass of 74 kDa. Based on the known theoretical mass from the amino acid 
sequence of the protein (64 kDa) and the molecular mass of a trimannosyl unit added 
by insect cells (1.8 kDa/unit), the purified protein has six out of the seven potential 
sites glycosylated. Higher bands observed in the SDS-PAGE gel of Figure 3B have 
calculated molecular masses of 143 and 219 kDa, values in strong agreement with 
dimeric and trimeric forms of the molecule. Based on bicinchonic acid (BCA) total 
protein determination and optical density measurements, average yields between 2-4 
mgs pure material per liter of culture are obtained.  
HA proteins can be tested for their ability to agglutinate chicken RBCs in a 
standard hemagglutination activity assay  [Barrett and Inglis, 1995]. This activity 
assay is based on the ability of HA to bind erythrocytes through the sialic acid 
receptor binding site located on the globular headpiece of the properly folded 
molecule, causing the cells to aggregate. Figure 4 shows a typical activity assay 
performed in a 96-well plate. HA agglutination prevents cells from settling to the 
bottom of the wells and is observed as a uniform cell suspension. In the absence of 
agglutination, the cells settle out and form compact pellets as observed with PBS 
buffer serving as a negative control in lanes 1 and 5 (Fig. 4) The agglutination activity 
for H3 HA (lanes 2-4) spans three orders of magnitude and shows activity down to 
approximately 0.5 ng of pure protein (or 2,000 Units/mg of HA activity). 
 
 
 Figure 4. Hemagglutination assay for H3 
HA. PBS buffer serves as a negative control 
in lanes 1 and 5. Purified H3 HA diluted in 
PBS buffer is loaded into the first well of 
lanes 2, 3, and 4 at concentrations of 
100 µg/ml, 1 µg/ml, and 0.01 µg/ml, 
respectively. The protein aliquots are 
subsequently diluted twofold in a serial 
fashion down the plate using equal volumes 
of PBS buffer per row. Loose pellets are 
noticeable in lane 3, well H and lane 4, well 
A due to diminished activity as the protein 
concentrations reaches sub-nanogram levels 
(0.8–0.5 ng). One HA unit is defined as the 
amount of antigen at which 50% of the cells 
agglutinate (loose pellet).  
 
 
 
The correct quaternary structure of recombinant HA is important for its 
stability and biological activity. The trypsin resistance assay treats the final 
product with the trypsin endoprotease to distinguish properly folded, trimeric 
HA from denatured and/or monomeric molecules. In this assay, full-length, 
intact HA molecules that have associated into trimers are converted into two 
smaller fragments, the amino-terminal HA1 fragment and the carboxy-
terminal HA2 fragment, by proteolytic cleavage at an internal site (described 
in Chapter 1, Fig. 5). In the SDS-PAGE gel trypsin treatment of H3 HA 
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resulted in the characteristic HA1 and HA2 fragmentation with apparent 
molecular masses of ~50 kDa for HA1 and ~28 kDa for HA2 (Fig. 5, lane 3). 
The untreated samples show a major protein slightly above the 62 kDa marker 
for the HA monomer and two additional higher MW polypeptides above and 
below the 188 kDa marker that correspond to trimer and dimeric forms, 
respectively (lanes 2 and 4). No protein bands are observed for trypsin-treated 
HA that had been denatured by boiling prior to the assay, suggesting complete 
proteolytic degradation of the denatured HA protein (lane 5).  
 
 Figure 5. SDS-PAGE gel of the HA trypsin resistance 
assay. H3 HA samples (125 µgs) were left untreated 
(lanes 2 and 4) or treated with 50 µg/ml trypsin (lane 3 
and 5) for 30 minutes on ice, and then analyzed by 
SDS-PAGE. The H3 samples in lanes 4 and 5 were 
boiled for 10 min prior to the assay and serve as 
controls for denatured protein. Lane 1 contains  MW 
markers and lane 6 trypsin endoprotease (26 kDa).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Properly folded trimers of HA have been shown to join together end-to-end upon 
removal of detergent to form ‘rosettes’ visible by electron microscopy (EM) (Sato et 
al., 1983). H3 HA specimens from this study have been prepared and examined by 
EM. As shown in Figure 6, a highly dense arrangement of rosette structures is 
observed containing six to eight trimers or spikes. 
 
 Figure 6. Electron micrograph of H3 HA. A specimen 
of purified H3 HA (600 µg/ml in 10 mM Na 
phosphate, 0.01% Tween-20, 0.15 M NaCl pH 7.4) was 
prepared on a carbon 300-mesh grid, negatively stained 
with 1% phosphotungstic acid, and viewed with a Zeiss 
EM10A transmission electron microscope at a 
magnification of 80,000×. 
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Discussion 
 
The baculovirus-insect cell expression system supports the production of full-length 
HA molecules for a recombinant trivalent influenza vaccine. Recombinant 
baculovirus transfer plasmids for the expression of full-length HA molecules were 
constructed and cotransfected with AcMNPV baculovirus genomic DNA. Cell 
supernatants were subjected to plaque assay and the resultant isolated plaques 
containing recombinant baculoviruses were analyzed for expression of full-length, 
recombinant HA. The best candidates for protein expression as judged by SDS-PAGE 
and immunoblotting were selected and scaled to create virus stocks for infection of 
SF+ cells. Optimal cell culture conditions for production of the recombinant proteins 
were determined and 45-L fermentations were completed for each of the three HA 
antigens of the trivalent vaccine. The described process yields 2-4 mgs of highly pure 
HA per liter of culture. These yields are being improved through high-density cell 
culture, and improvements in the extraction of soluble HA from the insect cell 
membrane. The washing of the cell pellet prior to HA extraction from the cellular 
membrane results in HA losses (Fig. 2, lanes 2 and 4) and further development is 
needed to evaluate the necessity of this step. 
Recombinant HA proteins produced in the BEVS system are full-length, and 
largely uncleaved, indicating that insect cells lack the proteases that convert the 
molecule into its mature form of HA1 and HA2 subunits covalently linked by a 
disulfide bond. Although different from the cleaved HA molecules of TIV, full-length 
baculovirus-derived HAs associate into homotrimers, a molecular form shown to 
induce immunogenicity in healthy young and elderly adult populations [Johansson, 
1999; Powers et al., 1995; Treanor et al., 1996; Lakey et al., 1996; Powers et al., 
1997; Treanor et al., 2001].  
Three assays based on hemagglutination activity, trypsin resistance, and 
electron microscopy are currently in place to verify the correct tertiary and quaternary 
structure of HA proteins that is essential for biological activity and immunogenicity. 
The amino terminal HA1 region of HA forms a globular headpiece containing five 
antigenic sites and a receptor binding site used in viral attachment during infection. 
Purified HA molecules having a correct structure and an intact receptor binding site 
will recognize sialic acid residues on the surface of RBCs in a standard 
hemagglutination assay. This assay has been useful in identifying purification 
conditions that potentially alter the structure and lead to permanent inactivation of the 
protein. For example, exposure to high ionic strength (> 1 M NaCl) media has been 
found to affect the protein structure and reduce agglutination activity even after its 
removal (not shown). Also, agglutination activity is irreversibly reduced at acidic pH 
(= 5.5). This phenomenon is in agreement with the intended biological function of HA 
as a membrane fusogen undergoing a dramatic pH-induced conformational change 
that results in the fusion of the viral envelope with the endosomal membrane of the 
host cell. As described above, in baculovirus-insect cell-derived HA, the HA2 fusion 
peptide is not released from the HA1 domain for fusion; nevertheless, a structural 
change is suspected to occur at low pH leading to the readily observed reduction in 
agglutination activity (not shown).  
HA is unusually stable and biologically active when in its properly folded 
trimeric state. Trypsin sensitivity is useful as an assay for trimer formation. Each 
correctly folded full-length molecule of the trimer is cleaved by the protease trypsin at 
a single basic site to generate HA1 and HA2 as shown for H3 HA in Figure 5 (lane 3). 
The internally cleaved mature form of HA is resistant to further proteolysis despite 
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the presence of 54 potential digestion sites. In contrast, monomeric and denatured HA 
molecules are more susceptible to trypsin and are partially or completely degraded by 
the protease as shown in Figure 5 for heat denatured HA. Denaturation results in 
degradation of the protein into smaller peptides not resolvable by the SDS-PAGE 
analysis (Fig. 5, lane 5). Thus, the trypsin resistance assay is useful for confirming the 
correct quaternary structure of HA molecules as demonstrated here with H3 HA.  
Properly folded HA trimers associate end to end through their hydrophobic 
transmembrane domains to form micellular structures called rosettes (Sato, 1983). As 
shown in Figure 6 for H3 HA, the rosettes are visible with EM. Each spike of the 
rosette is a trimer of full-length, uncleaved HA monomers. Approximately 6-8 trimers 
participate in a single rosette. The rosette structures formed from aggregation of 
trimers at their transmembrane domains closely resemble the surface morphology of 
infectious virions having HA trimeric spikes protruding from the viral envelope. This 
higher order aggregation state observed by EM may be an indicator of HA 
immunogenicity.  
Previously, monovalent and bivalent HA molecules produced in the 
baculovirus- insect cell system were evaluated in six small human phase I/II clinical 
studies using both monovalent and bivalent preparations [Powers et al., 1995; Treanor 
et al., 1996; Lakey et al., 1996; Powers et al., 1997; Johansson, 1999; Treanor et al., 
2001]. The results of these studies are promising and indicate that a monovalent or 
bivalent HA vaccines appear to be safe and well tolerated in both young adults (ages 
18-45 years) and elderly adults (>65 years). The analysis of functional antibody titers 
(hemagglutinin-inhibition antibodies, HAI, and neutralizing antibodies) and binding 
antibody titers elicited by HA vaccines appears to comparable to that of TIV. Greater 
stimulatory effects have been observed for the recombinant HA vaccine using 
bivalent rather than monovalent preparations, and also with higher doses of HA. The 
higher purity of the HA vaccines has allowed the use of higher doses (up to 135 
µgs/HA based on BCA determinations) without an increase in adverse side effects 
that are more frequently reported with the TIV using significantly less HA (15 µg 
HA/strain based on SRID assay) [Williams, 1993]. The addition of alum adjuvant has 
not been found to significantly improve antibody response. From these studies, it has 
been inferred that the uncleaved state of HA expressed in insect cells and the potential 
differences in glycosylation compared to mammalian derived proteins does not affect 
the immunogenicity of the product.  
A clinical trial using the production and purification scheme discussed here for 
H3 HA will determine the efficacy of higher doses (15 µg, 45 µg and 135 µg) in a 
trivalent formulation in the elderly adult population and compare its performance with 
the current TIV (see Chapter 6). An enhanced stimulatory effect is expected from the 
inclusion of a third HA molecule and at the higher dosage (135 µg). The influenza 
vaccine based on recombinant HA produced in BEVS offers several potential 
advantages over TIV. The influenza HA antigens are produced under safe, sterile and 
stringently controlled conditions using a scaleable fermentation process in insect cells. 
Purification procedures for HA do not include virus inactivation or organic extraction 
procedures, thus avoiding possible denaturing effects and additional safety concerns 
due to residual toxic chemicals in the vaccine. The HA protein is highly purified and 
does not contain contaminants from eggs, eliminating possible adverse reactions in 
individuals with severe egg allergies. Selection or adaptation of influenza virus strains 
that produce at high levels in eggs is not required, making it possible to choose the 
best genetic match between the vaccine strains and the influenza virus strains that are 
causing disease. The cloning, expression, and manufacture of HA influenza vaccine 
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can be very rapid allowing for strain selection later in the year when more reliable 
epidemiological data are available.   
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Chapter 3 
Expression and Purification of an Influenza Hemagglutinin 
One Step Closer to a Recombinant Protein-Based Influenza Vaccine 
 
 
Abstract 
Numerous human infections with avian influenza viruses in Asia in recent years have 
raised the concern that the next influenza pandemic is imminent. The most effective 
way to combat influenza is through the vaccination of the public. However, a 
minimum of 3-6 months is needed to develop an influenza vaccine using the 
traditional egg-based vaccine approach. The influenza hemagglutinin protein (HA), 
the active ingredient in the current vaccine, can be expressed in insect cells using the 
baculovirus expression vector system and purified rapidly. An influenza vaccine 
based on such a recombinant antigen allows a more timely response to a potential 
influenza pandemic. Here, we report an innovative monitoring assay for recombinant 
HA (rHA) expression and a rapid purification process. Various biochemical analyses 
indicate that the purified rHA is properly folded and biologically active.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was slightly modified from: Wang K, Holtz KM, Anderson K, Chubet R, 
Mahmoud W, Cox MM (2006): Expression and purification of an influenza 
hemagglutinin--one step closer to a recombinant protein-based influenza vaccine. 
Vaccine 24: 2176-85.  
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1. Introduction 
  
Influenza is a highly contagious, acute viral respiratory disease, which causes 
significant morbidity and mortality worldwide each year [Glezen, 1982; Cox and 
Subbarao, 1999; Hilleman, 2002]. Influenza viruses are single-stranded ribonucleic 
acid (RNA) viruses surrounded by a lipid containing envelope spiked with two 
glycoproteins: hemagglutinin (HA) and neuraminidase (NA). These glycoproteins, 
and HA in particular, have been recognized as key antigens in the host response to 
influenza virus in both natural infection and vaccination [Clements et al., 1986; 
Skehel and Wiley, 2000]. The viruses are well known for their ability to mutate to 
circumvent immunity and reinfect the host. An antigenic shift, a major antigenic 
change of the virus due to the genetic re-assortment of two subtype strains that co-
infected a host, can cause an influenza pandemic since the population may have no 
inherent immunity against the new strain [Wood and Robertson , 2004; Stephenson et 
al., 2004]. The avian influenza A (H5N1) epizootic outbreak, numerous human 
infections with H5N1 in Asia in recent years, events such as the infection of two 
nurses attending to avian influenza patients in Vietnam (WHO, March 14, 2005) and a 
possible person-to-person transmission in a family cluster of the disease in Thailand 
[Ungchusak et al., 2005], continue to raise concern that the next influenza pandemic 
is imminent.  
A proven, effective way to combat influenza is through vaccination of the 
public using the trivalent vaccine produced in embryonated chicken eggs. In the 
current process, three influenza strains selected by WHO/CDC are propagated in 
chicken eggs, chemically inactivated, and semi-purified. The egg-based technology, 
however, is unable to respond to a pandemic crisis. Vaccine development and 
production takes several months following the identification of potential strains and 
typically requires the reassortment with a high yield strain to obtain adequate growth 
properties [Audsley and Tannock, 2004; Sheridan, 2004; Cox, 2005; Osterholm, 
2005]. A minimum of 3-6 months is needed to develop an influenza vaccine using this 
approach. More importantly, the H5 avian influenza strains responsible for recent 
epizootic outbreaks involving numerous human infections are lethal to chicken eggs 
used for vaccine production and to the chickens that lay the eggs. If the 2003 severe 
acute respiratory syndrome (SARS)-coronavirus outbreak serves as a guide, the next 
influenza pandemic will likely have global consequences spreading within weeks, if 
not within days. Thus, a system that can rapidly produce new influenza vaccine is 
needed to prevent or to effectively reduce th; e impact of pandemic influenza.  
Two new approaches have shown great promise to replace the egg-based 
technique Audsley and Tannock, 2004; Sheridan, 2004; [Cox, 2005]. One is cell 
culture-based, and the other is recombinant protein (antigen)-based. The cell culture-
based approach involves production of influenza viruses in cell culture followed by 
the same virus inactivation and purification procedures currently used in the 
downstream processing of the egg-based virus. The advantages are: cell cultures are 
easier to handle and can be scaled up in a short period of time. The influenza vaccines 
produced with this approach have been tested in Phase I and Phase II clinical trials 
and were found to be safe and at least as effective as the vaccines produced in 
embryonated chicken eggs [Alymova et al., 1998; Brands et al. 1999; Percheson et 
al., 1999]. A limitation of the cell culture-based approach is that the process still 
requires the production of a high-yielding re-assorted virus. This process also may 
introduce cell line specific mutations in the viral genes that can lead to the selection of 
variants with antigenic and structural changes in the HA protein, potentially resulting 
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in less-efficacious vaccines [Schild et al., 1983; Robertson et al., 1985; Meiklejohn et 
al., 1987]. Additional hurdles include: the production and handling of a dangerous 
virus requires the availability of high containment facilities; mammalian cells can 
harbor animal viruses that may lead to safety concerns; the residues from the 
expressing cells may cause some unknown side-effects since no thorough purification 
process has been introduced into the manufacturing process. On the other hand, the 
recombinant protein-based approach involves production of viral antigens such as HA 
and NA in cell culture with recombinant DNA technology and utilization of the 
purified antigens as the active ingredients in the vaccine. The rHA influenza vaccines 
developed using the baculovirus-insect cell expression system has been tested in 
several Phase I and Phase II human clinical trials involving over 1,200 subjects that 
demonstrated safety, immunogenicity and efficacy [Powers et al., 1995; Treanor et 
al., 1996; Lakey et al., 1996; Powers et al., 1997; Treanor et al., 2001]. In elderly 
adults, rHA vaccine is equally or more immunogenic than the egg-based vaccine 
[Treanor et al., 2006]. Interestingly, two H1N1 rHA vaccines (derived from two 
strains of A/New Caledonia/20/99 or A/Texas/36/91) provided partial protection 
against the lethal challenge of a reconstructed highly lethal 1918 pandemic influenza 
virus (also a H1N1 strain) in mice, suggesting that cross protection against drifted 
strains is definitely feasible [Tumpey et al., 2004]. To meet the challenge of a 
potential influenza pandemic, however, a reliable expression system and a quick, 
efficient downstream purification process are needed. In this chapter, a rapid process 
is reported capable to purify rHA (H1N1, A/New Caledonia/20/99) from an insect cell 
bioreactor to 95% purity within 6h with a 57% overall yield. Since all the 
chromatographic media used here are chemically stable and commercially available, 
the process can be easily scaled up in a GMP facility. Various biochemical analysis 
indicated that he purified rHA is properly folded and biologically active. In addition, 
we also developed a quick, simple analytical assay to monitor the expression of rHA 
in the insect cell fermentor to ensure the rHA production.  
 
 
2.  Materials and Methods 
 
2.1. Cloning and expression of influenza HA 
The influenza vaccine strain - A/New Caledonia/20/99 (H1N1) – was obtained from 
the CDC. The full-length HA gene (containing the HA1 and HA2 genes) from the 
influenza viruses was cloned using RT-PCR and inserted into a baculovirus transfer 
vector developed by Protein Sciences Corporation. This specialized vector contained 
the promoter from the baculovirus polyhedrin gene flanked by sequences naturally 
surrounding the polyhedrin locus. Next, the transfer vector was co-transfected into 
insect cells with the linearized baculovirus genomic DNA (Autographa californica 
Multiple Nuclocapsid Polyhedrosis Virus) depleted of the polyhedrin gene and part of 
an essential gene downstream of the polyhedrin locus. The homologous 
recombination between the transfer plasmid and the linearized viral DNA rescued the 
virus, resulting in recovery efficiencies of recombinant virus of nearly 100%. 
Recombinant viruses were then selected by plaque assay. The plaque-derived 
recombinant baculovirus was then used to create a virus stock by infecting 
increasingly larger cultures of the proprietary insect cells (expresSF+®, derived from 
Sf9 cells) in serum-free culture medium (Protein Sciences Fortified Medium). The 
virus stock was then used to infect insect cells (2.0 x 106 cells/ml) to produce rHA in a 
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15-liter Applikon bioreactor. The multiplicity of infection (MOI) was 1 (i.e. one 
plaque-forming unit [pfu]/cell was used) for this experiment.  
To monitor the infection process and the expression of HA, 4 ml samples were 
taken from the bioreactor at various times. One milliliter was used for analyzing the 
changes in cell density, cell viability and cell size distribution. Two milliliters were 
centrifuged at 1600 rpm. The supernatant and pellet were stored separately at – 80o C 
to be used the single radial immunodiffusion assay (SRID), gel and blot analysis. One 
milliliter was used for hemadsorption analysis. The remainder of the bioreactor 
content was used for protein purification. 
 
2.2. Hemadsorption assay 
To 0.5 ml fermentation samples (insect cells uninfected, infected with recombinant 
baculovirus containing HA genes, and infected with recombinant baculovirus 
containing a non-HA gene) in a 1.5 ml Eppendorf tube, 0.10 ml of 5% chicken red 
blood cells (RBCs [Charles River – Spafas, North Franklin, CT]) in PBS was added 
and shaken gently for 10 min at room temperature. At the end of the incubation, the 
tube was flipped gently for five times to get a homogenous suspension. Then, 10 µl of 
the suspension was pipetted on a glass plate and observed under a microscope (CK2, 
Olympus Optical Co., Japan) in three representative view fields. On average about 20-
70 insect cells were counted in each field. To reduce the chance of false positives, 
only the insect cells attached by three or more RBCs were counted as RBC-bound 
insect cells. The percentage of RBC-bound insect cells against the total insect cells in 
each time point was calculated from three fields. 
 
2.3.  Cell analysis 
At each time point, 1.0 ml of fermentation sample was analyzed with an automated 
cell analyzer (Cedex AS20, Innovatis GmbH, Germany) for cell density, cell viability 
and cell size distribution using the procedure described by the manufacturer. 
 
2.4. Buffers and columns 
Buffer A: 20 mM sodium phosphate, 1.0 mM EDTA, 0.01 % Tergitol-NP9, 5% 
Glycerol, pH 5.89. Buffer B: 20 mM sodium phosphate, 0.03 % Tergitol, 5% 
Glycerol, pH 7.02. Buffer C: 20 mM sodium phosphate, 150 mM NaCl, 0.03 % 
Tergitol, 5% Glycerol, pH 7.02. Buffer D: 40 mM sodium phosphate, 0.05 % Tween-
20, 5% Glycerol, pH 7.20. Buffer E: 100 mM sodium phosphate, 0.05 % Tween-20, 
5% Glycerol, pH 7.20. Buffer F: 500 mM sodium phosphate, 0.05 % Tween-20, 5% 
Glycerol, pH 7.20. Buffer G: 10 mM sodium phosphate, 150 mM NaCl, 0.01 % 
Tween-20, pH 7.22. Sanitation buffer: 1.0 M NaCl, 0.5 M NaOH. 
UNOsphere-Q (Bio-Rad, Hercules, CA) column, ø1.6 cm x 10 cm, 20 ml; SP-
Sepharose Fast Flow (GE/Amersham/Pharmacia, Piscataway, NJ) column, ø1.6 cm x 
10 cm, 20 ml; Hydroxyapatite Type I column (HX-I, Bio-Rad, Hercules, CA), ø1.0 
cm x 4.6 cm, 3.6 ml. 
  
2.5. Purification procedure 
The fermentations producing rHA were harvested by centrifugation at 56-65 h post 
infection. The cell pellet (approximately 6.4 g) was extracted with 225 ml of 1 % 
Tergitol NP-9 in buffer A by stirring on a magnetic stirrer at 4o C for 30 min. The 
extract was clarified by centrifugation at 10,000 x g for 25 min. The supernatant was 
loaded on Q/SP columns (equilibrated with Buffer A) in tandem at a flow of 5 
ml/min. After loading, the columns were washed with 140 ml of Buffer A. Then, the 
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columns were disconnected. HA was eluted from the SP column with 140 ml of 
buffer B and 80 ml of buffer C consecutively. The Q/SP columns were regenerated by 
washing with 5 column volumes (CV) of sanitation buffer and 5 CV of water and 
equilibrated with 5 CV of buffer A. 
The HA fraction in buffer B (40 ml) was loaded on a HX-I column at 2 
ml/min. The column was washed with 18 ml of buffer B. The HA was eluted from the 
HX-I column with increased phosphate concentration (buffers D, E and F). The HA 
preparation in buffer D was further purified and concentrated by ultrafiltration with a 
stir cell using a 100 kDa Molecular Weight Cut-off (MDCO) regenerated cellulose 
membrane with buffer G. The HX-I column was regenerated by washing with 10 CV 
of water, and equilibrated with 10 CV of buffer C. 
 
2.6. Single radial immunodiffusion (SRID) 
The rHA contents in all preparations were determined with SRID assay as described 
by Williams (1993) and Manchini  et al. (1965). The assay is based on the diffusion of 
rHA into a 1% agarose gel containing antibodies against the HA. The interaction 
between antigen and antibody produces a precipitation ring of which the size is 
directly proportional to the amount of antigen applied. The diameters of the rings in 
the SRID assay were determined with a measuring magnifier (Baush/lomb, 81-34-38). 
The diameters of the precipitate ring were used to determine the actual concentrations 
based on standards provided by the Center for Biologics Evaluation and Research of 
FDA. 
 
2.7. Deglycosylation  
For complete deglycosylation, 20 µg of purified rHA was deglycosylated with 5,000 
units of peptide-N-glycosidase F (PNGase F, New England BioLabs, Beverly, MA, 
USA) or Endoglycosidase H (Endo H, New England BioLabs, Beverly, MA, USA) at 
37oC for 60 min as described previously [Maley et al., 1989]. For limited 
deglycosylation, 20 µg of rHA was treated with 0.2 µg of trypsin on ice for 30 min. 
The digestion was stopped by adding 10x denaturing buffer and boiling for 5 min. 
Then the trypsin treated rHAs were deglycosylated with 2, 20 or 200 units of PNGase 
F or Endo H on ice, at 25oC or at 37oC for 2-60 min. The reactions were stopped by 
adding 2x SDS sample buffer and boiling for 5 min. The protein species at various 
deglycosylation stages were resolved on SDS-PAGE.  
 
2.8. Other biochemical analyses  
Vaxigrip influenza vaccine was purchased from Canada Drug Delivery (Nanaimo BC, 
Canada). The purity of rHA was measured on SDS-polyacrylamide gels stained with 
Coomassie blue using scanning laser densitometry (model 710, Bio-Rad, Hercules, 
CA, USA) and peak integration analysis. The total amino acid analysis was carried 
out with a Beckman amino acid analyzer at Keck Facility of Yale University. The N-
terminal amino acid sequence analysis was executed at the Protein Core Facility of 
Columbia University. The molecular size of the purified rHA was analyzed on size-
exclusion columns (TSK-4000, 7.5 x 300 mm, TosaHaas, Japan) at a constant flow 
rate of 0.8 ml/min, using protein molecular mass markers as reference (Sigma, St. 
Louis, USA) as previously described [Wang and Spector, 1994]. Elution buffer: 50 
mM sodium phosphate, 50 mM NaCl and 0.001% NaN3. A trypsin resistance assay 
was carried out by incubating rHA for 30 min.at 0ºC without or with 50 µg/ml L-
(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin as described 
by Copeland et al. (1986). For this assay, the denatured HA was produced by boiling 
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rHA for 5 min. Hemagglutination activity assays were done essentially as described 
by Barrett and Inglis (1991) with a 0.5% solution of fresh chicken red blood cells in a 
U-bottom 96-well microtiter plate.  
 
 
3.  Results 
 
3.1. Monitoring the expression of rHA in insect cell 
A critical issue in production of a therapeutic protein using recombinant DNA 
technology is determining when to harvest the fermentation [Molowa and Mazanet, 
2003; Palomares et al., 2004]. Too early, the yield may be suboptimal. Too late, the 
expressed protein may be degraded by a variety of proteases released during the lytic 
process of infected cells. Thus, a rapid and sensitive assay is needed to monitor 
protein expression and to choose the right harvest time. HA is well known for its 
ability to bind the sialic acid on the surfaces of red blood cells (RBCs) and agglutinate 
these cells [Barrett and Inglis, 1991]. This phenomenon has been successfully used to 
detect cells and tissues infected with influenza viruses [Flint et al., 2004]. To 
determine whether the insect cells infected with the recombinant baculoviruses 
containing the HA gene can also agglutinate RBCs, both uninfected and infected 
insect cells were incubated with RBCs for 10 min. and observed under a microscope. 
In the uninfected insect cell sample, the RBCs (the smaller cells) were scattered 
around on the slide, and no specific binding of RBCs to the insect cells (the larger 
cells, about 16 µm in diameter) was observed as (Fig. 1a). On the other hand, most of 
RBCs were bound to the insect cells infected with baculovirus containing the HA 
gene derived from influenza strain A/New Caledonia/20/99 (H1N1) (Fig. 1b). This 
method also works for expression of the HAs derived from other strains such as 
B/Jiangsu/10/2003 (Fig. 1c) and A/New York/55/2004 (H3N2) (data not shown). To 
verify that the observed hemadsorption is due to the HA genes and not to the other 
genes expressed by the baculovirus, insect cells infected with recombinant 
baculovirus containing a non-HA gene were also incubated with RBCs. In this case, 
no binding of RBCs to insect cells was observed (Fig. 1d). These observations clearly 
demonstrate that the binding of RBCs to the surface of insect cells is HA expression 
dependent, not infection dependent. The data also support the conclusion that the HAs 
expressed in insect cells are displayed at the cell surface, are properly folded and 
biologically active.  
This hemadsorption assay was further optimized to monitor the expression of 
HA during fermentation. Even though the infection of insect cells can be seen by 
observing morphological changes as early as 6 hours post infection (HPI), the first 
binding of RBCs to insect cells was only observed around 23 HPI, when about 20% of 
insect cells were bound by three to eight RBCs. Almost all insect cells were infected 
at 23 HPI according to cell morphology. The binding reached its peak around 45-55 
HPI, when 70-80% of the insect cells were bound by 8-20 RBCs (in some 
fermentations, almost all insect cells were bound by RBCs during this time), as shown 
in Table 1. At the peak of hemadsorption, clusters of 20-200 insect cells agglutinated 
by RBCs have also been observed. Later around 70 HPI, the binding gradually 
reduced to 30-40% of the insect cells, most likely caused by the breakdown of some 
infected cells and the loss of cell membrane, as evidenced by the rapid decrease of 
cell viability. To determine the rHA levels in the fermentation at each sampling time, 
the single radial immunodiffusion (SRID) assay has been used, since it is a simple, 
reproducible technique, and relatively unaffected by other proteins in the crude extract 
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[Mancini et al., 1965; Williams, 1993]. Consistently, the RBC binding to insect cells 
correlated well with the HA levels determined by SRID. Late HA expression is 
expected because the HA gene is regulated by the polyhedrin promoter, which is a 
late stage promoter in baculovirus infection. Similar results were also obtained for the 
expression of other HAs such as B/Jiangsu/10/2003 and A/New York/55/2004 (data 
not shown).  
 
  
(a) (b) 
  
(c) (d) 
Figure 1. Monitoring rHA expression with hemadsorption. (a) Uninfected insect cells. (b) 
The insect cells infected with the baculovirus containing the HA gene from the A/New 
Caledonia/20/99 (H1N1) influenza virus. (c) The insect cells infected with the baculovirus 
containing the HA gene from the B/Jiangsu/10/2003 influenza virus. (d) The insect cells 
infected with the baculovirus containing a non-HA gene.  
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Table 1.  Possible correlation among time post infection (HPI), hemadsorption, cell viability and HA 
yielda  
HPIb % Binding Viability HA (mg/L) 
0 0 92.9 0 
6 0 92.9 0 
23 20 87.6 4 
30 30 88.2 7 
46 65 74.7 18 
50 80 52.4 20 
54 70 50.1 20 
70 40 21.8 11 
75 30 16.1 11 
a HA yield was determined by SRID assay. The MOI using for the experiment was one. 
b hpi = hours post  infection 
 
3.2. Designing and optimizing the rHA purification process 
A major challenge in the biotechnology industry is purification of biologically active 
recombinant proteins [Ikonomou et al, 2003; Andersen and Krummen 2002]. An ideal 
purification process should be mild, efficient and capable of achieving high purity in a 
short period of time. Accordingly, each purification step has to be designed carefully 
to optimize the whole process. As demonstrated in the hemadsorption studies, rHAs 
are expressed, folded and transported to the cell membrane at a late stage. To extract 
rHA from the cell membranes, several non-ionic detergents at various concentrations 
were tested for their efficiency. The best result was obtained using 1% Tergitol NP-9. 
To get a relatively clean extraction, a magnetic stirrer was used to avoid the disruption 
of cell nuclei and other organelles. The extract was clarified by centrifugation to 
remove cell nuclei and other debris.  
The HA monomer of the A/New Caledonia/20/99 influenza virus strain 
consists of 547 amino acids with a theoretical molecular mass of 63,156.43 kDa and a 
pI of 6.30. Therefore, this rHA has the potential to be bound on cation-exchange 
media like SP using a lower pH buffer and eluted with a higher pH buffer to achieve 
primary purification and concentration. The supernatant of the extract was loaded on 
UNO Sphere Q/SP columns in tandem. The anion-exchange Q column acts as a 
scavenger by binding the negative-charged impurities that may foul the SP column. 
After loading and washing, the columns were detached and eluted separately. As 
shown in the chromatogram (Fig. 2a), about 50% of the proteins flow through Q/SP 
columns, a small amount of protein elutes from the SP with the pH 7 buffer and the 
rest of the proteins bind tightly to either the SP or the Q column. As shown on the 
SDS-PAGE (Fig. 2b), the rHA captured on the SP column at pH 6 was selectively 
eluted by a shift to pH 7. The pH shift resulted in a 14-fold increase in HA purity 
based on densitometry of the SDS-PAGE gel.  
To further purify rHA, use of hydroxyapatite type I (HX-I) media was 
explored. The binding preference of HX-I media is significantly different from the 
ion-exchange media, and yet the binding and eluting conditions are relatively mild so 
as to preserve the biological activity of the target protein [Schroder et al., 2003; 
Karlsson and Winge, 2003]. Thus, the pH 7 SP column eluate was loaded on a HX-I 
column. After washing, rHA was eluted from the column by increasing the phosphate 
concentration. As shown in Fig. 2c, most rHA was eluted in 40 mM phosphate, and 
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there was a small loss in the wash and in the 100 mM phosphate elution. The purity 
was increased from 52% to 91% according to the densitometry of the SDS-PAGE.  
However, there was still a protein contaminant of about 36 kDa in the 
preparation as revealed in lane 5 of Fig. 2c. Since the size of the rHA trimer is around 
210 kDa, the difference in size between rHA and this impurity could be explored to 
remove this impurity. Thus, the 40 mM phosphate eluate was further purified with 
ultrafiltration using a stir cell (100 kDa MWCO). As demonstrated in Fig. 2d, the 36 
kDa band (lane 5) was selectively removed from the retentate. The purified rHA 
migrated in SDS-PAGE gel as a single monomeric polypeptide (rHA) with an 
apparent molecular weight of approximately 70 kDa. On the blot, a small amount of 
rHA1 and rHA2 (the cleavage products of rHA) were also observed, with apparent 
molecular masses of ≈50 and ≈28 kDa, respectively (data not shown). Trace amounts 
of rHA dimers and trimers were also detectable, with apparent molecular weights of ≈ 
140 and ≈ 220 kDa, respectively.  
As summarized in Table 2, the process described here can purify rHA from the 
fermentation to 95% purity within 6 hours with a 57% overall yield. The largest single 
step loss (27%) is on the HX-1 column.  
 
Table 2. Stepwise mass balance of A/New Caledonia rHA purification by SRID assay 
 
HA 
(µg/ml) 
Volume 
(ml) 
HA 
(mg) 
Puritya 
(%) 
Step 
Recovery (%) 
Total 
Recovery (%) 
Starting 
Material 
53 225 12 3.6   
Q/SP 240 40 9.6 52 80 80 
HX-1 280 25 7.0 91 73 58 
Ultrafiltration 700 9.1 6.4 99 91 53 
a Purity was determined by the densitometry of SDS-PAGE. 
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a 
 
b c d 
 
Figure 2. The purification process of rHA. (a) The chromatogram of primary purification and 
concentration on Q/SP columns. (b) The SDS-PAGE of Q/SP fractions, lanes 1-6 are molecular markers, 
applied sample, flow through, wash, pH 7 (buffer B) eluate, and buffer C eluate, respectively. (c) The 
SDS-PAGE of secondary purification on HX-I, lanes 1-6 are molecular markers, applied sample, flow 
through, wash, 40 mM phosphate eluate, and 100 mM phosphate eluate, respectively. (d) The SDS-
PAGE of step-wise purification, lanes 1-5 are molecular markers, Q/SP applied sample, HA after the 
primary purification, HA after the secondary purification, HA after the final polish using ultrafiltration. 
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3.3. Characterizing rHA Protein  
To confirm the authenticity of rHA, the purified protein was examined by N-terminal 
amino acid sequencing and total amino acid analysis (AAA). The N-terminal amino 
acid sequence matched the predicted one (10 cycles were used) and the chitinase 
signal sequence (as described in Chapter 2 [the first 17 amino acids]) of the full-
length HA gene was absent in rHA. The measured amino acid composition of the 
purified rHA was consistent with the theoretical one (data not shown). The 
authenticity of rHA was further verified by Western blot analysis using A/New 
Caledonia/20/99 antibody provided by the Food and Drug Administration (FDA) (not 
shown) 
The purified rHA in 0.005% Tween/PBS solution was analyzed using size-
exclusion chromatography. It was eluted as a single peak at 9.1 min as shown in Fig. 
3a, corresponding to a molecular mass around 800-1000 kDa, likely a complex of four 
to five HA trimers ((4-5) x 3 x 70 kDa). To test whether the purified rHA still retained 
its native structure, the purified protein was treated with trypsin on ice (as described 
Chapter 2). As shown in lane 3 of Fig. 3b, rHA was cleaved into only two bands, 
HA1-50.9 kDa and HA2-27.5 kDa. On the other hand, the heat-denatured rHA was 
digested into numerous small fragments. The trypsin-resistance data demonstrate that 
the rHA expressed in insect cells folded properly and retained its native structure after 
purification. 
Since glycosylation may play an important role in the biological function of 
HA [Schulze, 1997; Klenk et al., 2002; Helenius and Aebi, 2004], it is of interest to 
explore whether the rHA produced in insect cells is properly glycosylated. Thus, rHA 
was deglycosylated with peptide-N-glycosidase F (PNGase F) or endoglycosidase H 
(Endo H) and resolved on SDS-PAGE. As shown in Fig. 3c, the untreated HA 
migrated at 70.4 kDa, PNGase F deglycosylated HA at 57.9 kDa, and Endo H treated 
HA at 64.8 kDa, respectively. These data indicate that the rHA produced in insect 
cells is indeed glycosylated with N-linked oligosaccharide side chains. About 5.6 kDa 
of oligosaccharide chains have a high mannose content susceptible to Endo H, and 6.9 
kDa of oligosaccharide chains have low mannose residues resistant to Endo H. To 
assess the number of N-linked oligosaccharide chains, the trypsin treated rHA was 
subjected to limited deglycosylation with PNGase F or Endo H under a variety of 
conditions. On the SDS-PAGE of PNGase F treated samples (Fig. 3d), there are seven 
distinguishable HA1 forms, 50.9, 49.0, 46.8, 45.2, 43.3, 42.0 and 39.8 kDa, and 2 
HA2 polypeptides 27.1 and 25.4 kDa, respectively. On the SDS-PAGE of Endo H 
treated samples (Fig. 3e), there are three distinguishable types of HA1 molecules, 
51.2, 49.4 and 46.5 kDa, and one HA2 of 27.1 kDa. The data suggest that there are six 
N-linked oligosaccharide chains in the HA1 region, and two of them have a high 
mannose content. There is only one N-linked oligosaccharide chain in the HA2 
region, which is likely a hybrid or a complex oligosaccharide. Consistently, there are 
six predicted N-linked glycosylation sites in the HA1 region and one predicted N-
linked glycosylation site in the HA2 region of A/New Caledonia/20/99 HA 
(schematically shown in Fig. 5, Chapter 1), according to the sequence analysis 
(NetNGlyc) at Technical University of Denmark [Web link 3-1]. 
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Figure 3. Characterization of rHA. (a) The SEC profile of the purified rHA. (b) The trypsin-resistant test 
analyzed on SDS-PAGE, lanes 1-4 are molecular weight markers, native rHA, native rHA treated with trypsin, 
and heat-denatured rHA treated with trypsin, respectively. (c) Deglycosylation of rHA with PNGase F and 
Endo H, lanes 1-6 are molecular weight markers, rHA, PNGase F, rHA treated with PNGase F, Endo H, and 
rHA treated with Endo H, respectively. (d) Limited deglycosylation of rHA with PNGase F. Lane 1, molecular 
weight markers; lane 2, rHA; lane 3, trypsin treated rHA; lanes 4-8, the trypsin treated rHAs were 
deglycosylated with 2 units of PNGase F on ice, at 25oC or at 37oC for 2-60 minutes; lanes 9-11, 
deglycosylated with 20 units of PNGase F; lane 12, deglycosylated with 200 units of PNGase F. (e) Limited 
deglycosylation of rHA with Endo H. Lane 1, molecular weight markers; lane 2, rHA; lane 3, trypsin treated 
rHA; lanes 4-8, the trypsin treated rHAs were deglycosylated with 2 units of Endo H on ice, at 25oC or at 37oC 
for 2-60 minutes; lanes 9-12, deglycosylated with 20 units of Endo H; lane 13, deglycosylated with 200 units 
of Endo H.  
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 To directly compare with the A/New Caledonia antigen present in the egg-
based vaccine, the purified rHA/A/New Caledonia was formulated either alone into a 
15 µg/0.5 ml solution or with 15 µg rHA/B/Jiangsu and 45 µg rHA/A/Wyoming in a 
0.5 ml dosage (FluBlok®, the expected trade name of Protein Sciences’ rHA vaccine). 
As judged by the hemagglutination assay, FluBlok is as active as Vaxigrip (a licensed 
egg-based vaccine manufactured by Sanofi-Pasteur-Aventis) in agglutinating RBCs 
and preventing them from forming a tight pellet as shown in Fig. 4a. The antigen 
specific SRID assay is widely used to determine the concentration of active 
ingredients in a vaccine. On the SRID gel prepared with A/New Caledonia/20/99 
antibody (Fig. 4b), the diffusion ring of FluBlok is slightly larger than that of 
Vaxigrip, suggesting that FluBlok is at least equivalent to Vaxigrip for the active 
ingredient of A/New Caledonia/20/99 strain. On the SDS-PAGE (Fig. 4c), the 
FluBlok lane shows only three major proteins, representing the HA, HA1 and HA2 of 
the 3 strains, respectively. The Vaxigrip lane is complicated with the major HA band 
around 59 kDa along with many minor bands. Similarly, numerous impurities have 
also been found in other egg-based vaccines Renfrey and Watts, 1994].  
All these data demonstrate that the purified rHA expressed in insect cells is 
correctly translated, properly glycosylated and folded and biologically active. 
 
a 
b c 
 
Figure 4. The comparison 
of FluBlok with Vaxigrip. 
(a) The hemagglutination 
activities of 1.0 µg/ml 
rHA or an equivalent 
amount from each of the 
vaccines. Row A, PBS as 
negative control; Row B, 
rHA; Row C, Vaxigrip; 
Row D, FluBlok. (b) 
Evaluation of the effective 
antigen concentration with 
SRID assay. (c) The SDS-
PAGE of the vaccines. 
Lane 1, molecular 
markers; lane 2, FluBlok; 
lane 3, Vaxigrip.  
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4. Discussion 
 
The traditional egg-based vaccines have been successfully used for more than 50 
years to prevent influenza. They are reliable, effective (if there is a good match), and 
affordable. However, the production cycle of the egg-based vaccines is lengthy and 
heavily dependent on egg supply and unable to be developed quickly in response to 
the urgent need in an influenza pandemic [Audsley and Tannock, 2004; Sheridan, 
2004; Cox, 2005; Osterholm, 2005]. To replace or supplement the egg-based 
vaccines, the new vaccine has to be equally effective, reliable, economical, and 
capable of being developed and delivered in a short period of time. The work reported 
here demonstrates important progress toward an alternative influenza vaccine - the 
recombinant protein-based vaccine.  
A new analytical method based on hemadsorption has been developed to 
closely monitor the expression of HA in insect cells. This method plays a critical role 
in ensuring optimal HA production and in determining the right harvest time, in 
addition to other harvest parameters such as HPI, cell’s morphology and viability. A 
purification process has been developed to quickly purify the recombinant HA from 
the bulk harvested from the bioreactor while retaining its biological activity. 
Previously, HA purifications were heavily dependent on affinity chromatography 
using specific monoclonal antibodies or various lectins as described in Chapter 2 
[Mir-Shekari et al., 1997; Holtz et al., 2003]. Such methods are highly selective, but 
difficult to scale up to commercial levels due to a number of limiting factors: (1) some 
of the ligands will leach off the column during the purification and they must be 
removed from the final product; (2) it is difficult to regenerate an affinity column after 
use, and thus the performance declines after each use; (3) the batch to batch variations 
in the quality of affinity media make it almost impossible to have a robust purification 
process from time to time; (4) most affinity media are too expensive to be used at 
large scale. On the other hand, all chromatographic media used in the present process 
are chemically stable (can be regenerated repeatedly), commercially available and 
relatively inexpensive; thus more suitable to scale up in a GMP facility. If the 
reagents, columns and ancillary equipment are well prepared in advance, the whole 
purification can be completed in one full working day, avoiding the overnight storage 
of intermediate rHA preparation and possible inactivation of rHA. Several factors 
have made this rapid process possible. First, there is no sample manipulation between 
purification steps, which makes a quick, continuous purification process possible. 
Second, Q/SP columns are connected in tandem, combining two chromatographic 
processes into one. Third, a chemically different chromatographic media – HX-I is 
used to differentiate rHA from the remaining impurities. Unlike ion-exchange media, 
the adsorption of proteins to HX-I involves both anionic and cationic interaction. The 
calcium group can interact with carboxylate residues, whereas the phosphate group 
can bind the basic residues on the surface of the protein. The bound proteins can be 
eluted by an increasing phosphate gradient or a gradient of calcium, magnesium ions. 
It is worth to point out that the purification process described here needs to be further 
optimized for large scale production, for example, a tangential flow filter should be 
used to replace a stir cell at the final buffer exchange step. Nonetheless, we believe 
the strategies described here can also be used to develop a rapid purification process 
for other recombinant proteins.  
Biologically, FluBlok is as active as the egg-based vaccine – Vaxigrip as 
determined by the hemagglutination assay. Based on the SRID assay, FluBlok is 
equivalent to Vaxigrip for the active ingredient of A/New Caledonia/20/99 strain of 
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influenza. In challenge studies, chickens were effectively protected against the H5N1 
virus infection after inoculation with the rHA of the virus [Crawford et al., 1999]. 
Moreover, two distantly related H1N1 rHA influenza vaccines using the baculovirus-
insect cell expression system have also been demonstrated to partially protect mice 
against the lethal challenge of a recombinant 1918 pandemic influenza virus [Tumpey 
et al., 2004]. In clinical trials, the trivalent rHA vaccine (FluBlok) stimulates anti-HA 
antibody production at least as well as, and in the case of H3 rHA, superior to the 
traditional egg-based vaccine [Powers et al., 1995; Treanor et al., 1996; Lakey et al., 
1996; Powers et al., 1997; Treanor et al., 2001]. The 2004/05 influenza season Phase 
II/III field trial of FluBlok that enrolled 460 healthy subjects aged 18 to 49 further 
showed that the 45/45/45 dose was 100% efficacious in preventing culture positive 
influenza illness compared to placebo (as described in Chapter 4 and Press Release, 
Protein Sciences Corp., June 14, 2005).  
Furthermore, a recombinant protein-based vaccine, such as the FluBlok 
described here, also has other advantages over the traditional egg-based vaccines. It 
consists solely of three antigens (proteins) stored in sterile phosphate buffered-saline 
and without preservatives such as thimerosal (a mercury derivative currently used in 
the egg-based vaccine), antibiotics or adjuvants. This may explain why FluBlok has 
shown lower side effects than the licensed vaccines in clinical trials [Powers et al., 
1995; Treanor et al., 1996; Lakey et al., 1996; Powers et al., 1997; Treanor et al., 
2001]. Unlike the egg-based vaccines, no live influenza viruses, high level 
biocontainment facilities or harsh chemicals such as formaldehyde are used in 
manufacturing.  
Therefore, a reliable, effective, and affordable recombinant protein-based 
influenza vaccine can be and should be developed to meet the challenge of a potential 
influenza pandemic. For pandemic preparedness, developing and stockpiling rHA 
influenza vaccines against the present H5N1 strain may be a good option to provide 
some protection for the first response personnel and the population in the hard-hit 
areas in the case of a pandemic, and to win the precious time for manufacturing of a 
more specific influenza vaccine. 
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Chapter 4 
Safety and Immunogenicity of a Baculovirus-Expressed 
Hemagglutinin Influenza Vaccine 
 
A Randomized Controlled Trial 
 
Abstract 
 
A high priority in vaccine research is the development of influenza vaccines that do 
not use embryonated eggs as the substrate for vaccine production. A randomized, 
double-blind, placebo-controlled clinical trial was conducted at 3 US academic 
medical centers during the 2004-2005 influenza season among 460 healthy adults 
without high-risk indications for influenza vaccine to determine the dose-related 
safety, immunogenicity, and protective efficacy of an experimental trivalent influenza 
virus hemagglutinin (rHA) vaccine produced in insect cells using recombinant 
baculoviruses. Participants were randomly assigned to receive a single injection of 
saline placebo (n=154); 75 µg of an rHA vaccine containing 15 µg of hemagglutinin 
from influenza A/New Caledonia/20/99 (H1N1) and B/Jiangsu/10/03 virus and 45 µg 
of hemagglutinin from A/Wyoming/3/03 (H3N2) virus (n=153) or 135 µg of rHA 
containing 45 µg of hemagglutinin each from all 3 components (n=153). Serum 
samples were taken before and 30 days following immunization. Rates of local and 
systemic adverse effects were low, and the rates of systemic adverse effects were not 
different in either vaccine group from the placebo group. Hemagglutinin inhibition 
antibody responses to the H1 component were seen in 3% of placebo, 51% of 75-µg 
vaccine, and 67% of 135-µg vaccine recipients, while responses to B were seen in 4% 
of placebo, 65% of 75-µg vaccine and 92% of 135-µg vaccine recipients. Responses 
to the H3 component occurred in 11% of placebo, 81% of 75-µg vaccine and 77% of 
135-µg vaccine recipients. Influenza infections in the study population were due to 
influenza B and A (H3N2), and influenza A infections were A/California/7/2004-like 
viruses, an antigenically drifted strain. Seven cases of culture-confirmed CDC-defined 
influenza-like illness occurred in 153 placebo recipients (4.6%) compared with 2 
cases (1.3%) in 150 recipients of the 75µg of vaccine, and 0 cases in recipients of 135 
µg of vaccine. In this study, a trivalent rHA vaccine was safe and immunogenic in a 
healthy adult population. Preliminary evidence of protection against a drifted 
influenza A (H3N2) virus was obtained, but the sample size was small. Inclusion of a 
neuraminidase component did not appear to be required for protection. 
 
 
This chapter is modified from: Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay 
CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox MMJ.: Safety and 
Immunogenicity of a Baculovirus-Expressed Hemagglutinin Influenza Vaccine: A 
randomized Controlled Trial. JAMA, 2007; 297: 1577-82. 
This trial was registered at Clinicaltrials.gov Identifier: NCT00328107 
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Introduction 
 
All currently licensed influenza vaccines in the United States are produced in 
embryonated hen's eggs. There are several well-recognized disadvantages to the use 
of eggs as the substrate for influenza vaccines. Eggs require specialized 
manufacturing facilities and could be difficult to scale up rapidly in response to an 
emerging need such as a pandemic. It is usually necessary to adapt candidate vaccine 
viruses for high yield-growth in eggs, a process that can be time consuming, is not 
always successful, and can select receptor variants that may have suboptimal 
immunogenicity [Katz et al., 1990]. In addition, agricultural diseases that affect 
chicken flocks might be an important issue in a pandemic caused by an avian 
influenza virus strain and could easily disrupt the supply of eggs for vaccine 
manufacturing. Therefore, development of alternative substrates for influenza vaccine 
production [Cox, 2005] has been identified as a high-priority objective. 
One potential alternative method for production of influenza vaccines is 
expression of the influenza virus hemagglutinin (HA) using recombinant DNA 
techniques. In this study, we evaluated an experimental influenza vaccine consisting 
of recombinant HA (rHA) expressed in insect cells by a recombinant baculovirus. 
This alternative avoids the dependence on eggs, and is very efficient because of the 
high levels of expression obtained under the control of the baculovirus polyhedrin 
promoter. Monovalent and bivalent baculovirus-derived influenza vaccines have been 
evaluated in other studies in young adults and in community-dwelling adults over the 
age of 65 [Powers et al., 1995; Treanor et al., 1996; Lakey et al., 1996; Powers et al., 
1997]. These studies found that the vaccines are well tolerated and immunogenic. 
Recently, doses of a trivalent vaccine ranging from 15 µg to 135 µg rHA per 
component were shown to be well tolerated in elderly persons and to induce antibody 
responses at rates comparable to or superior to the licensed trivalent vaccine [Treanor 
et al., 2006]. While a clear dose-response relationship has been shown for the H3 
component of the recombinant vaccine in both healthy adults and in elderly persons, 
relatively little difference has been observed in the immune response to rHA protein 
doses of the H1 and B components ranging from 15 µg to 135 µg. The comparative 
analysis between the H1 and B components of the recombinant vaccine and the 
trivalent inactivated vaccine (TIV) has been confounded by a poor correlation 
between the antigen content of the H1 and B components in the recombinant vaccine, 
as determined by measurement of total protein content (method previously used to 
standardize the recombinant vaccine), versus the antigen content determined by single 
radial immunodiffusion (SRID), the standard measurement used for the TIVs. 
Therefore, the primary objective of the current study was to evaluate the 
immunogenicity of the H1 and B components of the vaccine when formulated at 
either 15 µg or 45 µg per component, as determined by SRID. In addition, we used 
the opportunity to follow up participants throughout the influenza season to obtain 
preliminary evidence of protective efficacy in a healthy adult population. 
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Methods 
 
Vaccine 
The vaccine used in this study consisted of purified HA proteins produced in insect 
cells using a baculovirus expression system as previously described [Treanor et al., 
2006]. Genes encoding HA were amplified by RT-PCR using the same seed viruses 
used for the licensed TIV vaccine provided by the Centers for Disease Control and 
Prevention (CDC) as template and cloned. Insect cells were infected with the 
recombinant baculoviruses and the HAs were purified as described in Chapters 2 and 
3. Because the HA produced in this system is not cleaved into an HA1 and HA2 
component, the resulting product is also referred to as rHA. The vaccine was 
formulated as a trivalent preparation containing the purified rHA of the A/New 
Caledonia/20/99 (H1N1), A/Wyoming/3/03 (H3N2) and B/Jiangsu/10/03 influenza 
viruses in phosphate-buffer saline containing 0.005% detergent without preservative. 
Monovalent hemagglutinin preparations with purity of approximately 95% of the total 
protein as determined by SDS-PAGE) were mixed to prepare the trivalent vaccine. 
The experimental vaccine was formulated at 2 different concentrations. The 
high-dose formulation contained 45 µg of each component, for a total dose of 135 µg 
of rHA per 0.5-mL dose based on the SRID values of the preblend bulk. After 
formulation, it was determined that the high dose contained 35 µg, rather than 45 µg 
of the H1 component. The low-dose formulation contained 45 µg of the H3 rHA and 
15 µg each of the H1 and B rHA, for a total dose of 75 µg of rHA. The placebo 
consisted of normal saline for injection. Vaccine and placebo were supplied in coded, 
identical-appearing single-dose vials. 
 
Clinical Study Design 
The study was conducted as a randomized, double-blind, placebo controlled study at 3 
medical centers (University of Rochester, Rochester NY; Cincinatti Children’s 
Hospital, Cincinatti, OH; and University of Virginia, Charlottesville) during the 2004-
2005 influenza season. Participants were healthy adults aged 18 to 49 years, who did 
not belong to high-priority target groups for influenza vaccination as defined by the 
Advisory Committee on Immunization Practice and who had not received previous 
influenza vaccination for the 2004-2005 season. Women of childbearing potential had 
to have a negative urine pregnancy test result at the time of randomization and be 
willing to use an adequate form of contraception during the course of the study. 
Participants were recruited by newspaper and radio advertisements, posters, and word 
of mouth. Race/ethnicity data for all participants were collected from self reports. 
Participants were compensated for each visit (≈$25). 
After screening the medical history and a physical examination to determine 
eligibility of participants, 10 mL of blood was collected from an arm vein for 
serologic studies. Participants were randomly assigned to receive a single dose of 
either rHA at 135 µg, rHA at 75 µg, or saline placebo. Vaccine was administered as a 
single intramuscular injection in the upper deltoid. 
Participants measured their oral temperature daily and maintained a diary card 
for 7 days after vaccination on which they recorded local and systemic reactions 
graded as mild (noticeable but not interfering with normal activities), moderate (some 
interference with normal activities), and severe (symptom prevented normal daily 
activities). Participants returned on day 2 and day 7 after vaccination for review of the 
diary card, change in concomitant medications and medical history and examination 
of the vaccination site. Participants returned approximately 28 days after vaccination 
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for review of interim change in medical history. In addition, 10 mL of venous blood 
was obtained from an arm vein for assessment of Day 28 antibody to influenza virus. 
A final study visit occurred at day 180 during which participants underwent a physical 
examination and review of change in medical history. 
The study protocol was reviewed and approved by the investigational review 
boards at all 3 clinical sites, and written informed consent was obtained from all 
participants prior to study entry. 
 
Surveillance for Influenza 
Following the day 28 visit, participants started to complete a weekly diary to record 
influenza symptoms, and after influenza was recognized in the community, 
participants received weekly telephone calls to review the diary and ascertain 
presence or absence of respiratory illness symptoms. Participants were instructed to 
return to the clinic for illness evaluations if they observed any acute respiratory tract 
symptoms or fever. During these illness visits, symptoms were reviewed, a brief 
physical examination was conducted, and nasopharyngeal swabs for virus culture 
were obtained. 
 
Laboratory Assays 
Serum samples were assessed for antibodies titres to each of the 3 components of the 
vaccine by hemagglutination inhibition (HAI), using standard methods. Egg-grown 
influenza A/New Caledonia/20/99 and influenza A/Wyoming/03/2003 were obtained 
from CDC, while in assays against the influenza B/Jiangsu/10/03 antigen was used, 
which was prepared in Madin-Darby canine kidney cells from a seed virus also 
supplied by CDC. Serum samples were treated with neuraminidase (receptor-
destroying enzyme, Denka Seiken, Tokyo, Japan) to remove non-specific inhibitors of 
hemagglutination prior to testing and were tested in serial 2-fold dilutions at an initial 
dilution of 1:4. Serum samples with no reactivity at 1:4 were assigned a value of 1:2. 
Assays were performed using chick red blood cells (Colorado Serum Company, 
Denver) for influenza A/New Caledonia/20/99 and B/Jiangsu/10/03 viruses and 
turkey red blood cells (Viromed Laboratories, Minnetonka, Minn) for the influenza 
A/Wyoming/03/2003 virus. 
Nasopharyngeal swabs were stored at -70°C and shipped on dry ice to a 
central laboratory (Cincinnati Children’s Hospital Medical Center), where virus 
amplification was performed in primary rhesus monkey kidney cells (Diagnostic 
Hybrids Inc., Athens, Ohio). The presence of influenza A or B viruses in the culture 
was determined by immunofluorescence using type-specific monoclonal antibodies 
(Diagnostic Hybrids Inc.). Influenza A isolates were further subtyped at Protein 
Sciences Corp. by sequence analysis of the entire HA1 region after RT-PCR 
amplification of viral RNA from Madin-Darby canine kidney cell-grown virus. 
 
Definition of End Points 
The primary safety end points for this study were the rates and severity of solicited 
and unsolicited adverse events. The primary immunogenicity end points were the 
rates of 4-fold or greater increases in serum HAI antibody to each of the 3 vaccine 
strains comparing prevaccination and 28-day post-vaccination samples. The 
prespecified primary efficacy end point was culture-documented influenza illness, 
defined as development of a CDC-defined influenza-like illness associated with 
recovery of influenza virus from a nasopharyngeal swab. A CDC-defined influenza-
like illness was defined as the presence of documented fever with body temperature 
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higher than 37.7ºC (99.8ºF) plus either sore throat or cough.   
 
Statistical Analyses 
Rates of safety end points were based on the most severe response and were evaluated 
by a χ2 test. Differences between the proportions of participants with at least a four-
fold increase in HAI antibody for each pairwise treatment group comparison were 
also tested using a χ2 test.  
The sample size for this study was primarily based on the immunogenicity end 
point. Assuming that from 60% to 80% of the participants in an active treatment 
group would have a 4-fold or greater serum HAI antibody response to any specific 
strain, inclusion of 150 participants per group would have 80% power to detect an 
approximately 13% to 14% difference in response rates between study groups. 
Although not designed primarily as an efficacy trial, with a 5% attack rate in the 
placebo group, the study had the power ranging from 14%-53% to detect vaccine 
efficacy ranging from 40%-80%. A P<.05 level was considered to be statistical 
significant. The analyses were conducted using SAS software, version 9.1 (SAS 
Institute Inc, Cary, NC). 
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Results 
 
A total of 460 participants were randomized, 458 were vaccinated, and 451 (98.5%) 
completed all study procedures. The disposition of the participants is shown in Figure 
1. Of the 460 enrolled participants, 153 were randomized to 75 µg rHA vaccine, 153 
were randomized to 135 µg rHA vaccine, and 154 were randomized to placebo. There 
were 9 participants who did not complete the study, 1 withdrew consent, 5 were lost 
to follow-up, 2 participants in the 75 µg rHA treatment group were randomized but 
not vaccinated, and 1 was incarcerated. The majority of participants were white (86%) 
and female (63%) (Table 1). The mean age was 31.7 years (range, 18 - 49 years). 
There were no differences with respect to age, sex or race/ethnicity between the 
groups.  
 
Assessment of Vaccine Safety 
The rates and severities of local and systemic symptoms reported on the diary card are 
shown in Table 2. Injection of rHA vaccine was associated with local pain at the site 
of injection that was significantly more frequent than after saline placebo and that was 
dose dependent (P<0.001 for pain, P=0.04 for tenderness). However, 97% of all 
reports of pain after rHA vaccine were rated as mild. Systemic symptoms following 
vaccination also did not occur at significantly different rates in vaccine and placebo 
recipients (P>0.07 for all comparisons). The most frequently reported systemic 
symptom following vaccination was headache. The majority (86%) of reports of 
headache were also rated as mild, and there was no difference in the frequency of 
headache between vaccine and placebo recipients (P>0.07). There were no reported 
fevers (oral temperature >37.7ºC [>99.8ºF]) following vaccination. 
Two participants (1%) in the 135 µg group experienced serious adverse events 
that were considered to be unrelated to the vaccine (1 seizure related to hypoglycemia 
and 1 newly diagnosed lobular carcinoma in situ). Two additional participants (1 in 
the 75-µg group and 1 in the 135-µg group) experienced severe adverse events (1 
infected nevus and 1 knee injury) that were also considered to be unrelated to vaccine. 
No participants discontinued the study due to adverse events and no participants died. 
 
 
Table 1. Baseline Participant Characteristics 
Characteristics Placebo (n=154) 
75µg Vaccine 
(n=151) 
135µg Vaccine 
(n=153) 
Overall 
(N=458) 
Race/ethnicity, No. (%)     
White 139 (90) 126 (83) 130 (85) 395 (86) 
Black/African American 9 (6) 12 (8) 9 (6) 30 (7) 
Latino/Hispanic 1 (1) 2 (1) 5 (3) 8 (2) 
Asian 4 (3) 10 (7) 4 (3) 18 (4) 
American Indian/Alaskan Native 0 0 1 (1) 1 (<1) 
Native Hawaiian/Pacific islander 0 1 (1) 1 (1) 2 (<1) 
Other/not stated 1 (1) 0 3(2) 4 (1) 
Male, No (%) 65 (42) 48 (32) 57 (37) 170 (37) 
Age, median (range), y 32 (18-49) 32 (18-49) 30 (18-49) 31 (18-49) 
 
 
. 
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Figure 1. Flow of Participants Through the Trial 
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Table 2. Local and Systemic Symptoms Experienced in the 7 Days Following Vaccination* 
Symptoms Placebo (N = 154) 75-µg Vaccine (n=151) 135-µg Vaccine (n=153) 
 Mild Moderate  Severe Mild Moderate Severe Mild Moderate Severe 
Arthralgias 7 (5) 1 (1) 0 7 (5) 2 (1) 0 7 (5) 1 (1) 0 
Chills 3 (2) 0 0 2 (1) 2 (1) 0 2 (1) 2 (1) 0 
Fatigue 21 (14) 7 (5) 0 21 (14) 7 (5) 0 22 (14) 3 (2) 0 
Headache 48 (31) 15 (10) 0 48 (32) 4 (3) 0 53 (35) 12 (8) 0 
Myalgias 16 (10) 3 (2) 0 24 (16) 2 (1) 0 28 (18) 3 (2) 0 
Nausea 9 (6) 1 (1) 0 5 (3) 2 (1) 0 10 (7) 3 (2) 0 
Pain 24 (16) 1 (1) 0 67 (44) 0 0 88 (58) 5 (3) 0 
Sweats 6 (4) 1 (1) 0 6 (4) 1 (1) 0 2 (1) 2 (1) 1 (1) 
Tenderness 3 (2) 0 0 12 (8) 0 0 9 (6) 1 (1) 0 
* Data are expressed as No. (%) of patients experiencing local and systemic symptoms in the 7 days 
following vaccination based on the most severe responses as reported on the diary cards. Severity was 
graded as mild (no interference with daily activities), moderate (some limitation of activity due to the 
symptom), or severe (the symptom prevents normal daily activity). 
 
Immunogenicity 
The serum antibody responses to vaccination are summarized in Table 3. Overall, 
among participants vaccinated with the rHA vaccine, the frequencies of HAI antibody 
responses (≥4-fold increase comparing day 0 to day 28) to influenza A/New 
Caledonia, B/Jiangsu, and A/Wyoming were significantly greater (range, 51% to 
92%) than was observed for participants vaccinated with placebo (range, 3 to 11%; 
p<0.001). Antibody responses were seen in most participants receiving either the 75-
µg or the 135-µg dose of rHA vaccines. However, the frequency of responses to both 
the A/New Caledonia/99 and B/Jiangsu/03 influenza viruses were significantly higher 
in the group receiving the 135-µg dose (P = .003), consistent with the higher doses of 
H1 and B components in the 135-µg vaccine. The frequency of HAI antibody 
response to the A/Wyoming/03 (H3N2) influenza virus was not different between the 
75-µg and 135-µg doses, which contained identical amounts of the H3 component. 
Similarly, there were significant differences in the day 28 geometric mean titer of 
HAI antibody between the 75-µg and 135-µg doses for both the H1 and B component, 
but not the H3 component. 
 
Table 3. Serum Hemagglutination-Inhibiting Antibody Response to Vaccination 
 
Influenza Subtype 
Placebo 
 (n=151) 
75-µg Vaccine  
(n=150) 
135-µg Vaccine 
 (n=150) 
A/New Caledonia/20/99 (H1N1) 
Prevaccination* 
26.4 (19.9-35.0) 23.9 (18.0-31.7) 22.0 (16.6-29.2) 
Postvaccination* 28.8 (22.8-36.4) 115.6 (91.5-146.2) 206.0 (163.0-260.5) 
Response, %† 3 51 67 
A/Wyoming/3/03 (H3N2) 
Prevaccination* 
72.8 (56.4-93.9) 65.5 (50.7-84.6) 74.2 (57.5-95.8) 
Postvaccination* 68.9(57.9-81.9) 933.6 (784.4-1111.2) 1028.7 (864.3-1224.5) 
Response, %† 11 81 77 
B/Jiangsu/10/03 
Prevaccination* 
6.1 (5.1-7.3) 6.4 (5.4-7.6) 5.5 (4.6-6.5) 
Postvaccination* 5.7 (4.7-6.9) 33.4 (27.6-40.4) 74.9 (61.9-90.6) 
Response, %† 4 65 92 
*Day 0 (prevaccination) and day 28 (postvaccination) geometric mean titers (95% confidence intervals). 
†Four-fold or greater increase 
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Protection Against Influenza Illness 
Participants in this study were followed throughout the subsequent influenza season 
with weekly phone calls and instructed to return to the study clinics for acute 
respiratory illness, at which time a nasopharyngeal swab for viral culture was 
obtained. A total of 116 such cultures were obtained, 43 in the placebo group, 39 in 
the 75-µg vaccine group, and 34 in the 135-µg vaccine group. The primary efficacy 
end point for this study was the development of culture-confirmed influenza illness 
meeting the influenza-like ilness case definition of the CDC; ie, presence of fever 
higher than 37.7°C (99.8°F) and sore throat, cough, or both. 
There were a total of 13 positive cultures for influenza in the study population, 
of which 10 were influenza A (all of which were confirmed as influenza H3) and 3 
were influenza B. Sequence analysis of these viruses further revealed that all of the 10 
H3N2 isolates were A/California/7/2004-like. Of these 13 cases, 9 (69%) occurred in 
individuals meeting the CDC-influenza illness case definition. The rates of culture 
positive influenza illness, the prespecified primary efficacy end point, were 7 (4.6%) 
of 153 placebo recipients, 2 (1.4%) of 150 recipients of the 75-µg vaccine dose, and 0 
of 151 recipients of the 135-µg vaccine dose. Among the 4 positive cultures in 
individuals who did not meet the CDC case definition, 1 occurred in a placebo 
recipients, 2 occurred in recipients of the 75-µg vaccine dose, and 1 occurred in a 
recipient of the 135-µg vaccine dose, so the rates of participants with a positive 
culture associated with any acute respiratory illnesses were 8/153 (5.2%), 4/150 
(2.7%), and 1/151 (0.7%) in placebo, 75-µg vaccine, and 135-µg vaccine recipients, 
respectively.  
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Discussion 
 
We evaluated the safety, immunogenicity, and efficacy of a trivalent recombinant 
hemagglutinin (rHA) vaccine. We have shown that the rHA vaccine is well tolerated 
in healthy adults and immunogenic at both doses evaluated, and we obtained 
preliminary evidence of protection against influenza infection and disease. The safety 
data generated in this study are consistent with the safety profile observed in previous 
studies of the rHA vaccine [Powers et al., 2005; Treanor et al., 1996; Lakey et al., 
2006; Powers et al., 1997; Treanor et al., 2006 These vaccines have been well 
tolerated at all doses administered and are associated with low rates of local reactions. 
Because of wide-spread shortages of licensed TIV in the United States in 2004-2005, 
we were unable to perform a direct comparison of trivalent rHA vaccines and TIV. In 
other studies of TIV in healthy adult populations, pain at the injection site has been 
reported in 54% to 67% of recipients [Nichol et al., 1996; Treanor et al., 2005; Ohmit 
et al., 2006] and systemic symptoms have been similar to placebo, suggesting that the 
trivalent rHA vaccine and TIV have a similar safety profile. This is consistent with 
previous direct comparisons of rHA and TIV suggesting similar rates of local 
reactions between the two vaccines [Powers et al., 2005; Treanor et al., 1996; Treanor 
et al., 2006].  
Both doses of the recombinant hemagglutinin vaccine evaluated induced 
serum HAI antibody responses to all three components (H1, H3, and B) in the 
majority of recipients. As expected, there were no differences in either the frequency 
of responses or the postvaccination geometric mean titer to influenza A/Wyoming 
(H3N2) between the 75-µg and 135-µg doses, since both doses contained the same 45 
µg of the H3 component. Significant differences in both the frequency and the 
magnitude of the HAI response were demonstrated for both the H1 and B 
components. Although the responses to the 75-µg dose exceeded the European Union 
criteria for influenza vaccine licensure [Wood, 1998], the 135-µg dose (45 µg of each 
component) was more immunogenic and might be predicted to provide greater or 
longer-lasting protection. Therefore, further development of the rHA vaccine should 
use a formulation of 45 µg per component, and future studies should directly compare 
the safety and immunogenicity of this dose with that of TIV. A major advantage of 
the rHA approach is that these doses are well within the production capacity of the 
system at an economically and logistically feasible scale. 
We also found that recipients of the rHA vaccine had reduced rates of culture-
positive CDC-defined influenza-like illness compared with placebo recipients, 
although the numbers in this study were small. When considering both vaccine groups 
combined, the cumulative incidence of culture positive CDC-defined influenza-like 
illness was reduced by 86%. For comparison, in a recently reported study conducted 
in the same influenza season as was our study, the efficacy of TIV in healthy adults 
against culture confirmed influenza meeting a similar case definition was 77% (95% 
confidence interval, 37%-92%) [Ohmit et al., 2006]. The majority of cases were due 
to influenza A, and all of the influenza A viruses isolated in this study that were 
further subtyped were of the H3N2 subtype, consistent with the report that 98.5% of 
all influenza A viruses typed in the United States during the 2004-2005 season were 
H3N2 [MMWR, 2005]. In addition, all of the influenza A (H3N2) viruses isolated 
from participants in this trial were genetically similar to A/California/7/2004, a 
significant antigenic variant which reacts poorly with antiserum samples from persons 
who received the 2004-2005 formulation of TIV [WHO, 2005]. This is consistent 
with reports from CDC that indicated that 75% of Influenza A (H3N2) isolates 
58
  Chapter 4 
  
throughout the United States were genetically similar to A/California/7/2004 
[MMWR, 2005]. It has been suggested that the neuraminidase component of the TIV 
vaccine may be important for protection in situations where there is not a close 
antigenic match in the hemagglutinin [Brett and Johansson, 2005]. The current study 
suggests that it is possible to generate a substantial amount of protection in an 
immunologically primed population against influenza with a pure hemagglutinin 
vaccine, even in the presence of significant antigenic drift. 
The development of functional antibody responses and the preliminary 
evidence of protective efficacy of the vaccine suggests that in adults, the differences 
in HA glycosylation seen in insect cells compared with mammalian cells, the presence 
of HA as an uncleaved precursor, and the lack of neuraminidase in the rHAvaccine do 
not have a major impact on the actual protection provided by the vaccine. Although 
this study and other studies in adults have shown excellent HAI and neutralizing 
antibody responses to the rHA vaccine [Powers et al., 1995; Treanor et al., 1996; 
Lakey et al., 1996; Powers et al., 1997; Treanor et al., 2006] , further studies in 
immunologically naïve young children are clearly needed.  
The use of recombinant DNA techniques to express proteins in cell culture has 
been a successful approach for generation of highly effective vaccines for the 
prevention of e.g. hepatitis B and human papillomavirus [Valenzuela et al., 1982; 
Mao et al., 2006]. Among the available expression technologies, recombinant 
baculovirus technology is especially well suited for the production of influenza 
vaccines because the rapidity with which genes can be cloned and inserted into the 
baculovirus vector facilitates updating of the vaccine at regular intervals. In addition, 
the extraordinarily high yields of protein possible in this eukaryotic system provide 
the opportunity to use higher and potentially more effective doses of vaccine. 
Expression of the HA protein in insect cells using recombinant baculovirus also 
avoids the need to work with large amounts of potentially pathogenic influenza 
viruses, and the attendant biocontainment issues that would be a particular concern for 
generation of pandemic vaccines [Treanor et al., 2001]. The preliminary 
demonstration of protective efficacy in adults provides further support for the 
development of this promising approach for prevention of seasonal and pandemic 
influenza. 
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Chapter 5 
Production of a Novel Influenza Vaccine using Insect Cells: 
Protection Against Drifted Influenza Strains 
 
 
Abstract 
 
A recombinant trivalent hemagglutinin (rHA) vaccine produced in cell culture using 
the baculovirus insect cell expression system provides an attractive alternative to the 
current egg-based influenza vaccine (Trivalent Inactivated Influenza Vaccine = TIV) 
manufacturing process. The HA genes from the annual vaccine strains recommended 
by the World Health Organization were cloned, expressed and purified using a 
general purification process. The highly purified rHA vaccine was administered at a 
three times higher antigen content than TIV and resulted in stronger immunogenicity 
than TIV and a long-lasting immune response. In contrast to TIV, the baculovirus-
derived rHA vaccine does not contain egg proteins, adjuvants, preservatives, 
endotoxins or antibiotics and can therefore be used in a broader human population. In 
this chapter the cross-protection of the rHA vaccine against a drifted variant of H3N2 
influenza was also studied and shown to be effective.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was adapted from: Cox MMJ and Anderson DK. Production of a Novel 
Influenza Vaccine using Insect Cells: Protection Against Drifted Strains. Influenza 
and other Respiratory Viruses 2007; 1: 35-40. 
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Introduction 
 
Influenza is a highly contagious, acute viral respiratory disease, occurring seasonally 
in most parts of the world. Epidemics occur annually and are the cause of significant 
morbidity and mortality worldwide [Glezen, 1982]. Influenza disease affects all age 
groups, with the highest hospitalization rates found in children and the elderly. 
Influenza causes an average of 110,000 hospitalizations and 20,000 to 50,000 deaths 
annually in the USA alone [Bridges et al., 2002]. Over 90% of influenza-related 
deaths occur in people over 65 years. Children under age 5 and women in the first and 
third trimester of pregnancy are also at higher risk for serious complications.  
Influenza viruses are single-stranded ribonucleic acid viruses with a 
segmented genome encoding 10 proteins. The virus particles have a lipid containing 
envelope containing two major glycoproteins: hemagglutinin (HA) and 
neuraminidase. Both proteins have been recognized as key antigens in the host 
response to influenza virus in both natural infection and vaccination. Antibodies 
against HA have the ability to neutralize the virus [Kida et al., 1983; Yoden et al., 
1986] and, for this reason, HA is generally considered to be the active ingredient in an 
influenza vaccine and the licensed inactivated vaccines are standardized to contain a 
least 15 µg HA from each of three influenza viruses selected to be contained in the 
vaccine. The HA protein consists of two subunits: HA1 and HA2. The HA1 domain 
contains all the structural epitopes and is connected with the HA2 domain through al 
disulfide bond. Both inactivated viral vaccines (Trivalent Inactivated Influenza 
Vaccine [TIV]) and a live-attenuated viral vaccine are approved for use to prevent 
influenza. The manufacturing of these vaccines involves the adaptation of the selected 
variants for high yield in eggs by serial passage or reassortment with other high-yield 
strains. Selected influenza viruses are grown in embryonated chicken eggs and the 
influenza virions purified from allantoic fluid. For the inactivated virus vaccines, the 
influenza virus preparations are then killed by treatment with an inactivating agent, 
such as formaldehyde [Chiron, 2002]. Split virion vaccines such as FluZone (Sanofi 
Pasteur, Swiftwater, PA, USA) are produced by splitting the virus particles using 
detergents or solvents. Subunit vaccines such as Fluvirin (Novartis Vaccines Ltd., 
Liverpool, UK) are further purified to remove the internal virion proteins, leaving 
mostly HA and neuraminidase in the vaccine.  
As described in Chapter 1, the existing influenza vaccines are immunogenic in 
healthy adults and induce increased levels of HAI antibodies in 70% to 90% of 
recipients [LaMontagne et al., 1983; Quinnan et al., 1983]. However, the 
effectiveness of these vaccines is typically low during those seasons when a 
suboptimal match between vaccine strains and circulating strains is reported caused 
by the antigenic evolution (genetic drift) of the influenza viruses [Wright and 
Webster, 2001]. As a result, influenza vaccines require adjustment on an annual basis 
and vaccine manufacturing needs to be sufficiently flexible to support these annual 
updates to the vaccine. 
The baculovirus-insect cell expression system is a suitable system for the 
production of viral antigens [van Oers, 2006] and has recently lead to the first vaccine 
registered for human use, against human papiloma virus causing cervical cancer  
(GardesilR, GlaxoSmithKine). The excellent safety profile makes this technology 
specifically suitable for influenza vaccines, which are generally given to healthy 
individuals. Furthermore, as shown in Chapters 1-3 [Holtz et al., 2003; Wang et al., 
2006], a recombinant baculovirus encoding a new HA can be produced within weeks 
and a single well- characterized cell line is used in the manufacturing process, making 
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the annual adjustments required for influenza vaccines feasible in the limited time 
available. 
Recombinant HA (rHA) produced using the baculovirus-insect cell expression 
system has been tested in multiple phase I/II human clinical trials conducted with the 
help of the National Institute of Allergy and Infectious Diseases (NIAID) and 
academic institutions. These studies involving over 600 subjects demonstrated safety, 
immunogenicity and efficacy as reported in four published studies [Powers et al., 
1995; Treanor et al., 1996; Lakey et al., 1996; Powers et al., 1997]. In addition, a 
safety and immunogenicity study of a H5 rHA avian influenza vaccine as a potential 
pandemic influenza vaccine was performed by NIAID in response to the threat posed 
by the 1997-98 Hong Kong “Bird Flu”. The vaccine candidate proved to be 
efficacious in chickens in a challenge study (100% prevention of illness, shedding of 
the virus and death) conducted by the United States Department of Agriculture in a 
high containment facility in Georgia [Crawford et al., 1999]. Subsequently, it was 
administered to over 200 healthcare workers and researchers and produced antibody 
responses that were believed to be protective in approximately 50% of the recipients 
who received two doses of the vaccine [Treanor et al., 2001]. In 2003-04, a clinical 
study was completed in 399 elderly subjects (average age 70 years). In this trial, the 
immune response to TIV was compared with three different doses of trivalent rHA 
vaccine (15, 45, or 135 µg of each HA) containing the same HA antigens, produced in 
insect cells [Treanor et al., 2006]. Recombinant HA was well tolerated and resulted in 
higher Hemagglutinin Agglutination Inhibition (HAI) antibody levels against the 
H3N2 influenza virus. This is an important observation because since 1968 the H3N2 
influenza viruses cause the majority of the 30,000 - 40,000 excess influenza-related 
deaths each year in the USA. Of particular interest was a subset analysis of vaccine 
performance in a group of 100 subjects aged 75 and older where rHA vaccine 
performance was as good as in the group as a whole, whereas TIV performance was 
reduced. In addition, in 2003-04 Safdar et al. (2006) completed a study of the 
performance of a baculovirus-derived influenza rHA vaccine in immuno-
compromised subjects and reported encouraging dose-dependent immunogenicity 
results. Recently, a proof of principle/field study was completed with a trivalent rHA 
vaccine in healthy adults (18-49 years) showing that the trivalent rHA vaccine was 
safe, immunogenic, and effective in the prevention of influenza disease (Chapter 4). 
The clinical studies conducted to date have been summarized in Table 1. 
The World Health Organization (WHO) and the Centers for Disease Control 
and Prevention (CDC) reported that the majority of H3N2 influenza viruses 
circulating during the period October 2004 through January 2005 were similar to the 
A/California/7/04 strain [WHO, 2005; MMWR, 2005]. However, the rHA vaccine 
used in the trial contained the A/Wyoming/3/03 as H3N2 strain. This situation 
presented the opportunity to determine if the baculovirus-derived rHA vaccine 
protected against the circulating drifted H3N2 influenza strains. 
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Table 1.  Overview of clinical studies using various prototypes of the hemagglutinin 
(HA) vaccine 
 
 
Clinical Studies n* Influenza Strain    Dosage recombinant HA0 (µg)          Reference 
 
93A (young adults) 127 A/Beijing/32/92 15, 90; Fluzone; [Powers et al.., 1995] 
 
94A (young adults) 113 A/Beijing/32/92 15, 45, 135; FluShield [Treanor et al., 1996] 
       
94B (young adults) 153 A/Beijing/32/92 45 [Lakey et al.., 1996] 
   A/Texas/36/91 15, 45, 135 
   A/Beijing + B/Texas 2x 45†; Subvirion 
 
94C (elderly adults) 109 A/Beijing/32/92 15, 45, 135; FluShield  [Treanor et al., 1996] 
 
94D (young adults) 100 A/Beijing/32/92 45 [Powers et al.., 1995] 
 
 
 00 (healthy adults) 147 A/Hong Kong/156/97      25/25‡,45/45‡,90/10‡ , [Treanor et al., 2001] 
    90/90‡    
 03 (elderly) 399 A/New Caledonia/20/99 3x15§,3x45§, 3x135§; [Treanor et al., 2006] 
   A/Panama/2007/99 + FluZone 
   B/HongKong/330/01 
 
 03 (B-Cell lymphoma) 27 A/New Caledonia 20/99+ 3x15§,3x45§, 3x135§; [Safdar et al., 2006] 
   A/Panama/2007/99 + FluZone 
   B/HongKong/330/01 
 
 04 (healthy adults) 460 A/New Caledonia/20/99 Low 2x15 (H1,B)/45 (H3);[Chapter 4; 
   A/Wyoming/3/03 High 3x45 [Treanor et al., 2007] 
   B/Jiangsu/10/03 
 
*Number of subjects included in each study. 
 † A single bivalent vaccine formulation. 
 ‡ Subjects received two doses 21-28 days apart  
§ A single trivalent vaccine formulation 
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Materials and Methods 
 
Field efficacy study  
Subjects in the study received various doses of rHA vaccine, produced in the 
baculovirus-insect cells system (Chapter 2 and 3), to establish the final commercial 
dose. The vaccine contained rHA from the influenza strains A/Wyoming/3/03 HA (45 
µg), A/New Caledonia/20/99 (15 or 45 µg) and B/Jiangsu/10/03 (15 or 45 µg)  (Table 
1). The field efficacy study is described in detail in Chapter 4. 
 
Virus Isolation and Sequence Analysis of the HA1 region 
Virus isolation was carried out at the Cincinatti Children’s Hospital test laboratory 
(Cincinatti, OH) using standard cell culture methods in primary rhesus monkey 
kidney (PRhMK) cells. Thirteen positive cultures were obtained from a total of 116 
clinical samples (nasopharyngeal swabs). Briefly, clinical samples were adsorbed 
onto PRhMK monolayers for approximately 60 min, and then monitored daily for 
cytopathic effects up to 14 days.  If a cytopathic effect score of 2+ was reached, the 
presence (or absence) of either influenza A or B was determined by fluorescent 
antibody testing with monoclonal antibodies (Diagnostic Hybrids, Inc). Ten isolates 
were characterized as influenza A and three were characterized as influenza B.  
The ten influenza A isolates were further amplified on Madin-Darby canine 
kidney cells. Virions were disrupted in a buffer containing guanidine thiocyanat, to  
inactivate ribonucleases, thereby ensuring the purification of intact RNA. Viral 
RNA was purified over silicabased columns and stored at -70oC. The purified 
influenza viral RNAs were then used as a template in a reverse transcriptase (RT) 
reaction to generate a single stranded cDNA for the required HA. The RT reactions 
were primed with H3  specific 3’ oligonucleotides (Table 2). Subsequently, the HA1 
region was amplified using high fidelity DNA Polymerase and and oligonucleotides 
specific for regions conserved in the H3 HA (Table 2). PCR-products were purified 
and subjected to sequence analysis. Primers used for sequence-analysis were spaced 
approximately every 300 nucleotides. The sequence reactions were carried out by 
MWG-Biotech, Inc. (Highpoint, NC). For each clone data from individual 
sequencing runs were compiled into a single contiguous sequence, which was then 
compared to the reference sequence obtained from the Influenza Sequence Database 
[ISD, web link: 5-1] or from GenBank [web link: 5-2]  
 
Table 2.  Oligonucleotides used for PCR amplification  
 
Nucleotides in capital font match the HA sequence. Nucleotides in small type are added for 
cloning purpose.  
 
 
Primer # Description Sequence* 
A/Wyoming/03/03 (H3N2) 
2336 H3 strain 5’ primer gttagtaacgcgCAAAAGCTTCCCGGAAATG 
2439 H3 strain 3’ primer ttaattaattacTTAAATGCAAATGTTGCACCTAATGTTG 
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Results 
 
Clinical Results  
Recently, a proof of principle/field study was completed with a trivalent rHA vaccine 
in 460 healthy adults (18-49 years) to establish the final commercial dose (Chapter 4). 
The trivalent rHA vaccine was safe, immunogenic, and effective in the prevention of 
influenza disease, with the higher dose containing 45 µg of each HA showing a 100% 
protective efficacy against cell culture confirmed influenza in subjects presenting with 
influenza-like illness (CDC-ILI). In addition, the number of subjects presenting with 
CDC-ILI in the group receiving the high dose formulation (45 µg of each antigen) 
was reduced by 54.4% when compared to the placebo group [Chapter 4; Treanor et 
al., 2007]. Finally, protection appears long-lasting as the geometric mean titers for the 
H3 component still exceeded 500 after a period of 6 months. This higher dose 
containing 45 µg of each HA has been selected for further development and testing. 
 
Characterization of Influenza Isolates 
The WHO and CDC both reported that the majority of H3N2 influenza viruses 
circulating during the period October 2004 through January 2005 were similar to the 
A/California/7/04 strain [WHO, 2005; MMWR, 2005]. On the other hand, all 
commercial (TIV) vaccines and the experimental rHA vaccine for this influenza 
season contained A/Wyoming/3/03 as H3N2 strain. In addition, HA antibodies 
stimulated by the vaccine were lower in titer to A/California/7/04-like viruses than to 
the A/Wyoming/3/03 virus contained in the vaccine [WHO, 2005]. This suggests that 
the rHA vaccine used in the trial had the capacity to protect against the circulating 
drifted H3N2 strain.  
To analyse this further, 10 influenza isolates from the 2004 to 2005 field efficacy 
study were characterized by sequence analysis of an RT-PCR cDNA product using 
primers for amplification of the variable HA1 gene region. The results are 
summarized in Table 3. The A/Wyoming/3/03 and A/California/7/04 strain H3 
proteins differ from each other in 10 amino acid positions spread throughout the 
antigenic regions of the HA1 portion of the proteins. All of the influenza strains 
isolated from subjects (PS1-PS10) matched the A/California/7/04 strain H3 protein 
sequence in seven of the 10 positions. Isolates PS4 and PS5 also matched the 
A/California/7/04 strain H3 protein sequence at amino acid position 188. As shown in 
Table 4, many of the isolated influenza viruses contained additional mutation(s) in 
their HA amino acid sequences found in neither the A/Wyoming/3/03 nor the 
A/California/7/04 strain H3 proteins, further emphasizing their drifted nature. 
 
Table 3. Comparison of HA amino acid sequence of field isolates (PS1 – PS10), 
A/Wyoming/3/03 and A/California/7/04  
Wyoming A A K Y V D S A Y S 
↕  128 138 145 159 186 188 189 196 219 227 
California T S N F G N N T S P 
D 
PS1-PS3, 
PS6-P10 
 
PS4, PS5 
T 
 
T 
A 
 
A 
N 
 
N 
F 
 
F 
G 
 
G N 
N 
 
N 
A 
 
A 
S 
 
S 
P 
 
P 
 Grey area indicates similarities between field isolates and A/California/7/04 
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These results confirmed the WHO report that the majority of H3N2 influenza viruses 
circulating during this period were similar to the A/California/7/04 strain.  Despite the 
changes in the HA sequence of the circulating compared to the vaccine strain, we 
were unable to culture H3N2 influenza viruses from any of the subjects in the study, 
who received the high dose of the rHA vaccine containing 45 µg of A/Wyoming/3/03 
HA, 45 µg A/New Caledonia/20/99 and 45 µg B/Jiangsu/10/03. As shown in Table 4, 
the majority of subjects who were influenza culture positive had previously received 
placebo (six out of 10). Surprisingly, four individuals receiving the low dose vaccine 
containing 45 µg of A/Wyoming/3/03 HA as well, but only 15 µg A/New 
Caledonia/20/99 and 15 µg B/Jiangsu/10/03 were culture positive. Two of these 
subjects did not develop fever and were shown to be CDC-ILI negative, suggesting 
that the lower dose vaccine reduced the severity of the influenza infection in these 
subjects. One of the remaining two subjects (isolate PS10) showed an extremely poor 
antibody response to the A/Wyoming/3/03 strain, making cross protection very 
unlikely. Both the high-dose vaccine and the low-dose vaccine contained 45 µg 
A/Wyoming/3/03 HA, yet the protective efficacy against the circulating 
A/California/7/04 differs, suggesting that a higher content of the other HA antigens 
plays a role in providing protection against infection with drifted influenza H3N2 
strains. 
 
Table 4. Evaluation of Influenza H3N2 isolates (PS1 – PS 10)  
Influenza  
H3N2 isolate ID 
Treatment CDC-ILI HAI Titer 
Wyoming day 28 
Additional 
mutations  
PS8 Placebo Positive 4 N206S; V213I; 
I216V 
PS1 Placebo Positive 8 F174Y 
PS9 Placebo  Positive 16 A198S; R299K 
PS5 Placebo Positive 32  
PS7 Placebo Positive 64 V88I 
PS4 Placebo Positive 256  
PS10 Low dose Positive 32 G50E; L164M 
PS6 Low dose Positive >1024 R150K 
PS2 Low dose Negative 512 N278K 
PS3 Low dose Negative 512  
CDC-ILI, Center for Disease Control Influenza-like illness, subjects presenting with fever plus at least 
one respiratory system. 
Gray area indicates subjects receiving the low dose vaccine 
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Discussion 
 
The formulation of the rHA influenza vaccine intended for commercialization 
contains 45 µg of each HA; this is three times more than the antigen content of 
existing inactivated influenza vaccines. The mechanism of action of this vaccine 
candidate is similar to TIV, namely the induction of HA antibodies to prevent 
influenza infection. The recombinant vaccine offers significant advantages over the 
traditional egg-based vaccines as it is highly purified, free of preservatives, 
endotoxins or adjuvants, and produced in cell culture. As a result the rHA vaccine is 
well tolerated by a wider patient population (e.g. those with egg allergies).  
The higher HA content in the vaccine offers not only the possibility for the 
presence of circulating antibodies over an extended period of time, but also the 
potential to provide cross-protection for which the first evidence was presented here. 
The current results are consistent with the previously reported studies that showed that 
increased doses of purified HA and increased doses of subvirion vaccines result in an 
enhanced antibody response in both the elderly and the healthy adult population 
[Keitel et al., 1994; Keitel et al., 1996]. Characterization of the H3N2 influenza virus 
field isolates by sequence analysis clearly reveals the drifted nature of these viruses, 
with a minimum of 7 amino-acid changes from the HA represented in the vaccine. 
Even though the H3N2 HA content was 45 µg in both the low and high dose rHA 
vaccine, H3N2 influenza viruses were isolated from four low dose recipients (two of 
whom had only mild disease) whereas no influenza viruses were isolated from the 
high dose vaccine recipients. This result suggests that the other vaccine components 
(i.e. H1 and B rHA) may contribute to the overall vaccine performance.  
The TIV provides an economical and effective means to reduce the impact of 
an influenza infection. It is effective in prevention of influenza in young adults with 
reported levels of protection as high as 70-90% [Meiklejohn et al., 1987; Ruben, 
1987]; however only 30% to 50% of vaccinated subjects older than 65 years achieve 
protective titers against the H3 strain [Powers and Belshe, 1993]. Therefore, there is 
need to develop a better vaccine for this at risk population. Furthermore, a reduction 
of 30% in the effectiveness of TIV was reported for the 2003-04 season when the 
influenza vaccine was not well matched to the dominant circulating strain [MMWR, 
2004], suggesting that a vaccine that provides cross protection would also be 
beneficial. 
 The egg-based manufacturing technology used to produce all currently 
approved influenza vaccines has reached its limits, in terms of productivity, safety and 
production security and is likely to be replaced in the future with a modern cell-based 
production technology in the near future. Given the availability of a cheap and 
relatively effective vaccine with a well-defined mechanism of action, limited effort 
has been directed towards the development of protein-based vaccines. However, many 
new cell-based and protein vaccines are now in clinical development [Cox, 2005] and 
are expected to address some of the limitations of the current licensed vaccine, 
including egg-associated allergies and the need for surge capacity in a pandemic 
situation. 
The recombinant trivalent HA vaccine (proposed trade name FluBlok; Protein 
Sciences Corporation, Meriden, CT, USA) is similar to TIV in that it contains 
antigens (HA proteins) that are derived from the three influenza virus strains that are 
selected for inclusion in the annual influenza vaccine by the WHO. The rHA antigens 
are developed using recombinant DNA and cell culture technology enabling the 
production of a perfect matching HA protein instead of introducing egg or cell culture 
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mutations that may result in a less effective vaccine [Schild et al., 1983; Katz et al., 
1987; Rajakumar et al., 1990]. Unlike the licensed egg grown vaccines and many cell 
culture vaccines in development, no live influenza viruses are used in manufacturing, 
which eliminates the need for biocontainment facilities or harsh chemical treatment 
such as formaldehyde. The vaccine is a pure protein preparation containing the three 
antigens (proteins) in sterile buffered salt water without preservatives such as 
thimerosal, a mercury derivative used in egg-production process, or adjuvants. The 
potential of a high dose influenza vaccine that can provide cross-protection would be 
extremely valuable especially since the influenza virus is constantly antigenically 
evolving both in time and in space (geographic regions). Finally, the recombinant, 
cell-based influenza vaccine offers an extremely rapid development cycle. This was 
demonstrated in making a vaccine for the 1997-98 Hong Kong “Bird” flu in only 8 
weeks. In 2006 (more than 6 years later), similar clinical results were achieved with a 
“reverse genetics” vaccine candidate produced in embryonated chicken embryos by 
Sanofi Pasteur [Treanor et al., 2006]. In addition to pandemic preparedness, a rapid 
development cycle would allow the inclusion of late appearing influenza virus strains 
in the annual vaccine preparations.  
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Chapter 6 
Novel Cell Substrate: Safety and Immunogenicity of 
FluBlok, a Recombinant Influenza Vaccine Manufactured 
in Insect Cells 
 
Abstract 
 
FluBlok, a recombinant trivalent hemagglutinin (rHA) vaccine produced in insect cell 
culture using the baculovirus expression system, provides an attractive alternative to 
the current egg-based trivalent inactivated influenza vaccine (TIV). Its manufacturing 
process presents the possibility for safe and expeditious vaccine production. FluBlok 
contains three times more HA than TIV and does not contain egg-protein or 
preservatives. The high purity of the antigen enables administration at higher doses 
without a significant increase in side-effects in human subjects.  
The insect cell - baculovirus production technology is particularly suitable for 
influenza where annual adjustment of the vaccine is required. The baculovirus-insect 
expression system is generally considered a safe production system, with limited 
growth potential for adventitious agents. Still regulators question and challenge the 
safety of this novel cell substrate as FluBlok continues to advance toward product 
approval. This chapter describes a study on cell substrate characterization for the 
expresSF cell line used for the manufacturing of FluBlok. 
In addition, data from the four main clinical studies that were used to support 
licensure of FluBlok under the “Accelerated Approval” mechanism in the United 
States are presented. The highly purified protein vaccine, administered at three times 
higher antigen dose than TIV is well tolerated and results in stronger immunogenicity, 
a long lasting immune response and provides cross protection against drifted 
influenza viruses. 
 
 
 
 
 
 
 
 
 
 
 
Data included in this chapter has been published as: Cox MM. Patriarca PA, Treanor 
JJ: FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza and other 
Respiratory Viruses 2008; 2: 201-209 and Cox MM and Hollister JR FluBlok: A next 
generation influenza vaccine manufactured in insect cells. Biologicals 2009; 37: 182-
189 
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1. Introduction 
 
Most current influenza vaccines are generated in embryonated hen's eggs. Virions are 
harvested from the egg allantoic fluid, chemically inactivated and treated with 
detergent, and either a whole virion preparation is generated, or the hemagglutinin 
(HA) and neuraminidase (NA) proteins are partially purified to produce split-product, 
subvirion, or subunit vaccines [Wood, 1998]. Although this system has served well 
for over 50 years, there are several well-recognized disadvantages to the use of eggs 
as the substrate for vaccine production. The licensed egg-grown trivalent inactivated 
influenza vaccines (TIVs) are standardized to contain 15 µg of each of three HAs, 
derived from influenza A subtype H1N1, H3N2 and influenza B [Bridges et al., 
2002]. Thus, HA, the dominant surface glycoprotein on the influenza virus and 
recognized key antigen in the host response to influenza virus in both natural infection 
and vaccination, is a logical candidate for recombinant vaccine technology [Huber 
and McCullers, 2008]. 
 FluBlok is a trivalent recombinant HA (rHA) vaccine, is under development, 
which contains rHA protein antigens that are derived from the three influenza virus 
strains, which have been selected for inclusion in the annual influenza vaccine by the 
World Health Organization (WHO) and are updated on an annual basis. As a result 
the composition of FluBlok and TIV (i.e. Fluzone) may change each influenza season 
and region. 
The mechanism of action of FluBlok is the same as that of the licensed TIVs, 
thereby simplifying the regulatory pathway for product approval. FluBlok is 
formulated to contain 45 µg of each rHA, three times the amount of HA as is 
contained in TIV. The higher rHA content offers the potential to provide cross-
protection for which preliminary evidence has been presented, but also the possibility 
for longer lasting and improved immunogenicity [Treanor et al., 2006; Cox and 
Anderson, 2007; Treanor et al., 2007] . Clinical results suggest that FluBlok may 
provide superior protection against influenza infection especially in at-risk 
populations (adults over 65 years, immuno-compromised individuals, etc.) as has 
been reported for increased antigen concentration of TIV [Keitel et al., 1994; Keitel et 
al., 1996]. This chapter describes the use of a novel cell substrate based on the 
baculovirus-insect cell system for the production of hemagglutinin and summarizes 
some key immunogenicity results from clinical studies that were used to support 
licensure of FluBlok under the “Accelerated Approval” mechanism in the United 
States. In addition, the correlation between post-vaccination titer (Day 28) and 
acquisition of influenza infection is discussed.  
  The three HA proteins in FluBlok are produced in a non-transformed, non-
tumorigenic continuous cell line (expresSF+® insect cells) grown in serum-free 
medium. The cell line is derived from Sf9 cells of the fall armyworm, Spodoptera 
frugiperda [Smith et al., 2000]. Each of the three recombinant HAs (rHAs) is 
expressed in this insect cell line using a viral vector (the baculovirus Autographa 
californica multicapsid nucleopolyhedrovirus). The HA antigens included are full 
length proteins containing the transmembrane domain and the HA1 and HA2 
domains. The rHA proteins form trimeric structures visible by electron microscopy 
and are not cleaved in insect cells in the absence of exogenously added proteases 
(with the exception of HAs containing a highly cleavable sequence of basic amino 
acids at the cleavage site). Therefore, they are sometimes referred to as rHA0. Since 
the cleavage site is not known to be involved in the immune response, a significant 
difference between the immune response to cleaved or uncleaved HA is unlikely. The 
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individual rHAs are extracted from the cells with buffer and detergent and further 
purified by using a combination of filtration and column chromatography methods. 
Details on the production and characterization of rHA are described elsewhere 
[Chapter 2 and 3; Holtz et al., 2003; Wang et al., 2006]. The mechanism of action of 
this vaccine candidate is expected to be similar to TIV; namely, the induction of 
hemagglutination inhibition (HAI) antibodies to prevent influenza infection [Kida et 
al., 1983; Yoden et al., 1986].  
Manufacturing in insect cells offers a number of advantages over currently 
licensed influenza vaccines that are produced in embryonated chicken eggs: (i) the 
influenza rHA antigens are produced using a scaleable, reproducible, and low 
bioburden fermentation process in insect cells, which results in a consistent, protein-
based vaccine with low endotoxin content [Holtz et al., 2003; Cox and Anderson, 
2007]; (ii) selection or adaptation of influenza virus strains as for production at high 
levels in eggs is not required, enabling a good genetic match between the vaccine 
strains and the disease causing influenza virus strains [Holtz et al., 2003; Cox and 
Anderson, 2007]; (iii) the cloning, expression and manufacture of FluBlok can be 
accomplished within a brief period of time, generally less than two months; and (iv) 
the manufacture of FluBlok does not require high-level bio-containment facilities, 
which may result in more rapid vaccine production at lower costs in the event of the 
emergence of a new epidemic or pandemic strain of influenza virus; and (v) 
purification procedures for rHA do not include influenza virus inactivation or organic 
extraction procedures, thus avoiding possible denaturing effects and additional safety 
concerns because of residual toxic chemicals in the vaccine  [Holtz et al., 2003; Cox 
and Anderson, 200]. Perhaps most importantly, from a clinical perspective, FluBlok is 
highly purified and does not contain antigenic proteins present in eggs [Holtz et al., 
2003; Cox and Anderson, 2007]. 
In addition to presenting advantages in manufacturing, as discussed above, 
insect cells provide safety advantages for the production of biologicals. Insect cells 
can be grown in the absence of fetal bovine serum and other animal derived 
ingredients, significantly reducing the chances of introducing an adventitious agent 
during manufacturing [Rohwer, 1996; Nims, 2006; Chen et al., 2008]. The genetic 
distance between insects and vertebrates also reduces the likelihood of insect cells 
serving as a host for vertebrate viruses or the likelihood of vertebrates serving as a 
host for insect viruses. In fact, many insect viruses described to date exhibit a 
relatively narrow host range with only a small number of viruses capable of 
amplifying in both insects and vertebrates [Miller and Ball, 1998; Kuno and Chang, 
2005]. These insect viruses along with some tick viruses that can also amplify in 
vertebrates are informally referred to as arboviruses reflecting their arthropod-borne 
origin, and have closely co-evolved with the hematophagous arthropods and the 
vertebrate hosts upon which they feed [Kuno and Chang, 2005]. The susceptibility of 
Sf9 cells to arbovirus infection is reported to be very low; with St. Louis encephalitis 
virus being the only arbovirus tested to date that could produce a persistent, 
productive and cytopathic infection [Zhang et al., 1994]. In addition, Menzel and 
Rohrmann (2008) recently described the presence of errantivirus (retrovirus) 
sequences in two insect cell lines, including Spodoptera frugiperda (Sf) cells. 
The recent progress in using novel animal cell lines as substrates for the 
production of biologicals has led to the re-evaluation of existing criteria used for 
evaluating the acceptability of such cell lines. Improvements to existing criteria for 
determining the acceptability of novel cell substrates as well as development of new 
criteria have recently been the focus of regulatory agencies [Knezevic et al., 2007].  
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2. Insect cell substrate- expresSF+ 
 
The baculovirus expression vector system is used to produce recombinant proteins in 
the proprietary lepidopteran insect cell line expresSF+ (SF+). SF+ cells were derived 
from the Sf9 cell line, which was first cloned via dilution plating of the mixed 
population cell line IPLB-Sf-21AE by Cherry and Smith at Texas A&M University 
(unpublished, 1983). At the time the Sf9 line was developed, the IPLB-Sf-21AE cell 
line had been in continuous culture since its isolation in 1970 from primary cultures of 
normal ovarian tissues dissected from pupal ovaries of the fall armyworm, Spodoptera 
frugiperda [Vaughn et al., 1977].  
Several characteristics of SF+ cells make them well suited as cell substrates 
for the manufacture of biologicals using the baculovirus expression vector system: (i) 
SF+ cells are grown in suspension in an inexpensive animal product-free medium to 
high densities and without clumping; (ii) cultures of SF+ cells are routinely scaled to 
450L under cGMP conditions and maintain a consistent cell doubling time of 
approximately 18-24 hours; (iii) significantly higher yields of recombinant proteins 
are obtained in SF+ cells as compared to the parental cell line Sf9; (iv) SF+ cells 
support robust growth of recombinant baculoviruses resulting in high titer stocks of 
virus, thus allowing for protein expression and virus stock production to be carried out 
using a single qualified cell line; and (v) these attributes are consistent for over 50 cell 
culture passages allowing for significant flexibility in maintenance of seed stocks 
during large scale cGMP production and have been described elsewhere [McPherson, 
2008]. 
Qualification testing on the SF+ cell line has been previously described [Mc 
Pherson, 2008] and was performed according to the International Conference on 
Harmonization (ICH) document Q5A (2005), the Food and Drug Administration’s 
(FDA) “Points to Consider in the Characterization of Cell Lines Used to Produce 
Biologicals,” dated 1993, and the FDA’s 2006 draft guidance “Characterization and 
Qualification of Cell Substrates and Other Biological Starting Materials Used in the 
Production of Viral Vaccines for the Prevention and Treatment of Infectious 
Diseases.” In addition to the testing described in McPherson (2008), additional 
subsequent testing has been performed based on product-specific comments from the 
FDA. A description of the testing undertaken and the results are described in sections 
2.1 below.  
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2.1 Qualification testing 
2.1.1 Transmission electron microscopic examination of stressed expresSF+ cells   
Visual detection of virus particles in cells that harbor latent viral genomes or 
inefficiently replicating viruses is virtually impossible unless the virus can be induced 
to replicate, which sometimes occurs as a consequence of cellular stress. To address 
the potential that SF+ cells might harbor such an infection, cells from an SF+ 
Working Cell Bank (WCB) at the end of the production passage (>P50) were 
chemically treated or incubated at elevated temperatures to induce cellular stress prior 
to examination by transmission electron microscopy (TEM).  
To induce stress by chemical treatment, SF+ cells were treated with the 
halogenated pyrimidine analog 5-iododeoxyuridine (IdU), which has been previously 
reported to potentiate viral replication in mammalian and insect cell cultures [Green 
and Baron, 1975; Carreno and Esparza, 1977; Patch et al., 1981; Khan and Sears, 
2001; Khan et al., 2001]. Treatment with IdU was carried out by growing the cells in 
the presence of IdU for 1 day, followed by a 1 day recovery period. Analysis of the 
chemically treated cells by TEM revealed no virus-like particles or other biological 
contaminants in any of the 200 cells examined (Charles River Laboratories, MA).  
A high temperature shock was used as a second independent method of 
inducing stress in SF+ cells. To ensure that the cells would genuinely be stressed by 
the temperature treatment, we chose conditions that have been previously reported to 
induce heat shock proteins in the related cell line Sf9 [Huhtala et al., 2005]. In that 
study heat shock proteins were observed to be induced when cells were incubated for 
15 minutes to 1 hour at temperatures above 37° C. Samples of heat shocked SF+ cells 
were prepared by incubating cells at 43° C for 45 minutes, followed by a 1-day 
recovery period and then analysis by TEM. No virus-like particles or other biological 
contaminants were observed in any of the 200 cells heat-treated cells examined. 
It is important to note however, that a limitation of both analyses is a lack of 
an insect cell induction control. Even though there is a recent report on the presence 
of errantivirus (retrovirus) sequences in Sf cells [Menzel and Rohrmann, 2008], there 
are no retrovirus-like viruses reported to infect Sf cells, thus an adequate positive 
control for the treatments described above was not available. Treatment conditions 
were therefore developed based on assumptions using studies in mammalian cell lines 
as a guideline.  
 
2.1.2 Adventitious virus detection  
 
2.1.2.1 Approach.  
Viruses that use insects as their primary natural host species are classified into 17 
virus families and more than 30 genera, and utilize most known niches for genome 
coding. This great diversity among insect viruses coupled with large gaps in our 
scientific understanding of these viruses has created a challenging environment in 
which to develop viral assays to detect the presence of insect viruses in cell substrates. 
Ideally, a generic test that is capable of detecting all known insect virus members 
within a specific virus family is needed. Recently, PCR primers have been designed 
with the capability to detect both known and novel herpes- and papillomavirus species 
[Rose, 1995; Baines et al., 2005; Jarrett et al., 2006]. For these assays, PCR primers 
were designed according to the consensus-degenerate hybrid oligonucleotide primers 
(CODEHOPs) strategy [Rose et al., 1998]. The CODEHOP approach is well suited to 
take advantage of short (3-4 amino acids) highly conserved amino acid motifs found 
in related proteins encoded by virus species within the same family. Based on the 
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success of others using this approach we have begun developing a PCR based assays 
utilizing the CODEHOP strategy to screen the SF+ cell line for the presence of 
contaminating insect viruses.  
 
2.1.2.2 Virus family selection 
To focus assay development towards insect virus species with the highest potential 
risks for contaminating SF+ cells, we assessed which families contained viruses 
known to infect lepidopteran insects. Table 1 lists the current virus families known to 
contain insect viruses excluding those families which only insect virus members are 
arboviruses, such as the Flaviviridae, Bunyaviridae and the Togaviridae. Based on 
this analysis we excluded the family Dicistroviridae due to the absence of a known 
lepidopteran infecting virus as well as the family Birnaviridae, which contains in the 
genus Entomobirnavirus so far only one insect-infecting virus species, Drosophila X 
virus [8th ICTV report, 2005]. Also excluded were the families Reoviridae and 
Polydnaviridae, both of which are comprised of viruses for which there is limited 
genetic information. Finally, assays for viruses belonging to the families Metaviridae 
and Pseudoviridae were also excluded for CODEHOP primer design due to their 
relatedness to retroelements, for which insect cells have been reported to be a rich 
source [Terzian et al., 2001], The SF+ genome and members from the latter virus 
families most likely share DNA sequences encoding for conserved domains in 
proteins; Therefore, a positive result by PCR would not necessarily indicate an 
infectious agent was present.  
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Table 1. Virus families containing insect virus species [8th ICTV report, 2005] 
 
Family 
Genome 
Type 
Genera Type Species 
Ascoviridae dsDNA Ascovirus Spodoptera frugiperda ascovirus 1a 
Nuclear Polyhedrosis 
Virus AcMNPV Baculoviridae dsDNA 
Granulovirus Cydia pomonella granulovirus 
Birnaviridae dsRNA Entomobirnavirus Drosophila X virus 
Dicistroviridae ssRNA(+) Cripavirus Cricket paralysis virus 
Iridovirus Invertebrate iridescent virus 6  Iridoviridae dsDNA Chloriridovirus Invertebrate iridescent virus 3 
Metavirus Saccharomyces cervisiae Ty3 virus 
Errantivirus Drosophila melanogaster gypsy virus Metaviridae ssRNA-RT 
Semotivirus Ascaris lumbricoides tas virus 
Nodaviridae ssRNA(+) Alphanodavirus Nodamura virus Flockhouse virus 
Densovirus Junonia coenia densovirus  
Iteravirus Bombyx mori densovirus 
Brevidensovirus Aedes aegypti densovirus Parvoviridae ssDNA 
Pefudensovirus Periplanta fuliginosa densovirus 
Ichnovirus Campoletis sonorensis ichnovirus Polydnaviridae dsDNA Bracovirus Cotesia melanoscela bracovirus 
Entomopoxvirus A  Melolontha melolontha 
entomopoxvirus 
Entomopoxvirus B Amsacta moorei entomopoxvirus Poxviridae dsDNA 
Entomopoxvirus C Chironomus luridus entomopoxvirus 
Pseudoviridae ssRNA(+) Hemivirus Drosophila melanogaster copia virus 
Cypovirus Cypovirus 1 Reoviridae dsRNA Idnoreovirus Idnoreovirus I 
Betatetravirus Nudaurelia capensis β virus; Tetraviridae ssRNA(+) Omegatetravirus Nudaurelia capensis ω virus 
Note: Iflaviridae with the infectious Bombyx mori flacherie virus as the type species (Genera 
Iflavirus) has recently been identified as a family to infect insect cells as well. 
 
2.1.2.3 Selection of the viral protein target 
Viral proteins targeted for the design of CODEHOPs were selected by performing a 
systematic manual survey of the genetic information available for virus species in 
each family. Criteria for selecting a protein sequence as the target for primer design 
were based on: (i) the number of virus species within the same family for which a 
target protein sequence was available and (ii) the ability to identify conserved amino 
acids in alignments using the available sequences. The target proteins chosen from 
each virus family and an accession number corresponding to a representative 
sequence from the type species are listed in Table 2. After selection of the target 
sequence all available amino acid sequences from each virus family were used to 
generate multiple sequence alignments that were then formatted into blocks of aligned 
amino acids using a block multiple alignment processor [Web link 6-1]. The blocks of 
aligned amino acids were then imported into the CODEHOP analysis program located 
online [Web link 6-2] to generate recommended primer designs.  
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Table 2. Viral proteins targeted for CODEHOPs 
Family Target Protein Accession # 
Ascoviridae Major Capsid Protein CAF05815 
Iridoviridae Major Capsid Protein Q05815 
Nodaviridae RNA dependant RNA Polymerase ABS29339 
Parvoviridae Non-Structural Protein 1 NP051020 
Poxviridae DNA Polymerase/Spheroidin AAA92858 
Tetraviridae Major Capsid Protein AA073881 
 
 
2.1.3 Specific screen for the Tn5 cell line (TNCL) virus 
In a recent report by Li et al. (2007), Tn5 cells maintained in the investigator’s 
laboratory or obtained fresh from a commercial source were found to be latently 
infected with a previously unknown nodavirus. Replication of the new nodavirus, Tn5 
cell line (TNCL) virus, appears to be induced by infection with baculovirus, although 
genomic sequences were detected in uninfected Tn5 cells by PCR. Interestingly, Li 
and co-workers also tested Sf9 cells by PCR before and after infection with 
baculovirus and found no evidence of infection with TNCL virus. To address the 
potential that SF+ cells are latently infected with TNCL virus, we tested our SF+ 
WCB using PCR primers based on the published nucleotide sequence for the TNCL 
virus isolate. No amplification products were obtained with either uninfected or 
baculovirus infected SF+ cell samples, but a positive result was obtained when 
samples were spiked with TNCL virus control RNA. In addition to these findings, 
analysis using primers designed based on the CODEHOP strategy, as described 
above, also failed to produce a product except in the presence of spiked control RNA.  
 
2.1.4 Quantitative PCR-Enhanced Reverse Transcriptase Assay 
Cell-free supernatant samples from the SF+ Master Cell Bank (MCB) and end of 
production cells from a WCB (passage 60) were tested by a quantitative Fluorescent- 
PCR Based Reverse Transcription (PERT) assay in order to compare reverse 
transcriptase (RT) activity and rule out increased production of retroviral-like 
particles due to the manufacturing process. This assay can detect as few as 10 – 100 
molecules of RT present in a sample. Samples of cell free supernatant were judged to 
contain RT activity in agreement with the presence of retro-elements in these cells. 
However, no increase in RT activity was observed between low passage cells from the 
master cell bank versus cells at passage 60 (end of production passage), ruling out an 
increased production of retroviral-like particles due to cell passaging. It should also be 
noted that end of production cell samples were determined not to contain infectious 
retrovirus particles when tested in a cellular co-cultivation assay [Mc Pherson, 2008]. 
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3. Clinical Assessment 
 
3.1 Clinical studies PSC01, PSC03, PSC04 and PSC06 used to support licensure  
The studies described below were performed to support licensure of FluBlok, a 
recombinant hemagglutinin influenza vaccine indicated for active immunization of 
adults 18 years of age and older against influenza disease caused by influenza virus 
subtypes A and type B represented in the vaccine. FluBlok is a sterile liquid with no 
added preservatives or adjuvants for intramuscular injection. FluBlok is supplied as a 
single-dose vial (0.5 mL) and each dose contains three recombinant influenza 
hemagglutinin (rHA) proteins (45 µg of each of the subtype antigens).  
The main goal of trial PSC01 was to determine safety and the optimal dose of 
rHA of the vaccine in healthy adults [Treanor et al., 2007]. It was a randomized, 
prospective, double-blind, placebo-controlled multicenter study in which healthy 
adults 18-49 years of age were enrolled during the 2004-2005 influenza season. A 
total of 458 subjects were vaccinated with either a single dose of FluBlok at a total 
rHA dosage level of 135 µg (containing 45 µg of each antigen [153 subjects]) or 75µg 
(containing 45 µg of H3 rHA and 15 µg of B and H1 rHA [151 subjects]), or a saline 
placebo (154 subjects). The mean age of the subjects receiving FluBlok (135 µg) was 
31 years and the majority was female (63%). Additionally, 85% had a Caucasian, 6% 
an African American, 3% a Latino/Hispanic, 3% an Asian, and 2% a Native American 
background The evaluable efficacy population consisted of 451 subjects (150 in the 
FluBlok 135 µg group, 150 in the FluBlok 75 µg group and 151 in the placebo group) 
with complete serological data as per protocol. 
The main goal of the next study (PSC03) was to compare the safety and 
immunogenicity of FluBlok with a licensed vaccine, Fluzone, in elderly adults 
[NCT00395174]. PSC03 was a randomized, double-blind, active-controlled study in 
which 869 medically stable adults age 65-92 years (mean age 73 years) were enrolled 
during the 2006-2007 influenza season. Participants were randomly assigned to 
receive either a single dose of FluBlok (135 µg, 436 subjects) or commercially 
available trivalent influenza vaccine (Fluzone®, Sanofi Pasteur, Swiftwater, PA, USA; 
433 subjects). The majority of subjects receiving FluBlok were female (52%). The 
majority was of Caucasian origin (99%). The evaluable efficacy population consisted 
of 431 FluBlok-treated subjects and 430 Fluzone-treated subjects. A total of 854 
subjects completed all study procedures. 
PSC04 was a randomized, double-blind, placebo-controlled clinical efficacy 
study in which 4648 healthy adults age 18-49 years (mean age 33 years) were enrolled 
during the 2007-2008 influenza season [NCT00539981]. The main goal of this study 
was to determine safety, immunogenicity and efficacy of the vaccine in healthy 
adults. Only data from the first 28 days of study are included herein. Participants were 
randomly assigned to receive either a single dose of FluBlok (135 µg, 2344 subjects) 
or placebo (2304 subjects). The majority of subjects receiving FluBlok were female 
(59%). Additionally, 67% were Caucasian, 18% were African American, 11% were 
Latino/Hispanic, 3% were Asian, and < 1% were Native American. A total of 4272 
subjects completed all study procedures through Day 28. A subset of 391 subjects 
who received FluBlok served as the evaluable immunogenicity population. The 
efficacy data of this study were not included in the initial license application. 
PSC06 was a randomized, double-blind, placebo-controlled study in which 
602 healthy adults age 50-64 years (mean age 56 years) were enrolled during the 
2007-2008 influenza season [NCT00539864]. Participants were randomly assigned to 
receive either a single dose of FluBlok (135 µg, 300 subjects) or commercially 
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available trivalent influenza vaccine (Fluzone®, 302 subjects). The majority of 
subjects receiving FluBlok were female (62%). Additionally, 73% were Caucasian, 
4% were African American, 8% were Latino/Hispanic and 12% were Asian. A total 
of 602 subjects completed all study procedures through Day 28. There were 601 
subjects in the evaluable population. Only data from the first 28 days of study are 
included herein. The main goal of this study was to compare the safety and 
immunogenicity of FluBlok with the licensed vaccine, Fluzone, in adults 50 -64 years 
of age. 
In summary these four trials investigated the safety, optimal dosing and 
efficacy in adults in three age groups (18-49; 50-64, and 65 and older), and compared 
between the immunogenicity of FluBlok and the commercial trivalent vaccine in 
adults above 50 years of age.  
 
3.2 Vaccine safety 
The total population used for safety analysis performed with the data from these trials 
included 6577 adults 18 years of age and older. The four studies together included 
5106 subjects age 18 - 49 years of age randomized to receive FluBlok (2497 subjects 
received 135 µg; 151 subjects received 75 µg) or placebo (2458 subjects), and 1471 
subjects age 50 years and older who were randomized to receive FluBlok (736 
subjects) or a US-licensed trivalent, inactivated influenza virus vaccine (Fluzone®) 
(735 subjects). 
Collectively 59% of the volunteers were women; 73% of subjects were 
Caucasian, 8% Hispanic/Latino, 14% African-American, < 1% Native American, and 
3% Asian. The mean age of subjects in the studies was 40 years (range 18-92 years); 
9% of subjects were 50 to 64 years of age and 13% were 65 years of age and older.  
In all studies, a series of symptoms and/or findings were specifically solicited 
by a memory aid used by subjects for the 7-day period following vaccination (see 
Table 3). In addition, in all 4 studies, spontaneous reports of adverse events were also 
collected for 28 days following vaccination (see below) and subjects were actively 
queried about changes in their health status 6 months after vaccination for studies 
PSC01 and PSC03.  
PSC01 included 458 subjects for safety analysis, ages 18 - 49 years, 
randomized to receive FluBlok 75 µg (151 subjects), FluBlok 135 µg (153 subjects) 
or placebo (154 subjects). Serious adverse events (SAEs) reported from day 0 (day of 
vaccination) through 6 months were included in the safety analysis. Two subjects 
(1%) in the 135 µg FluBlok group experienced SAEs that were considered to be 
unrelated to treatment (one seizure related to hypoglycemia that occurred at 26 days 
post-vaccination and one lobular carcinoma in situ at day 55 and syncope at day 125). 
No subjects discontinued the study because of adverse events and no subjects died. 
Three female subjects became pregnant after vaccination with FluBlok. Two 
pregnancies ended in elective termination and one proceeded normally to full-term, 
resulting in the birth of a normal infant. 
In the same age group of 18 - 49 years, PSC04 included 4648 subjects for 
safety analysis, randomized to receive FluBlok (2344 subjects) or placebo (2304 
subjects). Results from an interim analysis are reported herein and include safety data 
reported from day 0 through day 28, when subjects were interviewed during a visit or 
phone call. A total of 24 possible SAEs were reported through the day 28 visit/phone 
call (eight in the FluBlok and 16 in the placebo treatment groups). Of these, five were 
pregnancies (1 FluBlok and 4 placebo). Only one SAE, “pericardial effusion,” 
diagnosed 11 days post-vaccination in a FluBlok recipient, was judged to be possibly 
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related to treatment. None of the remaining six SAEs reported in the FluBlok 
treatment group were considered by the investigators to be related to study treatment.  
In the age group of 50 - 64 years (PSC06) 602 subjects were included for 
safety analysis, randomized to receive FluBlok (300 subjects) or TIV (Fluzone) (302 
subjects). Results from an interim analysis are reported herein and include safety data 
reported from day 0 through the day 28 visit/phone call. One subject receiving 
FluBlok reported a treatment-related SAE on the day of vaccination (syncope 
vasovagal) of moderate severity that resolved without sequelae. No subjects 
discontinued the study due to adverse events. 
In the group of 65 years and older (PSC03) 869 subjects were available for 
safety analysis, randomized to receive FluBlok (436 subjects) or TIV (Fluzone) (433 
subjects). SAEs reported herein include safety data reported from day 0 through 9 
months (end of influenza season). A total of 70 (8%) SAEs were reported (36 [8%] 
for FluBlok and 34 [8%] for Fluzone). No SAEs were judged to be related to the 
study treatment by the investigators.  
Across the four trials, there were no deaths that were considered as possibly or 
probably related to vaccination treatment. Table 3 shows the solicited adverse events 
reported by the subjects using a memory aid during the first 7 days post vaccination. 
In general, local and systemic reactogenicity events occurred with similar frequency 
across the four clinical studies except in PSC01, where most events tended to be 
reported more frequently. The only statistically significant difference between the 
FluBlok group (135 µg dose) and the placebo group was pain at the injection site in 
one study PSC01; 95% of these pain events were reported as mild.  
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Table 3.  Solicited adverse events in the first 7 days after administration of FluBlok, 
placebo, or comparator influenza vaccine 
 Study PSC01 Study PSC04 Study PSC06 Study PSC03 
 Adults age  
18-49 yrs 
Adults age  
18-49 yrs 
Adults age  
50-64 yrs 
Adults age 
 ≥ 65 yrs 
 FluBlok* Placebo FluBlok Placebo FluBlok Fluzone FluBlok Fluzone 
Number of Subjects 153 154 2344 2304 300 302 436 433 
Local Adverse Events (%) 
Pain  61 17 37 8 51 55 22 23 
Redness  5 2 4 2 8 8 10 12 
Swelling  10 3 3 2 8 10 11 13 
Bruising 7 4 3 3 5 5 3 5 
Systemic Adverse Events (%) 
Headache  42 41 15 15 20 21 11 9 
Fatigue  16 18 15 14 13 21 9 10 
Muscle Pain 20 12 10 7 13 14 7 9 
Fever*** 0 1 < 1 < 1 < 1 0 < 1 0 
Joint pain  5 5 4 4 5 6 5 6 
Nausea  8 6 6 5 4 5 4 3 
Chills  3 2 3 3 4 5 4 4 
Sweating  3 5 NA** NA NA NA 3 2 
NOTE: Data based on the most severe response reported by subjects on the memory aid. Results > 1% 
reported to nearest whole percent; results > 0 but < 1 reported as < 1%.  
* Data restricted to 135 µg formulation; **
 
NA = data not available (not collected during the study); 
***Fever defined as ≥ 99.6°F (37.6°C). In other studies fever was defined as > 100.4°F (38°C).  
 
 
Table 4 summarizes the most common unsolicited adverse events reported during the 
four clinical studies during the 28 day post-vaccination period. These events were 
reported either spontaneously or in response to general queries about changes in 
health status. The most common events were headache and signs or symptoms of 
upper respiratory tract infection in the four studies. These, as well as diarrhea and 
muscle aches, were the only adverse events reported by > 1% of subjects. Older 
subjects were, in general, less likely to report adverse events, despite similar methods 
of ascertainment in PSC03 compared to the other three studies. The relatively high 
rates of reactogenicity in study PSC01 may have been due to an additional clinic visit 
on study day 2, along with the requirement of a third visit to the clinic on day 8. 
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Table 4.  Adverse events reported by ≥ 1% of subjects in any group in the four 
clinical trials of FluBlok within 28 days of vaccination, irrespective of 
causality 
 
 Study PSC01 Study PSC04 Study PSC06 Study PSC03 
 Adults age  
18-49 yrs 
Adults age  
18-49 yrs 
Adults age  
50-64 yrs 
Adults age  
≥ 65 yrs 
 FluBlok Placebo FluBlok Placebo FluBlok Fluzone FluBlok Fluzone 
Number of 
Subjects 153 154 2344 2304 300 302 436 433 
Any adverse events (%) 35 42 16 15 14 17 21 20 
Diarrhea (%) 1 3 1 1 1 0 1 1 
Nasophayngitis (%) 3 3 1 1 < 1 < 1 1 2 
Upper respiratory tract 
infection (%) 6 5 1 1 1 < 1 1 1 
Myalgia (%) 1 3 < 1 < 1 0 < 1 < 1 < 1 
Headache (%) 8 8 2 2 < 1 < 1 < 1 1 
Cough (%) 4 2 2 2 2 < 1 1 2 
Nasal congestion (%) 3 4 2 1 1 < 1 1 1 
Pharyngolaryngeal pain 
(%) 5 5 2 2 1 3 < 1 1 
Rhinorrhea (%) 1 3 1 1 1 2 < 1 1 
Fatigue (%) 1 2 1 1 0 < 1 < 1 < 1 
Nausea (%) 2 0 1 1 0 0 < 1 1 
Sinusitis (%) 1 1 1 1 0 < 1 1 < 1 
Pyrexia (%) 1 0 < 1 < 1 0 0 < 1 <1 
Back pain (%) 1 2 < 1 < 1 < 1 1 < 1 1 
Injection site erythema 
(%) 0 0 0 0 2 < 1 2 < 1 
Injection site 
 hemorrhage (%) 1 0 < 1 < 1 0 < 1 1 1 
Injection site swelling 
(%) 0 0 0 0 0 < 1 1 < 1 
Pain in extremity (%) 0 0 < 1 < 1 0 < 1 1 < 1 
Tooth abscess (%) 0 0 < 1 0 <1 0 < 1 1 
Arthralgia (%) 1 2 < 1 < 1 < 1 < 1 < 1 < 1 
Insomnia (%) 1 1 < 1 0 0 0 < 1 < 1 
Sinus congestion (%) 1 1 < 1 < 1 0 0 < 1 < 1 
Hyperhidrosis (%) 1 1 < 1 < 1 0 0 0 0 
 
 
3.3 Immunogenicity results 
In all four FluBlok studies, hemagglutination-inhibition (HAI) antibody titers to each 
virus strain represented in the vaccine were measured in sera obtained approximately 
28 days after vaccination. Analysis of endpoints was performed for each HA 
contained in the vaccine, active control and/or placebo according to the criteria 
specified in the Food and Drug Administration (FDA) Guidance for Industry: 
“Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza 
Vaccines” (May 2007). In studies PSC04 and PSC06, the following two pre-specified 
primary immunogenicity endpoints were assessed: (i) the lower bounds of the two-
sided 95% confidence intervals (CI) for the proportion of subjects with HAI antibody 
titers of:40 or greater after vaccination (seroprotection rate), which should meet or 
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exceed 70% for each vaccine antigen strain; and (ii) the lower bounds of the two-
sided 95% CI for rates of seroconversion (defined as a fourfold increase in post-
vaccination HAI antibody titers from pre-vaccination titers of 10 or greater, or an 
increase in titers from less than 10 to 40 or greater), which should meet or exceed 
40% for each vaccine antigen strain. 
For study PSC03, these endpoints were pre-specified as secondary endpoints, 
except that criteria for subjects ≥ 65 years of age were applied (seroprotection rate 
should meet or exceed 60% for each vaccine antigen strain and the seroconversion 
rate should meet or exceed 30% for each vaccine antigen strain). 
For study PSC01, the primary endpoints, as originally specified, were 
descriptive comparisons of immune response in the various study groups; therefore, a 
post hoc analysis of the endpoints, as using the same criteria as described earlier for 
study PSC04, was performed. For PSC01 only, seroprotection is defined (post hoc) as 
a post-vaccination (day 28) HAI titer of ≥64.  Based on the serum dilution series used 
in the HAI antibody assay, 1:64 is the first dilution in which the antibody titer would 
be ≥40, the criterion specified in the Center for Biologics and Research (CBER) 
Guidance Document. Likewise, for PSC01 only, seroconversion is defined as a ≥4-
fold increase in HAI titer on day 28 in subjects with a prevaccination titer of ≥4, with 
a minimum day 28 titer of 64; or an HAI titer of ≥64 on day 28 in subjects with a pre-
vaccination titer <4 (Limit of detection or LOD) of the HAI assay used in PSC01).  
As shown in Table 5, across all four studies, serum HAI antibody responses to 
FluBlok usually met the pre-specified seroconversion criteria for all three virus 
strains, and also the pre-specified criterion for the proportion of subjects with HAI 
titers ≥ 40 (seroprotection). In study PSC01 and PSC03, FluBlok did not meet the pre-
specified seroprotection or seroconversion criterion, respectively, for the influenza B 
virus. The clinical relevance of these findings on vaccine-induced protection against 
illness caused by influenza type B strains is unknown, especially given the good 
responses against type B in young adults in study PSC04, and the lack of a head-to-
head comparison for the B vaccine component in study PSC03 (see Table 5). In study 
PSC04 (subjects age 18-49 years), FluBlok met the pre-specified seroprotection and 
seroconversion criterion for all three strains. In study PSC06 (subjects age 50-64 
years), FluBlok met the pre-specified seroprotection criterion for all three strains 
while Fluzone marginally passed the seroprotection criterion for the H3 strain (lower 
end of two-sided CI was rounded up to 70%). In addition, in PSC06, FluBlok met the 
seroconversion criterion for the H1 and H3 strains but not for the B strain, while 
Fluzone failed to meet the pre-specified seroconversion criterion for the H3 and B 
strains. 
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Table 5. Serum HAI antibody responses at post-vaccination day 28 in subjects age ≥ 18 years  
 Study PSC01 Study PSC04 Study PSC06 Study PSC03 
 Adults age 18-49 yrs Adults age 18-49 yrs Adults age 50-64 yrs Adults age ≥ 65 yrs 
 FluBloka Placebo FluBloka FluBloka Fluzone FluBloka Fluzone 
Number of Subjects 150 151 391 299 302 431 430 
A/H1N1 A/New Caledonia A/Solomon Islands A/Solomon Islands A/New Caledonia 
% Seroprotectedb 
  (95% CI)  
87 
(81, 92) 
40 
(33, 49) 
98 
(97, 99) 
96 
(94, 98) 
96 
(93, 98) 
95 
(92, 97) 
95 
(92, 97) 
%Seroconversionc 
  (95% CI)  
60 
(52, 68) 
0 
(0, 2) 
78 
(74, 82) 
72 
(67, 77) 
66 
(61, 72) 
43 
(39, 48) 
33 
(28, 37) 
A/H3N2 A/Wyoming A/Wisconsin A/Wisconsin A/Wisconsin 
% Seroprotectedb 
  (95% CI)  
100 
(98, 100) 
66 
(57, 73) 
96 
(94, 98) 
85 
(81, 89) 
75 
(70, 80) 
97 
(94, 98) 
93 
(90, 95) 
%Seroconversionc 
  (95% CI)  
77 
(69, 83) 
9 
(5, 15) 
81 
(76, 84) 
61 
(55, 67) 
44 
(38, 50) 
78 
(74, 82) 
58 
(53, 62) 
B B/Jiangsu B/Malaysia B/Malaysia B/Ohio B/Malaysia 
%Seroprotectedb 
 (95% CI)  
65 
(57, 73) 
7 
(3, 12) 
96 
(93, 98) 
93 
(90, 96) 
94 
(91, 97) 
92 
(89, 94) 
97 
(95, 99) 
%Seroconversionc 
  (95% CI)  
63 
(55, 71) 
1 
(0, 4) 
53 
(48, 58) 
41 
(35, 47) 
41 
(36, 47) 
29 
(25, 34) 
39 
(34, 44) 
a Values shown for FluBlok are for those subjects who received the 135 µg dose. Numbers in bold meet the 
criteria listed in the FDA Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal 
Inactivated Influenza Vaccines (May 2007) (see definitions below). These criteria were specified as secondary 
endpoints in study PSC03. 
 b Seroprotection rate (HAI titer ≥40) is defined as the proportion of subjects with a minimum post-vaccination 
HAI antibody titer of  40. The lower bound of the 2-sided 95% Confidence Interval (CI) for the seroprotection rate 
should be ≥ 70% for adults age 18-64 years, and ≥ 60% for adults age 65 years and older. However, for PSC01 
only, seroprotection rate is defined (post-hoc) as the proportion of subjects with a minimum post-vaccination HI 
titer of 64. (Based on the serum dilution series used in the HAI antibody assay in PSC01, 1:64 is the first dilution 
in which the antibody titer would be ≥40.) 
c Seroconversion rate is defined as a ≥ 4-fold increase in post-vaccination HAI antibody titer from the pre-
vaccination titer ≥ 10 or an increase in titer from < 10 to ≥40. The lower bound of the 2-sided 95% CI for the 
seroconversion rate should be ≥ 40% for adults age 18-64 years, and ≥ 30% for adults age 65 years and older. 
However, for PSC01 only, seroconversion rate is defined (post-hoc) as a ≥4-fold increase in post-vaccination HAI 
titer from prevaccination titer ≥1:4, with a minimum Day 28 titer of 64; or an increase in titer from <4 (= limit of 
detection) of the HAI assay used in PSC01) to ≥64.  
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In study PSC03, the following co-primary endpoints were pre-specified for each HA 
contained in the vaccine and/or active control: (i) the upper bound of the two-sided 
95% Confidence Interval (CI) on the ratio of Geometric mean Titer (GMTs) (GMTUS 
licensed vaccine/GMTFluBlok) should not exceed 1.5; and (ii) the upper bound of the 
two-sided 95% CI on the difference between seroconversion rates (SeroconversionUS 
licensed vaccine – Seroconversion FluBlok) should not exceed 10% points. These endpoints 
were specified as secondary in study PSC06. As shown in Table 6, for Study PSC03, 
non-inferiority of GMTs (in comparison to Fluzone) were met for all three strains, and 
non-inferiority of the difference in seroconversion rates was met for the two A strains. 
In PSC06, FluBlok, non-inferiority of both the GMTs and the difference in 
seroconversion rates was met for all three strains. 
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Table 6. Serum hemagglutination-inhibition responses following immunization with 
FluBlok (135 µg) or Fluzone in studies PSC03 (subjects ≥ 65 years of age) 
and PSC06 (subjects 50-64 years of age). 
 PSC06 PSC03 
 FluBlok Fluzone FluBlok Fluzone 
Number of Subjects 299 302 431 430 
A/H1N1 A/Solomon Islands A/New Caledonia 
Pre-vaccination GMT* 28.7 (25.6, 32.2) 27.8 (25.1, 30.8) 69.0 (62.1, 76.6) 70.2 (62.8, 78.6) 
Post-vaccination GMT* 181.3 (159.6, 206.0) 139.7 (124.6, 156.7) 176.8 (159.4, 196.0) 148.1 (134.2, 163.4) 
Post-vax GMT ratio, 
Fluzone:FluBlok 
(two-sided 95% CI) 
0.77 (0.75, 0.79) 0.84 (0.81, 0.86) 
No. (%) seroconverting** 
 [two-sided 95% CI] 
216 (72) 
[67, 77] 
200 (66) 
[61, 72] 
187 (43) 
[39, 48] 
140 (33) 
[28, 37] 
Difference in 
Seroconversion rate, 
Fluzone–FluBlok  
(two-sided 95% CI) 
-6% (-13, 1), p = 0.113 -11% (-17, -4), p = 0.001 
A/H3N2 A/Wisconsin A/Wisconsin 
Prevaccination GMT* 18.6 (16.4, 21.1) 18.2 (16.1, 20.6) 42.7 (37.6, 48.4) 44.7 (39.2, 51.0) 
Postvaccination GMT* 105.4 (91.0, 122.1) 60.9 (53.6, 69.2) 338.5 (299.7, 382.5) 199.2 (176.8, 224.4) 
Post-vax GMT ratio, 
Fluzone:FluBlok 
(two-sided 95% CI) 
0.58 (0.53, 0.62) 0.59 (0.57, 0.60) 
No. (%) seroconverting** 
[two-sided 95% CI] 
183 (61) 
[55, 67] 
132 (44) 
[38, 50] 
335 (78) 
[74, 82] 
248 (58) 
[53, 62] 
Difference in 
Seroconversion rate, 
Fluzone–FluBlok  
(two-sided 95% CI) 
-18% (-25, -10), p < 0.001 -20% (-26, -14), p < 0.001 
B B/Malaysia B/Ohio B/Malaysia 
Prevaccination GMT* 48.5 (43.4, 54.2) 49.2 (43.8, 55.3) 79.9 (71.3, 89.5) 80.3 (72.0, 89.5) 
Postvaccination GMT* 110.9 (100.1, 123.0) 116.0 (104.2, 129.3) 149.6 (134.5, 166.3) 194.8 (177.5, 213.7) 
Post-vax GMT ratio, 
Fluzone:FluBlok 
(two-sided 95% CI) 
1.05 (1.01, 1.09) 1.30 (1.26, 1.34) 
No. (%) seroconverting**  
[two-sided 95% CI] 
122 (41) 
[35, 47] 
124 (41) 
[36, 47] 
126 (29) 
[25, 34] 
168 (39) 
[34, 44] 
Difference in 
Seroconversion rate, 
Fluzone–FluBlok  
(two-sided 95% CI) 
0.3% (-8, 8), p = 1.00 10% (4, 16), p = 0.003 
NOTE:  Numbers in bold meet the non-inferiority criteria listed in the FDA Guidance for Industry: 
Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines (May 2007) 
(see definitions below). 
* Day 0 (pre-vaccination) and day 28 (post-vaccination) geometric mean titers (95% confidence 
intervals [CI]). The upper bound of the two-sided 95% CI on the ratio of GMTs (GMTU.S. licensed 
vaccine/GMTFluBlok) should not exceed 1.5; **  Seroconversion rate is defined as a ≥ 4-fold increase in 
post-vaccination HAI antibody titer from pre-vaccination titer ≥10 or an increase in titer from <10 to 
≥40. The lower bound of the two-sided 95% CI for the seroconversion rate should be ≥ 40% for adults 
age 18-64 years, and ≥ 30% for adults age 65 years and older. 
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3.4 PSC01: correlation between post-vaccination titer and the acquisition of 
influenza infection 
Study PSC01 also assessed the development of laboratory documented (culture-
confirmed) influenza illness meeting the influenza-like illness case definition 
specified by the US Centers for Disease Control and Prevention (CDC-ILI), i.e., 
presence of fever ≥ 99.8°F (37.7°C) and either sore throat or cough, or both [Treanor 
et al., 2007]. During the surveillance period in PSC01 in the 2004-2005 season, 10 
influenza isolates were found to be genetically similar to A/California/7/04 (H3N2), 
based on complete cDNA sequencing of the HA1 region obtained from reverse 
transcriptase-polymerase chain reaction (RT-PCR) amplified Madin-Darby Canine 
Kidney cell-grown virus [Treanor et al., 2007]. These strains were considered to 
represent significant drift from the H3N2 vaccine strain, first isolated in 2003, 
A/Wyoming/3/03. Table 7 shows the HAI titers on day 28 and day 180 in subjects 
with a positive H3N2 culture.  
Table 7.  HAI Titers on day 28 and day 180 in influenza A culture-positive (n=10) by  
 study group 
Lab 
Sample ID 
Characterization 
Date of swab 
collection 
HAI Titer 
on Day 28
HAI Titer 
on Day 
180 
Study 
Group 
Met CDC-ILI 
criteria? 
Isolate No. 
38 H3 3 Jan 05 8 256 Placebo Yes 
301 H3 21 Dec 04 256 256 Placebo Yes 
356 H3 18 Feb 05 32 128 Placebo Yes 
484 H3 15 Feb 05 64 256 Placebo Yes 
606 H3 18 Mar 05 4 32 Placebo Yes 
617 H3 8 Feb 05 16 128 Placebo No 
54 H3 7 Feb 05 512 1024 75µg No 
146 H3 31 Jan 05 256 256 75µg  No 
446 H3 6 Jan 05 >1024 512 75µg Yes 
653 H3 24 Jan 05 32 64 75µg  Yes 
 
In study PSC01 13.9 % of the placebo recipients showed serological evidence of H3 
influenza infection (i.e. four-fold increase in antibody titer between day 28 and day 
180 for the H3 antigen) versus 5 % of the vaccinated subjects. This difference is not 
surprising since the day 28 titers of the vaccinated subjects are higher than the non-
vaccinated subjects and therefore obtaining a four-fold increase in titer may be more 
difficult than among placebo recipients. As shown in Table 4, influenza infection in 
the placebo group as evidenced by culture is associated with low day 28 antibody 
titers. Five (83.3%) of the 6 placebo recipients who were culture-positive for A/H3N2 
met the case definition for CDC-ILI. All but one of the 6 placebo recipients with 
laboratory-confirmed A/H3N2 infection associated with CDC-ILI had day 28 titers 
lower than 64. Only one had day 28 titers of 256. The results for the FluBlok group, in 
contrast, showed that cell culture confirmed infections occurred throughout a wide 
spectrum of post-vaccination titers (64 – 1024). Three of the 4 culture-confirmed 
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A/H3N2 infections occurred in subjects with day 28 titers of ≥256, including one in a 
subject with a post-vaccination titer of 4096; however, none of the culture-confirmed 
A/H3N2-infected individuals showed serological evidence of infection. In contrast to 
the experience in the placebo group, only 2 (50%) of the culture-confirmed A/H3N2 
infections in the FluBlok group met the case definition for CDC-ILI. Although the 
numbers are small, the difference in outcome between placebo and FluBlok 
recipients, especially with regard to CDC-ILI, suggests a high degree of clinical 
efficacy.  
 
3.5 PSC03: Immunogenicity in Subjects Ages 75 and older 
In an exploratory analysis of PSC03, the proportions of subjects achieving 
seroconversion and seroprotection were examined in a subset of 322 subjects 
characterized by age 75 years and older. As shown in Table 8, vaccination with 
FluBlok yielded similar rates of seroprotection and seroconversion for this 
subpopulation when compared with the overall population of subjects 65 years of age 
and older. In addition, FluBlok met the CBER criterion for non-inferiority of 
geometric mean titers (GMTs) for all three strains in this subpopulation of older 
subjects. 
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Table 8.  Serum HAI responses following immunization with FluBlok (135 µg) or 
Fluzone in subjects ≥ 65 yrs and ≥ 75 yrs from study PSC03 
 PSC03 
 Adults age ≥ 65 yrs Adults age ≥ 75 yrs 
 FluBlok Fluzone FluBlok Fluzone 
Number of Subjects 431 430 163 159 
A/(H1N1) A/New Caledonia A/New Caledonia 
Pre-vaccination GMT a 69.0 (62.1, 76.6) 70.2 (62.8, 78.6) 63.3 (53.6, 74.8) 65.5 (55.3, 77.6) 
Post-vaccination GMT a 176.8 (159.4, 196.0) 148.1 (134.2, 
163.4) 
152.7 (128.1, 182.0) 125.3 (107.1, 146.7) 
Post-vax GMT ratio, 
Fluzone:FluBlok 
(2-sided 95% CI) 
0.84 (0.81, 0.86) 0.82 (0.79, 0.85) 
% Seroprotectedb 
  (95% CI)  
95 
(92, 97) 
95 
(92, 97) 
91 
(87, 96) 
94 
(91, 98) 
%Seroconversionc 
  (95% CI)  
43 
(39, 48) 
33 
(28, 37) 
39 
(32, 47) 
30 
(23, 37) 
A/(H3N2) A/Wisconsin A/Wisconsin 
Prevaccination GMT a 42.7 (37.6, 48.4) 44.7 (39.2, 51.0) 39.7 (32.7, 48.1) 43.1 (35.2, 52.8) 
Postvaccination GMT a 338.5 (299.7, 382.5) 199.2 (176.8, 
224.4) 
300.2 (244.7, 368.3) 178.4 (147.8, 215.3) 
Post-vax GMT ratio, 
Fluzone:FluBlok 
(2-sided 95% CI) 
0.59 (0.57, 0.60) 0.59 (0.58, 0.61) 
% Seroprotectedb 
  (95% CI)  
97 
(94, 98) 
93 
(90, 95) 
96 
(93, 99) 
93 
(89, 97) 
%Seroconversionc 
  (95% CI)  
78 
(74, 82) 
58 
(53, 62) 
79 
(73, 85) 
54 
(46, 62) 
B B/Ohio B/Malaysia B/Ohio B/Malaysia 
Prevaccination GMT a 79.9 (71.3, 89.5) 80.3 (72.0, 89.5) 101.9 (86.7, 119.9) 102.6 (86.1, 122.1) 
Postvaccination GMT a 149.6 (134.5, 166.3) 194.8 (177.5, 
213.7) 
185.7 (160.8, 214.4) 224.8 (193.2, 261.5) 
Post-vax GMT ratio, 
Fluzone:FluBlok 
(2-sided 95% CI) 
1.30 (1.26, 1.34) 1.21 (1.18, 1.24) 
% Seroprotectedb 
  (95% CI)  
92 
(89, 94) 
97 
(95, 99) 
96 
(93, 99) 
99 
(98, 100) 
%Seroconversionc 
  (95% CI)  
29 
(25, 34) 
39 
(34, 44) 
26 
(20, 33) 
35 
(28, 43) 
NOTE: Numbers shown in bold meet the non-inferiority criteria listed in the FDA Guidance for Industry: Clinical 
Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines (May 2007) (see definitions 
below). 
a. Day 0 (prevaccination) and Day 28 (postvaccination) geometric mean titers (GMT) (95% confidence intervals 
[CI]). The upper bound of the 2-sided 95% CI on the ratio of GMTs (GMTU.S. licensed vaccine/GMTFluBlok) should not 
exceed 1.5. 
b. Seroprotection rate (HI titer ≥40) is defined as the proportion of subjects with a minimum post-vaccination HI 
antibody titer of 40. The lower bound of the 2-sided 95% CI for the seroprotection rate should be ≥ 70% for adults 
age 18-64 years, and ≥ 60% for adults age 65 years and older. 
c. Seroconversion rate is defined as a ≥ 4-fold increase in post-vaccination HI antibody titer from pre-vaccination 
titer ≥10 or an increase in titer from < 10 to ≥40. The lower bound of the 2-sided 95% CI for the seroconversion 
rate should be ≥ 40% for adults age 18-64 years, and ≥ 30% for adults age 65 years and older. 
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4. Conclusions 
 
The baculovirus-insect cell expression system is particularly suitable for influenza 
vaccine production where annual adjustment of the vaccine is required. Extensive 
qualification testing performed on the SF+ cell line supports its application for this 
purpose. Additionally, the initial results from ongoing adventitious insect virus testing 
have failed to detect any contaminating viruses providing further safety assurances.  
FluBlok is a trivalent rHA vaccine with a mechanism of action likely to be 
similar to that of the trivalent inactivated licensed influenza vaccine, namely the 
induction of HAI antibodies to prevent influenza infection [Kida et al., 1983; Yoden 
et al.,1986] The commercial formulation of FluBlok contains three times the amount 
of HA of the inactivated influenza vaccines and consequently induces higher antibody 
titers (Tables 5, 6 and 8), which may be of particular importance to those most at risk 
for influenza (for example, the elderly [Keitel et al., 1994; Keitel et al., 1996; Treanor 
et al., 2006] or immunologically compromised [Safdar et al., 2006]. The 
immunogenicity results for the B/strain in the elderly study PSC03 must be 
interpreted cautiously in the context of a lack of a direct antigen comparison. 
Although the two strains (B/Ohio and B/Malaysia) were considered to be 
antigenically related by WHO Reference Laboratories, and therefore interchangeable 
for purposes of vaccine production, previous studies of influenza vaccines have 
shown that HAI titers achieved following vaccination with different influenza 
antigens of the same subtype typically differ from each other, often to variable 
degrees. 
 While FluBlok contains 135 µg HA per dose, the total amount of protein (HA 
plus host cell proteins) contained within one dose of FluBlok is roughly comparable 
to the total amount of protein contained in FluZone, which is approximately 115 µg 
total protein per dose (viral plus egg protein) [Renfrey and Watts, 1994; Hehme et al., 
2003]. The vaccine was shown to be well tolerated and immunogenic in more than 
3000 adults older than 18 years. Importantly, this vaccine has demonstrated protective 
efficacy in a field efficacy trial against drifted influenza viruses [Chapter 5; Cox and 
Anderson, 2007; Treanor et al., 2007].  
 Based on these studies FluBlok received Fast Track Designation from the 
FDA in December 2006 and a Biological License Application (BLA) has been filed in 
April 2008, and expects to receive FDA approval in 2010. 
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Chapter 7 
General Discussion 
 
1. Synopsis 
 
The process to obtain licensure of a biologic product for human use is complicated 
and challenging. This thesis describes the path leading towards licensure of a novel 
influenza vaccine using a novel cell substrate. Specifically, the development of a safe, 
immunogenic and effective novel recombinant trivalent hemagglutinin (HA) influenza 
vaccine manufactured in insect cell cultures using the baculovirus-insect cell 
expression system is described.  
The greatest challenge in the manufacturing of influenza vaccines results from 
the fact that the vaccine requires adjustments on an annual basis. The time available to 
make these adjustments is extremely short, a matter of months. Therefore it is 
important that a versatile, robust manufacturing process is established that can result 
in timely delivery of the new antigens. In Chapter 2 and 3, it was shown that cloning 
the influenza HA from the influenza virus into a baculovirus vector can be 
accomplished within a few weeks. The biochemical properties of recombinant HA 
(rHA) produced in the baculovirus-insect cell system appear to be similar to those of 
authentic viral HA as is demonstrated by various methods that were developed to 
assess the biological activity. Progress was also made towards scalable purification 
processes at the 500-L scale that enabled purification of sufficient amounts of diverse 
hemagglutinin molecules.  
Preliminary evidence for the efficacy of a recombinant HA vaccine produced 
in the baculovirus-insect cell system was presented in Chapter 4. The fact that none 
of the high dose vaccine, containing 45µg rHA of each antigen, recipients developed 
cell culture confirmed influenza suggests that absence of influenza neuraminidase 
(NA) and differences in glycosylation in insect versus vertebrate cells do not interfere 
with vaccine performance. The H3N2 influenza viruses isolated from six placebo 
recipients and four low dose vaccine recipients were characterized by sequence 
analysis in Chapter 5 and it was shown that they had high similarity to an 
A/California/7/04 virus - a drift variant from the Wyoming/3/03 virus, from which the 
HA in the vaccine originated. This experiment provided preliminary evidence that the 
use of more antigen per vaccine dose can result in cross-protection of the vaccine 
against drifted viruses.  
Finally, questions and concerns were addressed specifically relating to the 
safety of this vaccine using this novel cell substrate in Chapter 6. Specifically, the 
potential presence of latent viruses in the insect cell line was studied using various 
techniques, including transmission electron microscopy of stressed insect cells and 
PCR methods to detect an array of viruses. Also, the safety and immunogenicity data 
from four clinical studies, that were used to support licensure of FluBlok® in the 
U.S., are included in this chapter. The total safety database for FluBlok included 2497 
subjects 18-49 years and 736 subjects older than 50 years who received the 
commercial formulation of FluBlok. The vaccine was shown to be well tolerated and 
immunogenic in adults older than 18 years.  
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2. Implications of this work for public health and pandemic 
preparedness 
 
All influenza vaccines currently licensed in the U.S. are manufactured in embryonated 
chicken eggs. FluBlok, manufactured using the baculovirus-insect cell production 
system eliminates the potential for anaphylaxis or other severe reactions in individuals 
with egg allergy. Although the number of persons who fall into this category is not 
precisely known, government and academic authorities have estimated that 
approximately 2-6% of children and 2-5% of adults in the U.S. have self-reported 
allergies to eggs [Kucukosmanoglu et al., 2008; Vierk et al., 2007]. This equates to up 
to approximately 2.4 million children age 10 and under and a minimum of 
approximately 5 million allergic adults aged 18 years and above. An estimated two-
thirds of these egg allergic individuals fall into the Advisory Committee for 
Immunization Practices recommended target groups for annual influenza vaccination, 
that is, at least 1.5 million egg-allergic children and 3 million egg-allergic adults 
presently have no alternative other than to risk an anaphylactic shock or other severe 
allergic reactions upon receipt of an egg-derived trivalent inactivated influenza 
vaccine (TIV). Thus, there is a very substantial unmet medical need for an alternative 
influenza vaccine that is free of egg proteins. Such a need was specifically 
acknowledged by former Secretary of the Department of Health and Human Services 
(DHHS) Michael Leavitt in a press release, issued on April 1, 2005, as a key driver 
for the development of cell-derived influenza vaccines [web link: 7-1] 
Clinical studies have shown that FluBlok, which contains three times more 
HA than TIV, is well tolerated and highly immunogenic, particularly in the elderly 
population [Treanor et al., 2006; Keitel et al., 2009; Chapter 6]. This is beneficial 
since the majority of the influenza related serious illness and death occur within the 
latter age group. 
The baculovirus-insect cell production process does not include the production 
of large quantities of live influenza virus, followed by the inactivation of the virus, 
and therefore does not require a high bio-containment manufacturing environment. 
This has a number of clear advantages: manufacturing personnel is not exposed to live 
influenza viruses and escape of a live virus is impossible during production. Reports 
of a product contaminated with a residual live influenza virus H5N1 accidentally 
released from a facility where large quantities of live viruses are processed are 
alarming [web link: 7-2] and demonstrate that the risk of accidental release is far from 
zero. 
Epidemics on a global scale also called pandemics may occur when a new 
virus capable of causing severe disease transmits easily among humans. Since there is 
no or little immunity to a newly emerging virus in the human population, it may 
spread quickly world wide. A pandemic was officially declared on June 11, 2009 
when the World Health Organization (WHO) raised its influenza H1N1 alert to its 
highest level – phase 6 – for the first time in over 40 years. The events that let to this 
decision are described briefly. Responding to what some health officials feared could 
be the leading edge of a global pandemic emerging from a swine flu outbreak in 
Mexico, American health officials declared a public health emergency on Sunday 
April 26, 2009 as 20 cases of swine flu were confirmed in the U.S., including eight in 
New York City. At this time Mexico was already in a state of alarm with virtually all 
schools, restaurants and businesses closed in Mexico City, resulting in an estimated 
economic loss of around U.S. $400M per day. On April 29, 2009, WHO raised the 
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level of pandemic alert from Phase 4 to Phase 5, indicating that human-to-human 
spread of the virus had occurred in at least two countries in one WHO region. As of 
the end of May, over 15,000 cases of H1N1 had been confirmed in more than 53 
countries, including 99 deaths, with 85 reported in Mexico alone. The case fatality 
rate in Mexico of H1N1 was estimated to be 1.5%, whereas in the U.S. it was only 
0.1%. In addition, the virus seemed to be behaving similarly to seasonal influenza, 
although the transmission rate is relatively high (est. 22-33% and similar to the usual 
transmission rate reported in children). On May 19, WHO and the United Nations 
organized a meeting with influenza vaccine manufacturers to discuss the status of 
influenza vaccine supply. The conclusion was that influenza vaccine manufacturers 
are still relying on the growth of live influenza viruses, mostly using chicken eggs. 
Attendees were informed by WHO that if they were to ask manufacturers to switch 
production by June 30 to the new H1N1 strain, only 30% of the usual seasonal supply 
of TIV would be available since the manufacturers just started producing the B- (or 
third) component of the vaccine. By the end of July 2009, approx 65% of the usual 
supply would be available. In addition, no seed virus was available to enable 
manufacturers to begin production at this time.  
By the middle of August, 2009, the number of human cases of pandemic 
(H1N1) 2009 is still increasing substantially in many countries, particularly in the 
Southern hemisphere, which entered its winter flu season. WHO stopped reporting 
individual cases mid July, in part because many epidemiologists have pointed out that 
many millions of people have had mild forms of the novel  H1N1 influenza [web link: 
7-3].  
The insect cell-baculovirus production technology is particularly suitable to 
address health care emergencies as currently posed by the H1N1 swine flu influenza 
virus. This manufacturing technology can be readily introduced into other countries, 
which would enable rapid expansion and availability of local vaccine production; for 
example, in Korea 50,000-L cell culture capacity exists that could supply millions of 
vaccine doses in a relatively short time. Assuming that yields obtained at the 500-L 
scale can also be achieved in a 10,000-L bioreactor, it is estimated that sufficient 
monovalent bulk protein for approximately 9 M doses containing 15µg of rHA can be 
produced in a 5-day cycle. As reported by Fedson and Dunnill (2007) 425 million 
doses of vaccine containing 10µg/dose could be produced within one month if 25% of 
the global bioreactor capacity (or 500,000-L) were to be allocated to rHA vaccine 
production. Furthermore, technology transfer would avoid the serious political 
impediments to export vaccine from manufacturing countries during a pandemic. For 
example, it has been described that the U.S. closed its borders in 1976 for vaccine 
export in anticipation of a potential swine flu outbreak [web link 7-4]. Shipment of a 
recombinant baculovirus that can be used to produce vaccine would generally not be 
limited by such regulations. It is essential that the above assumptions relating to yield 
and feasibility of technology transfer be tested. 
The development of a rHA vaccine against the H1N1 A/California /04/2009 
was started up on April 29, 2009 and by mid June, merely 6 weeks later, the first 
batches of vaccine were produced that could be used for clinical testing in human 
subjects. As shown in Figure 1 commercial production of a novel vaccine could start 
as early as 45 days after receipt of the virus. This timeline could be further improved 
by reducing the time needed to create a virus bank. Also shown in Figure 1 is the time 
required to release the product. Modern methods that are acceptable to the regulatory 
authorities are needed to release, for example the mycoplasma/spiroplasma cultivation 
test takes 30 days and could be replaced by a simple PCR test. It is unclear though at 
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this moment what vaccine formulation is needed to induce an acceptable immune 
response in various age groups, i.e. what potency is needed, will one dose be 
sufficient, and will an adjuvant be required? These questions need to be answered 
before an acceptable vaccination strategy can be formulated. Early June, the 
recombinant baculovirus was also shipped to various collaborators across the world 
and the University of Queensland reported successful vaccine production 
demonstrating a first step of the feasibility of technology transfer and local vaccine 
production [web link 7-5]. 
 
Figure 1. The development timeline of rH1 vaccine in insect cells. 
Commercial vaccine production could begin as early as 45 days after receipt 
of the virus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, as this technology matures it is likely to offer a powerful first line defense in 
combating the emergence of new viruses due to the increased contact between human 
and wildlife [Daszak et al.., 2001]. Vaccines against zoonotic diseases caused by for 
example Human Immunodeficiency Virus, West Nile Virus, Chikungunya Virus, 
Marburg Virus and Ebola Virus are desperately needed. It is important to 
acknowledge that it may not be easy or even feasible to identify the antigen that may 
offer protection as demonstrated by the failure to develop an effective vaccine against 
HIV over the past two decades. However, surface antigens offer a promising fast 
approach as exemplified by the virus neutralizing antibodies induced by the spike 
protein antigen derived from SARS coronavirus [Zhou et al., 2006]. The most 
attractive aspect of this technology is its versatility, i.e. it is perfectly suited as an 
emergency vaccine production system. 
Also, many malaria vaccine candidates are being produced using the 
baculovirus-insect cell production system [van Oers, 2006]. Furthermore, baculovirus 
insect cell-derived recombinant proteins are used as vaccines against cancer [Neidhart 
et al., 2004; Mao et al., 2006; Betting et al., 2009]. Thus, commercialization and 
further scale–up of this manufacturing technology beyond viral vaccines may have 
broad implications for disease control in general.  
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3. Other influenza vaccines in clinical development 
 
Inactivated influenza vaccines and efforts to improve performance 
It is widely recognized that there is a need to improve the efficacy of the inactivated 
egg-based influenza vaccines. Adjuvants, alternative antigen presentation forms, 
alternative routes of administration, or increasing the antigen content are the four key 
areas being pursued to improve the performance of existing vaccines (Table 1).  
 
Table 1. Key areas for improving the efficacy of existing egg-based influenza 
vaccines and their stage of development.  
 
Technology Description Product name /Manufacturer 
Stage of 
development 
MF59 (oil-in water 
emulsion) Fluad®/ Novartis 
Approved for 
adults, age 
≥60 by EMEA 
AS103 (oil-in water 
emulsion) Pandemrix®/GSK 
Approved for 
pandemic use 
by EMEA 
Adjuvants 
Alum 
Pandemic vaccines 
(CSL/Solvay/Denken 
Seiken) 
Approved for 
pandemic use 
by EMEA 
Inflexal® / Berna 
Biotech 
Approved by 
EMEA Alternative presentation form Virosomes 
Invivac® / Solvay Approved 
Nasal: adjuvanted flu 
vaccine 
Nasalflu® / Berna 
Biotech Withdrawn 
Other vaccine for 
intranasal delivery include 
a variety of adjuvants, 
such as MF 59 
lipid/polysaccharide ect.  
Various Early stage: Phase 1 
Inflexal® / Berna 
Biotech 
Early stage: 
Phase 1 
Alternative route of 
administration 
Intradermal Fluzone ®/ Sanofi 
Pasteur 
BLA 
submitted to 
FDA 
High antigen content 60 µg (4x)/ antigen Fluzone HD®/ Sanofi Pasteur 
BLA 
submitted to 
FDA 
 
The role of an adjuvant such as Alum, MF59 or AS103 or AS104 is to enhance – or 
reduce the amount of antigen needed, accelerate or prolong the immune response. 
MF59 (oil in water emulsion) is included in Novartis seasonal influenza vaccine Fluad 
which has been approved in Europe for use in adults older than 60 years. GSK’s 
AS103 (oil-in-water emulsion containing squalene) has been approved in Europe for 
use in its pandemic influenza vaccine candidate Pandemrix. To date Alum is the only 
approved adjuvant in the U.S., however, none of the currently used seasonal influenza 
vaccines contains Alum. The Alum adjuvant is used in various egg-based, pandemic 
vaccine products, including CSL, Denka-Seiken, and Solvay’s vaccine candidates. 
While adjuvants hold promise, especially from a dose reduction standpoint, concerns 
have been raised relating to their long-term safety. 
Alternative presentation forms such as virosomes are being pursued by Solvay 
and Berna Biotech. Virosomes are virus-like particles, resembling the native virus, but 
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lacking its genetic material. Virosomes are made using a process that includes 
solubilization of the viral envelope with detergents, centrifugation for removal of the 
nucleocapsid and reformation of virus-like particles lacking nucleic material 
[Stegmann et al., 1987]. Immunogenicity and safety data from two virosome based 
influenza vaccines currently on the market Inflexal V® (Berna Biotech) [Glück et al., 
2004] and Invivac® (Solvay) [de Bruin et al., 2004] suggests that this is an attractive 
approach to improve immunogenicity without apparent safety drawbacks. 
The standard influenza vaccine is administered by intramuscular injection. 
Alternative delivery methods include intradermal delivery or intranasal delivery. 
Various clinical studies have shown that alternative delivery methods can lead to dose 
reduction For example, Inflexal V® was shown to be overall highly immunogenic and 
well tolerated when given intradermal at reduced doses to healthy adults, eliciting an 
immune response similar to that observed with full dose intramuscular administration 
[Künzi et al., 2009]. Earlier Kenney et al. (2004) already demonstrated that in young 
adults an intradermal administration of one fifth of the standard intramuscular 
influenza vaccine dose elicited similar or better immune responses than a full dose 
intramuscular injection. Thus, suggesting that intradermal delivery can offer a 
promising antigen-saving strategy for influenza vaccination. Intranasal vaccine 
delivery has also been actively explored for delivery of inactivated influenza vaccines, 
however, due to the relatively low immunogenicity as measured by the induction of 
serum antibody responses, the combination with adjuvants was required. In 2001, the 
first adjuvanted, intranasal vaccine (Nasalflu®; Berna Biotech, Switzerland) was 
licensed in Switserland, however, it was taken off the market because there appeared 
to be an increased number of cases of Bell’s palsy (acute paralysis of the facial nerve 
leading to inability to control facial muscles), in association with vaccination [Mutsch 
et al., 2004]. Other adjuvants for intranasal influenza vaccines in human clinical 
development include an MF59 adjuvanted subunit vaccine [Boyce et al., 2000], a 
lipid/polysaccharide molecule carrier [Halperin et al., 2005], a nontoxigenic 
Escherichia coli enterotoxin and a novel bioadhesive delivery vector as mucosal 
adjuvants [Stephenson et al., 2006], a chitosan carrier [Read et al., 2005] and a 
proteosome, consisting of the outer membrane proteins of Neisseria meningitides 
[Treanor et al., 2006]. In general these approaches show vaccine candidates to be well 
tolerated and modestly immunogenic, stimulating different parts of the immune 
system. The largest increase in circulating antibodies usually occurs in response to 
intramuscular vaccination; the largest mucosal immunoglobulin A (IgA) response 
occurred in response to mucosal vaccination. None of the alternative delivery methods 
has been approved yet for inactivated or subunit vaccines. 
The fourth approach to improve immunogenicity is based on an increased 
antigen content of the vaccine. Human clinical studies conducted in the early nineties 
already demonstrated that increased doses of purified HA and subvirion vaccines 
produced an enhanced antibody response in both the elderly and healthy adult 
populations [Keitel, 1994; Keitel et al., 1996]. Recently, a large multicenter, 
randomized, double-blind controlled study in over 4000 adults 65 years and older 
compared a High Dose (FluZone HD vaccine - which contains 60 µg of 
hemagglutinin per strain) with the licensed standard-dose (SD) vaccine (FluZone - 
which contains 15 µg of hemagglutinin per strain) and showed FluZone HD to be well 
tolerated and more immunogenic than SD [Falsey, 2009]. Sanofi Pasteur has recently 
filed a biological license application with the FDA for this FluZone HD vaccine.  
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Live attenuated influenza vaccines (LAIV) 
LAIV, delivered as an inhaled mist, closely mimics a natural influenza infection. 
While these vaccines have been used for decades in Russia, Flumist was approved in 
2003 in the U.S. initially for healthy individuals between 5 – 49 years of age and more 
recently the label was expanded to include children between 2 – 5 years as well. The 
vaccine is made by re-assortment of a cold-adapted virus and gene segments from 
currently circulating influenza viruses. High levels of efficacy against influenza 
illness caused by both matched and mismatched strains in children and adults are 
reported in studies comparing LAIV and inactivated influenza vaccine in children, 
LAIV recipients experienced 35-53% fewer cases of culture-confirmed influenza 
illness caused by antigenically matched strains [Ambrose et al., 2008]. In contrast, a 
recent study by Wang et al. (2009)  which  compared the effectiveness inactivated 
influenza vaccines and LAIV over three influenza seasons from 2004 – 2007, reported 
that vaccine effectiveness for inactivated influenza vaccines ranged from 28 – 55%, 
and from 10.7 – 20.8% for LAIV. The efficacy depended primarily on the degree to 
which the vaccine strains were antigenically related to circulating wild-type strains. 
 
Alternative production methods to produce influenza vaccines 
More than 95% of all available influenza vaccine is manufactured in embryonated 
chicken eggs. An urgent need for alternative production methods for influenza 
vaccines was identified more than a decade ago in a WHO report (1995) and as a 
consequence different cell culture systems are being explored. Production of influenza 
viruses in cell systems has proven to be challenging as demonstrated by the fact that 
none of the current manufacturers has been successful in commercializing a cell-
based vaccine to date, even though both Solvay and Novartis received regulatory 
approval in Europe. Table 2 summarizes cell-culture based influenza vaccines in 
development. 
 
Table 2. Different cell substrates used by manufacturers for the production of 
influenza various vaccines and their stage of development. 
 
Cell Substrate Vaccine Type Product name /Manufacturer 
Stage of 
development 
Sub-virion vaccine Solvay Approved by EMEA  
Sub-unit vaccine Novartis Approved by EMEA MDCK  
Live-attn vaccine 
Pandemic vaccine 
(MedImmune) 
 
Early stage: 
Phase 1 
VERO Whole-virus-vaccine Baxter Approved by  EMEA 
PER.C6© Sub-virion vaccine Fluzone ®/ Sanofi Pasteur 
Early stage: 
Phase 1 
 
The choice of a cell line for an industrial process is usually dictated by the yield 
obtained. When comparing three different cell lines (MDCK, VERO and BHK-21 C-
13), Merten et al. (1999) concluded that the MDCK cells are most suitable as a 
substrate for the production of influenza viruses in serum-free media. VERO cells 
offer an advantage from a regulatory perspective since already licensed polio vaccines 
are produced using this cell substrate [Montagnon et al., 1983], however, yields of 
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influenza virus obtained with VERO cells were found to be approximately 10-fold 
lower than with other cell lines. This may explain why BAXTER decided to develop a 
whole-virus vaccine despite reports that whole-virus trivalent influenza vaccines, 
although more immunogenic than sub-virion vaccines, are also more prone to cause 
adverse reactions [Nicholson, 1976]. (Note: All currently licensed influenza vaccines 
are either sub-virion or sub-unit influenza vaccines). 
Clinical evaluation of sub-virion influenza vaccines produced in MDCK cells 
has shown that these vaccines have a comparable immunogenicity and safety profile 
as egg-based vaccines [Palache et al., 1999; Halperin et al., 2002]. Cell culture offers 
significant advantages from a production perspective. Technologies described in 
Table 1 can also be used to improve the performance of cell-based vaccines. 
 
Other recombinant influenza vaccine approaches in clinical development 
Alternative recombinant influenza vaccine approaches in human clinical development 
are summarizes in Table 3. 
 
Table 3. Alternative recombinant influenza vaccines in development  
 
Technology Description Product name /Manufacturer 
Stage of 
development 
VLP Vaccines 
VLP containing M1, HA and NA 
produced in the baculovirus-insect 
cell system 
Novavax Early stage: Phase 1/II 
HA/flagellin 
Combination 
HA fused to a toll-like receptor 
antagonist Vaxinnate Phase 1 
HA Viral Vector 
Vaccine 
HA is produced a non-replicating 
adenovirus using Per.C6© cells Vaxin Phase 1 
NA subunit Vaccine NA protein produced in the baculovirus-insect cell system 
Protein Sciences 
Corporation Phase 1/2 
M2e linked to the Hepatitis B core 
protein 
ACAM-FLU-A/ 
Acambis Phase 1 Universal Vaccine 
Multi-epitope vaccine fused to a toll-
like receptor antagonist BiondVac Abandoned 
HA based Powermed Phase 1 DNA vaccines 
NP, M2, HA based Vical Phase 1 
 
VLP vaccines 
VLPs are produced using the baculovirus-insect cell system by co-expressing the M1 
and various combinations of HA, NA, and/or M2 proteins of the influenza virus. All 
VLPs contain the M1 protein, presumably because this protein apparently possesses 
all the functions necessary for structure, budding and release of VLPs [Latham et al., 
2001; Gómez-Puertas et al., 2000]. Novavax' s VLP vaccine candidate, contains M1, 
HA and NA and is currently being evaluated in Phase I/II clinical studies [Bright et 
al., 2007; Clinical Trial NCT00519389]. Human clinical data presented at various 
meetings suggest that the VLP vaccine induces comparable immune response to other 
inactivated influenza vaccines. The potential strength of VLP vaccines is that they 
may provide broader protection against heterologous viruses [Bright et al., 2007]. 
However, a challenge in the use of VLP vaccines is the production of particles of a 
consistent nature, since this is thought to be critically important in inducing strong 
immune responses [Quan et al., 2007].  
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HA/flagellin combination vaccine 
Vaxinnate (www.vaxinnate.com) is developing a recombinant HA combination with 
the bacterial protein flagellin. In this vaccine the protective subunit of the HA 
molecule is genetically fused to the Toll-like receptor (TLR) agonist, flagellin. The 
recombinant HA-flagellin protein is produced in E. coli.  Flagellin derived from 
Salmonella typhimurium is a protein that through pathogen-associated molecular 
patterns (PAMS) interacts with TLR-5 (TLRs) [Huleatt et al., 2007] and as such has 
the ability to enhance the cellular and humeral immunity of the vaccine. This vaccine 
- if proven to be safe and efficacious- could offer advantages from a manufacturing 
perspective, speed and cost-wise. VaxInnate’s HA-flagellin vaccine for seasonal flu 
generated positive Phase I clinical results. Interestingly, BiondVax, decided to 
abandon clinical development when their “universal” influenza vaccine was citing 
mild side effects possibly attributed to the flagellin (see below). 
 
HA Viral Vector Vaccines 
The only viral vector vaccine that is currently in clinical development is a non-
replicating adenovirus-vectored, nasal HA-based influenza vaccine candidate from 
Vaxin. The product has completed an initial Phase I clinical trial using a monovalent 
formulation. This study demonstrated safety and serological response in 48 healthy 
adults when a recombinant adenovirus vector was used to deliver the influenza 
hemagglutinin (HA) gene by nasal administration [van Kampen et al., 2005]. The 
non-replicating adenovirus containing the HA gene is produced using the PER.C6© 
cell line (licensed from the Dutch biotechnology company Crucell©) which is also 
used by Sanofi-Pasteur for the production of an inactivated influenza vaccine. 
Insufficient information is available in the public domain to determine whether this 
vaccine approach may offer advantages compared to other vaccines in development. 
 
Recombinant NA Influenza Vaccine  
An NA vaccine produced using the baculovirus-insect cell system consisting of the 
NA protein from A/Johannesburg/33/94 (N2) was tested in human individuals for 
safety and immunogenicity [Matthews, 2000; Dr. G.E. Smith, Novavax, personal 
communication]. The vaccine candidate proved to be safe and immunogenic using 
doses ranging from 5 to 45 µg without the use of an adjuvant. In a follow-up clinical 
trial, individuals were vaccinated with TIV or with TIV supplemented with NA and 
then challenged with an attenuated influenza virus [Matthews, 2000]. Even though the 
results from this trial were not statistically significant, a trend toward reduction of 
severity of illness, reduced shedding and shorter duration of illness in those 
individuals vaccinated with the NA supplemented vaccine was apparent. This 
suggests that an NA vaccine may have potential as an additive to the licensed vaccine.  
 
Universal Vaccine 
Acambis is targeting a universal vaccine that targets all influenza A virus strains. The 
ACAM-FLU-A™ vaccine is based on the influenza M2e region, linked to the 
Hepatitis B core protein. M2e is a conserved region in the M2 ion-channel protein of 
all influenza A strains [Fiers et al., 2004; Neirynck et al., 1999]. M2 antibodies have 
been detected in humans following influenza virus infection; however, their role in 
the influenza-related disease process and viral clearance is not certain [Black et al., 
1993]. It is clear that if this approach is successful this would offer a huge potential, 
offering the opportunity to vaccinate at any time of the year, to provide immunity for 
more than one influenza season and in that way to overcome the need for annual 
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vaccine reformulations. However, an M2-only based vaccine is limited because it 
would only protect against influenza A and not influenza B. 
BiondVax was developing an intranasal peptide vaccine using a combination 
of conserved epitopes derived from the influenza virus as immunogens. The 
"conserved epitopes" are common to most human influenza A and B virus strains 
regardless of their antigenic drift and shifts [Ben-Yedidia and Arnon, 2007]. The 
safety of the first generation epitope-based vaccine within flagellin was evaluated in a 
Phase I clinical trial. At a safe dose, with a low concentration of influenza epitopes, 
cross-reactive immunological responses specific to the influenza viruses were found, 
demonstrating the protective potential of a vaccine based on these epitopes. 
Nevertheless, due to the appearance of mild side effects possibly attributed to the 
flagellin to which the epitopes were fused, the company decided to discontinue the 
trial. 
 
DNA Vaccines 
Formerly PowderMed (now Pfizer) and Vical are both exploring the development of a 
DNA vaccine. Historically DNA vaccines have been shown only to be immunogenic 
when using large quantities of DNA. As a result innovative delivery vehicles have 
been developed to further this field. The advantage of DNA vaccines is that the 
plasmids can be manufactured using uniform methods of fermentation and processing. 
This could result in faster development and production times than technologies that 
require development of product-specific manufacturing processes. 
Powdermed recently reported results from a clinical study in healthy adults of 
a trivalent DNA vaccine for influenza consisting of three plasmids expressing HA 
from different seasonal influenza virus strains delivered using particle-mediated 
epidermal delivery (PMED) demonstrating an overall vaccine efficacy of 41%-53% 
[Jones et al., 2009]. The PMED requires 1 mg of gold/dose for efficient delivery, 
which appears to be expensive, but Powdermed claims that this represents only a 
fraction of the vaccine cost! It is unclear whether Pfizer is still pursuing the 
development of this vaccine. 
Vical (www.vical.com) is developing a three component DNA plasmid 
encoding two highly-conserved influenza virus proteins—nucleoprotein (NP) and ion 
channel protein (M2)—plus the HA influenza virus surface protein with novel 
adjuvant: A dose of 0.03 mg VaXfectin and 1 mg DNA (not a typo) is needed to 
induce any kind of meaningful immune response. Preliminary human safety and 
immunogenicity data from a Phase 1 study conducted in 100 subjects generated 
preliminary safety and immunogenicity data and showed that Vaxfectin®-formulated 
H5N1 pandemic influenza DNA vaccines can induce antibody responses in up to 67% 
without significant safety issues.  
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4. What’s Next: How can FluBlok be further improved? 
 
Improvements in product quality and performance 
FluBlok contains an increased antigen concentration compared to the standard TIV, 
i.e. 3x HA is included in the vaccine, which covers one of the four key areas 
discussed earlier to increase the performance of the licensed vaccine. So, the 
baculovirus insect-cell production system not only solves the qualitative, but foremost 
the quantitative constraints in producing a high number of doses of a protein-based 
vaccine, with adequate immunogenicity and in the shortest possible time. It meets all 
the requirements for a vaccine production system for both seasonal as well as 
emergency situations. 
The immunogenicity of the recombinant HA vaccine needs to be improved 
both for pediatric [King et al., 2009] and pandemic use [Treanor et al., 2001]. A 
suitable adjuvant would not only improve the potential potency of recombinant 
influenza vaccines, but could also be antigen-saving thereby ensuring a faster and 
greater supply of vaccine doses in an influenza pandemic, assuming that antigen 
production is likely to be the major time-critical constraint in this event. Other 
advantages of adjuvant inclusion in recombinant influenza vaccines include potential 
for enhancement of T-cell based immunity, faster kinetics of protection, improved 
cross-protection, and longer-lasting immunity. The adjuvant that offers the lowest 
regulatory hurdle, since it has been frequently used as an adjuvant, is aluminum 
hydroxide (Alum). Alum enhances immunogenicity by converting soluble protein 
vaccines into particulate mass to make them more suitable for ingestion by antigen-
presenting cells such as macrophages [Janeway et al. 2001]. Since Alum has provided 
mixed results in pandemic clinical studies [Cox, Review, 2007], we also plan to study 
inulin, a natural plant-derived polymer of fructose and glucose. Inulin exhibits many 
unique properties and has been used for many years in humans as an intravenous 
injection to measure renal function. When constituted into the appropriate delta 
isoform, inulin becomes an effective adjuvant that enhances both immunoglobulin 
and T-cell responses against many antigens including influenza HA (Vaxine Pty Ltd, 
Australia, unpublished results).  
The addition of neuraminidase to FluBlok and other licensed vaccines may be 
another avenue to further improve any influenza vaccine. Neuraminidase antibodies 
may act in a similar fashion as the neuraminidase inhibitors, oseltamivir (Tamiflu) 
and zanamivir (Relenza), albeit in a prophylactic manner. Disadvantages of antiviral 
drugs include their required use within 24-48 hours after onset of the disease, 
potential side effects and perhaps most importantly antiviral drug resistance. Drug 
resistance of H5N1 has been reported for oseltamivir and zanamivir [Kiso et al., 
2004]. The product label information for zanamivir states that a single point mutation 
in the NA gene can render the drug 1000-fold less efficacious. Also, a case study 
report by Le et al. (2005) suggests that drug resistance against oseltamivir can evolve 
within a two-week treatment period. Oseltamivir resistance has been reported 
frequently following treatment particularly against seasonal H1N1 influenza viruses 
[Stephenson, 2009]. Drug resistance of the novel H1N1 A/California/04/09 has now 
been reported on three occasions [Web link: 7-6] . Clearly, it would be desirable to 
analyze alternative delivery forms such as intra- or transdermal delivery for FluBlok 
or alternative presentation (virosomes). The preferred method would not require the 
use of needles or adjuvants because even the use of a well established adjuvant, such 
as aluminum hydroxide, can lead to discussions or questions regarding its safe use 
[Authier and Gherard, 2006]. Exploration of alternative delivery or presentation will 
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be initiated following licensure for the intramuscular FluBlok formulation. 
 
Improvements in production cycle and yields 
A universal process for seasonal influenza was established and only minor process 
changes to support the annual adjustment of the seasonal vaccine are evaluated and 
considered annually.  
Due to the ever changing nature of the influenza viruses and the rapid 
emergence and spread of novel viruses as exemplified by the unprecedented spread of 
the novel H1N1 it would be desirable to even further reduce the development 
timelines and production cycles. Here we provide a brief overview of ongoing efforts 
to improve the manufacturing cycle and product yields.  
Alternative baculovirus promoters, such as the p10 / p6.9 chimaeric promoter 
[Bonning et al., 1994; Sun et al., 2004] are being evaluated from a yield improvement 
perspective using the ∆ cathepsin- / chitinase-negative AcMNPV bacmid [Kaba et al., 
2004].  
Ongoing process improvement efforts include the development of a fed-batch 
fermentation process and the development of a defined growth medium. In the current 
influenza production process the insect cells are infected at a density of 2-2.5x106 
cells/ml. The development of a fed-batch process for HA will be aimed at increasing 
the cells density at infection to 8-10x106 cells/ml as previously described [Bédard et 
al., 1997; Elias et al., 2000] without reducing specific productivity. A simple single 
shot feed-strategy resulted in a two-fold increase of HA production [Meghrous et al, 
submitted]. A semi-continuous fed-batch system was described by van Lier et al. 
(1995). Further improvements in cell culture will be aimed at establishing a 
continuous fed-batch process for which 40-fold improvements in antibody production 
in mammalian cells was reported [Birch and Racher, 2006]. 
Yield improvement has also frequently been reported as a result of changing 
the cell culture media. Additions of plant hydrolysates, other growth and production 
enhancing factors and control of proteolysis were reviewed by Ikonomou et al. (2003) 
and offer promising areas for yield improvement. Specifically, adding the plant 
hydrolysate, Hypep 1510, to an insect cell culture resulted in a doubling in expression 
of a reporter gene [Kwon et al., 2005], but also simple changes in pH may offer great 
benefit [Jakubowska et al., 2009].  
It has further been shown that viral and host modifications can improve cell 
survival and production of heterologous proteins. Modifications to the host insect cell 
line for example by including the anti-apoptotic gene Bcl-2 may limit the cytopathic 
effects of the baculovirus and may result in enhancement of expression as well as was 
recently reported for Sindbis virus in a mammalian cell line [Nivitchanyong et al., 
2009]. Co-expression of chaperones may also be a promising prospect for the efficient 
production of recombinant secretory proteins in insect cells as was recently reported 
by for instance Kato et al. (2005).  
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5. Concluding Remarks: Lessons learned … 
 
Challenges of technical, regulatory and financial nature were encountered on the path 
to FluBlok product licensure. The technical challenges were mostly due to the 
required annual adjustment of the influenza vaccine within the limited time available, 
and the fact that insect cell manufacturing had yet to be established as a commercial 
manufacturing technology for human medicine. Some of these technical challenges 
were addressed in the previous chapters. The product approval of Cervarix, also 
manufactured in insect cells helped establishing this technology as a commercial 
manufacturing technology. 
The complexity of product licensure is amplified exponentially with the 
number of novel elements included in the process. The mechanism of action of the 
FluBlok vaccine is similar to that of the licensed inactivated influenza vaccines, i.e. 
the induction of antibodies against hemagglutinin. FluBlok is also like TIV 
standardized to contain a certain amount of HA determined by the same potency 
method used for TIV. However, FluBlok is a novel vaccine, containing only three 
times greater quantity and is produced using a novel cell substrate. Progress in science 
leads to new ideas and new, potentially better products. However, a new product 
brings uncertainty. The outset was to develop a better influenza vaccine for the 
population that most needed it, those 65 or 75 years and older. Regulators cautioned 
along the way stating that an rHA vaccine had to perform equivalent to the currently 
licensed vaccines suggesting that further improvements to this type of vaccine could 
be delayed until after product approval. Perhaps the regulatory challenge would have 
been easier had we indeed developed a recombinant vaccine with the same antigen 
content as the licensed vaccines first (i.e. 15 µg per antigen instead of 45 µg per 
antigen) and saved the higher antigen concentration for a later stage. This would have 
changed the number of unknown factors in the product from two to just one. 
FluBlok development nearly failed as a result of the challenge to secure 
adequate funding for development. The lesson taught in Business School that the next 
financing is always more difficult than the previous one and that you need to have 
sufficient cash to reach the next milestone (i.e. adequate revenue generation) is one 
that can not be underestimated. While there is no set recipe to entrepreneurship and 
establishing a successful business, it is key to success to have access to sufficient 
resources. 
Protein Sciences holds a family of key patents to the production of rHA in the 
baculovirus-insect cell system [USP5762939, USP5858368; USP6245532 and foreign 
counterparts]. Therefore other companies interested in the development of an rHA 
vaccine produced using the baculovirus-insect cell expression technology would 
require a license for commercial use. 
The baculovirus – insect cell technology addresses the need for new influenza 
vaccine production technology. Using this technology, influenza vaccines can be 
made available worldwide within a very short time, which is an absolute requirement 
in combating the next pandemic. The recent contract award from Health and Human 
Services [Web link 7-7] is not only a strong vote of confidence in FluBlok from the 
U.S. government, but also provide adequate financial support and other resources for 
the further development of a recombinant influenza vaccine. As a result, we expect to 
be able to provide a worldwide solution to pandemic preparedness within the next 5 
years. 
  
 
105
 106
  References 
  
References 
 
Alymova IV Kodihalli S, Govorkova EA, Fanget B, Gerdil C, Webster RG (1998): 
Immunogenicity and protective efficacy in mice of influenza B virus vaccines 
grown in mammalian cells or embryonated chicken eggs. J Virol 72: 4472-7. 
Ambrose CS, Luke C, Coelingh K (2008): Current status of live attenuated influenza 
vaccine in the United States for seasonal and pandemic influenza. Influenza 
Other Respir Viruses 2: 193-202.  
Andersen DC, Krummen L (2002): Recombinant protein expression for therapeutic 
applications. Curr Opin Biotechnol 13: 117-23.  
Audsley, JM, Tannock GA (2004): The role of cell culture vaccines in the control of 
the next influenza pandemic. Expert Opin Biol Ther 4: 709-17. 
Authier FJ and Gherardi RK (2006): Safety and immunogenicity of H5N1 vaccine. 
Lancet 368: 2209-10. 
Baines JE, McGovern RM, Persing D, Gostout BS (2005): Consensus-degenerate 
hybrid oligonucleotide primers (CODEHOP) for the detection of novel 
papillomaviruses and their application to esophageal and tonsillar carcinomas. 
J Virol Methods 123: 81-7. 
Barker WH and Mullooly JP (1980): Impact of epidemic type A influenza in a 
defined adult population. Am J Epidemiol 112: 798-813.  
Barrett T, Inglis SC (1995): Growth, purification, and titration of influenza viruses. 
In: Desselberger U, editor.Virology: A Practical Approach. Washington D.C.: 
IRL Press. 
Barrett PN, Mundt W, Kistner O, Howard MK (2009): Vero cell platform in vaccine 
production: moving towards cell culture-based viral vaccines. Expert Rev 
Vaccines. 8: 607-18. Review.  
Becker, R (2004): Partnership: Expanding R&D capabilities to address changing 
market needs. Phacilitate Vaccine Forum, Boston, MA. 
Bédard C, Perret S, Kamen A (1997): Fed-batch culture of Sf-9 cells supports 3 x 107 
and improves baculovirus-expressed recombinant protein yields. 
Biotechnology Letters 19: 629-32.  
Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, 
Shay DK; Marshfield Influenza Study Group (2009): Effectiveness of 
inactivated influenza vaccines varied substantially with antigenic match from 
the 2004-2005 season to the 2006-2007 season. J Infect Dis. 199: 159-67. 
Belshe, RB (1998): Influenza as a zoonosis: how likely is a pandemic? Lancet 351: 
460-1  
Ben-Yedidia T, Arnon R (2007): Epitope-based vaccine against influenza. Expert Rev 
Vaccines 6: 939-48.  
Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, Jirincova H, 
van Belle P, Jain V, Innis B, Devaster JM (2009): Challenge of conducting a 
placebo-controlled randomized efficacy study for influenza vaccine in a 
season with low attack rate and a mismatched vaccine B strain: a concrete 
example. BMC Infect Dis 7:13. 
Betting DJ, Mu XY, Kafi K, McDonnel D, Rosas F, Gold DP, Timmerman JM 
(2009): Enhanced immune stimulation by a therapeutic lymphoma tumor 
antigen vaccine produced in insect cells involves mannose receptor targeting 
to antigen presenting cells.  Vaccine 27: 250-9. 
107
  References 
  
Beutner K, Chow T, Rubi E, Strussenberg J, Clement J, Ogra P (1979): Evaluation of 
a neuraminidase-specific vaccine in children: antibody responses and effects 
of two successive outbreaks of natural infection. J Infect Dis 140: 844-850.  
Birch JR. and Racher AJ (2006): Antibody production. Adv Drug Deliv Rev 58: 671-
85. 
Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP (1993): Antibody 
responses of the M2 protein of influenza A virus expressed in insect cells. J 
Gen Virol 74: 143-6.  
Bonning BC, Roelvink PW, Vlak JM, Possee RD, Hammock BD (1994): Superior 
expression of juvenile hormone esterase and beta-galactosidase from the basic 
protein promoter of Autographa californica nuclear polyhedrosis virus 
compared to the p10 protein and polyhedrin promoters. J Gen Virol 75: 1551-
6 
Boyce TG, Hsu HH, Sannella EC, Coleman-Dockery SD, Baylis E, Zhu Y, Barchfeld 
G, DiFrancesco A, Paranandi M, Culley B, Neuzil KM, Wright PF (2000): 
Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza 
vaccines administered intranasally to healthy adults. Vaccine 19: 217-26. 
Brands R, Visser J, Medema J, Palache AM, van Scharrenburg GJ (1999): Influvac: a 
safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza 
vaccine. Dev Biol Stand  98: 93-100.  
Brett EC, Johansson BE (2005): Immunization against influenza A virus: comparison 
of conventional inactivated, live-attenuated and recombinant baculovirus 
produced purified hemagglutinin and neuraminidase vaccines in a murine 
model system. Virology 339: 273-80. 
Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, Lilac 
HA, Hall H, Klimov A, Fukuda K (2000): Effectiveness and cost-benefit of 
influenza vaccination of healthy working adults: A randomized controlled 
trial. JAMA 284:1655-63. 
Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA (2002): Prevention and 
control of influenza. Recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep 51 (RR-3):1-31. 
Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, 
Pushko P, Mytle N, Rowe T, Smith G, Ross TM (2007): Influenza virus-like 
particles elicit broader immune responses than whole virion inactivated 
influenza virus or recombinant hemagglutinin. Vaccine 25: 3871-8. 
Carle F, Bolgiani M, Zanon P, Moiraghi Ruggenini A, Zotti (1988): 
Immunoprophylaxis for influenza: comparison of a subunit and a whole virion 
vaccine. Boll Ist Sieroter Milan 67: 105-15.  
Carreno G, Esparza J (1977): Induction of Venezuelan equine encephalitis 
(Mucambo) virus by iododeoxyuridine in chronically infected 'cured' cultured 
mosquito cells. Intervirology 8: 193-203. 
Chiron Vaccines (2002): Agrippal Product Monograph. Adis International Limited, 
Starnberg, Germany. 
Claas EC, Osterhaus AD, van Beek R, de Jong JC, Rimmelzwaan GF, Senne DA, 
Krauss S, Shortridge KF, Webster RG (1998): Human influenza A H5N1 
virus related to a highly pathogenic avian influenza virus. Lancet 351: 472-6. 
Chen D, Nims R, Dusing S, Miller P, Luo W, Quertinmont M, Parekh B, Poorbaugh J, 
Boose JA, Atkinson EM (2008): Root cause investigation of a viral 
contamination incident occurred during master cell bank (MCB) testing and 
characterization - A case study. Biologicals 36: 393-402. 
108
  References 
  
Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, Perdue ML 
(1999): Baculovirus-derived hemagglutinin vaccines protect against lethal 
influenza infections by avian H5 and H7 subtypes. Vaccine 17: 2265-74 
Clements ML, Betts RL, Tierney RL, Murphy BR (1986): Serum and Nasal Wash 
Antibodies Associated with Resistance to Experimental Challenge with 
Influenza A Wild-Type Virus. J Clin Microbiol 22: 157-60. 
Clements ML (1992): Influenza Vaccines. In Vaccines: New Approaches to 
Immunological Problems, ed. Ronald W. Ellis, Butterworth-Heinemann, 
Stoneham, MA: 129-50.  
Copeland CS, Doms RW, Bolzau EM,  Webster RG, Helenius A (1986): Assembly of 
influenza hemagglutinin trimers and its role in intracellular transport. J Cell 
Biol. 103: 1179-91.  
Couch RB, Douglas RG Jr., Fedson DS and Kasel JA (1971): Correlated studies of a 
recombinant influenza virus vaccine. III. Protection against an experimental 
vaccine in man. J Infect Dis 124: 473-80. 
Couch RB, Kasel JA, Gerin JL, Schulman JL and Kilbourne ED (1974): Induction of 
partial immunity to influenza by a neuraminidase-specific vaccine. J Infect 
Dis 129: 411-20.  
Couch RB and Cate TR (1983): Managing influenza in older patients. Geriatrics 
38:61.  
Cox NJ, Subbarao K (1999): Influenza. Lancet 354: 1277-82.  
Cox, M (2005): Cell-based protein vaccines for influenza. Curr Opin Mol Ther 7: 24-
9. 
Cox MM, Anderson DK (2007) Production of a novel influenza vaccine using insect 
cells: protection against drifted strains. Influenza and Other Respir Viruses 
1:35-40. 
Cox, MMJ (2007): Review: Vaccines in development against avian influenza. 
Minerva Medica 98: 145-53. 
Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, Stone H, Perdue ML 
(1999): Baculovirus-derived hemagglutinin vaccines protect against lethal 
influenza infections by avian H5 and H7 subtypes. Vaccine 17: 2265–74.  
Daszak P, Cunningham, AA, Hyatt, AD (2001): Anthropogenic environmental 
change and the emergence of infectious diseases in wildlife. Acta Trop 78: 
103–16. 
Datamonitor (2007): Commercial / Pipeline Insight: Influenza Vaccines: Pandemic 
threat revitalizes the sector. Executive presentation. Reference Code: 
DMHC2280. 04/2007. 
de Bruijn IA, Nauta J, Gerez L, Palache AM. (2004): Virosomal influenza vaccine: a 
safe and effective influenza vaccine with high efficacy in elderly and subjects 
with low pre-vaccination antibody titers. Virus Res 103: 139-45. 
Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC (1973): 
Inactivated influenza vaccines: 2 laboratory indices of protection. Postgrad 
Med J 49:159-63.  
Durrer P, Glück U, Spyr C, Lang AB, Zurbriggen R, Herzog C, Glück R (2003): 
Mucosal antibody response induced with a nasal virosome-based influenza 
vaccine. Vaccine 21: 4328-34.  
Eckroade RJ, Silverman LA, Acland HM (1984): Avian influenza in Pennsylvania. 
In: Proceedings of West. Poultry Disease Conference. Davis: University of 
Calefornia: 1-2.  
109
  References 
  
Elias CB, Zeiser A, Bédard C, Kamen AA (2000): Enhanced growth of Sf-9 cells to a 
maximum density of 5.2 x 10(7) cells per mL and production of beta-
galactosidase at high cell density by fed batch culture. Biotechnol Bioeng 68: 
382-8.  
Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ (2009): Randomized, 
double-blind controlled phase 3 trial comparing the immunogenicity of high-
dose and standard-dose influenza vaccine in adults 65 years of age and older. 
J Infect Dis 200: 172-80. 
Fedson DS (1987): Influenza prevention and control. Past practices and future 
prospects. Am J Med 82(suppl 6A): 42 
Fedson DS and Dunnill P (2007): New approaches to confronting an imminent 
influenza pandemic. Permanente J 11: 63-9. 
Fiers W, de Filette M, Birkett A, Neirynck S, Min Jou W (2004): A "universal" 
human influenza A vaccine. Virus Res 103: 173-6.  
Flint S, Enquist L, Racaniello V, Skalka A (2004): Principles of Virology, 2nd Ed. 
Washington, DC: ASM Press. 
Garcia M, Crawford JM, Latimer JW, Rivera-Cruz E, Perdue ML (1996): 
Heterogeneity in the haemagglutinin gene and emergence of the highly 
pathogenic phenotype among recent H5N2 avian influenza viruses from 
Mexico. J Gen Virol 77: 1493-504.  
Gellin B (2005): Meeting Objectives. In: “Meeting Proceedings of the John R. La 
Montagne Memorial Symposium on Pandemic Influenza Research”. Inst. of 
Medicine,  pp.10-11.  
Glezen WP (1982): Serious morbidity and mortality associated with influenza 
epidemics. Epidemiol Rev  4: 24-44.  
Glück R, Moser C, Metcalfe IC (2004): Influenza virosomes as an efficient system 
for adjuvanted vaccine delivery. Expert Opin Biol Ther 4: 1139-45.  
Goji, NA, Nolan C, Hill H, Wolf M, Rowe T, Treanor JJ (2008): Immune responses 
of healthy subjects to a single dose of intramuscular inactivated influenza 
A/Vietman/1203/04 (H5N1 vaccine after priming with an antigenic variant. J 
Infect Dis 198: 629-31. 
Gómez-Puertas P, Albo C, Pérez-Pastrana E, Vivo A, Portela A (2000): Influenza 
virus matrix protein is the major driving force in virus budding. J Virol 74: 
11538-47. 
Govaert TME, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knottnerus JA (1993). 
Adverse reactions to influenza vaccine in the elderly people: randomized 
double blinded placebo controlled trial. BMJ 307: 988–90. 
Granados RR (1994): Trichoplusia ni cell line which supports replication of 
baculoviruses. United States Patent 5,300,435.  
Green JA, Baron S (1975): 5-iododeoxyuridine potentiation of the replication in vitro 
of several unrelated RNA and DNA viruses. Science 190: 1099-101. 
GSK website Study number 104438:  http://gsk-
clinicalstudyregister.com/files/pdf/20001. 
  pdf. 
Halperin SA, Smith B, Mabrouk T, Germain M, Trépanier P, Hassell T, Treanor J, 
Gauthier R, Mills EL (2002): Safety and immunogenicity of a trivalent, 
inactivated, mammalian cell culture-derived influenza vaccine in healthy 
adults, seniors, and children. Vaccine 20:1240-7. 
Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M (2005): Phase I, 
randomized, controlled trial to study the reactogenicity and immunogenicity 
110
  References 
  
of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Hum 
Vaccine 1: 37-42.  
Hehme N, Engelmann H, Raderecht C, Porstmann T (2003): Comparative laboratory 
results of different commercial influenza vaccines. Option for the control of 
influenza V, Okinawa, Japan: Poster W07P-41. 
Heimpel A, Thomas ED, Adams JR, Smith LJ (1973): The presence of nuclear 
polyhedrosis virus of Trichoplusia ni on cabbage from the market shelf. 
Environ. Ent 2: 72-6.  
Helenius A, Aebi M (2004): Roles of N-linked glycans in the endoplasmic reticulum. 
Annu Rev Biochem 73: 1019-49.  
Hilleman MR (2002): Realities and enigmas of human viral influenza: pathogenesis, 
epidemiology and control. Vaccine 20: 3068-87 
Holtz KM, Anderson DK, Cox MM (2003): Production of a recombinant influenza 
vaccine using the baculovirus expression vector system. Bioprocess. J 2:65-73. 
Huber VC, McCullers JA (2008): FluBlok, a recombinant influenza vaccine. Curr 
Opin Mol Ther 10:75-85. 
Huhtala A, Linko P, Mutharasan R (2005): Protein response of insect cells to 
bioreactor environmental stresses. J Biotechnol 118:278-89. 
Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, 
Powell TJ (2007): Vaccination with recombinant fusion proteins incorporating 
Toll-like receptor ligands induces rapid cellular and humoral immunity. 
Vaccine 25: 763-75. 
ICTV Report (2005): VIIIth Report of the International Committee on Taxonomy of 
Viruses. Edited by  Fauquet CM, Mayo MA, Maniloff J. Virus Taxonomy. 
Classification and nomenclature of viruses. Amsterdam: Elsevier/Academic 
Press. 
Ikonomou L, Schneider YJ, Agathos SN (2003): Insect cell culture for industrial 
production of recombinant proteins. Appl Microbiol Biotechnol 62: 1-20. 
Jakubowska A, Ferré J, Herrero S (2009): Enhancing the multiplication of 
nucleopolyhedrovirus in vitro by manipulation of the pH. J Virol Meth 
161:254-8.  
Janeway CA, Travers P, Walport, M, Shlomchik M (2001): Immunobiology. 5th ed. 
New York and London: Garland Publishing. 
Jarrett RF, Johnson D, Wilson KS, Gallagher A (2006): Molecular methods for virus 
discovery. Dev Biol (Basel) 123:77-88; discussion 119-32. 
Jehle JA, Blissard GW, Bonning BC, Cory JS, Herniou EA, Rohrmann GF, 
Theilmann DA, Thiem SM, Vlak JM (2006): On the classification and 
nomenclature of baculoviruses: a proposal for revision Arch Virol. 151:1257-
66. 
Johansson BE (1999): Immunization with influenza A virus hemagglutinin and 
neuraminidase produced in recombinant baculovirus results in a balanced and 
broadened immune response superior to conventional vaccine. Vaccine 17: 
2073-80. 
Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, 
Mant T, Nolan A, Zambon M, Ellis J, Beadle J, Loudon PT (2009): DNA 
vaccination protects against an influenza challenge in a double-blind 
randomised placebo-controlled phase 1b clinical trial. Vaccine 27: 2506-12.  
Kaba SA, Salcedo AM, Wafulo PO, Vlak, JM and van Oers MM (2004): 
Development of a chitinase and v-cathepsin negative bacmid for improved 
integrity of secreted recombinant proteins. J Virol Meth 122: 113-8. 
111
  References 
  
Karlsson G, Winge S (2003): Separation between the alpha and beta forms of human 
antithrombin by hydroxyapatite high-performance liquid chromatography. 
Protein Expr Purif  28: 196-201.  
Kato T, Murata T, Usui T, Park EY (2005): Improvement of the production of 
GFPuv-beta1,3-N-acetylglucosaminyltransferase 2 fusion protein using a 
molecular chaperone-assisted insect-cell-based expression system. Biotechnol 
Bioeng 89: 424-33. 
Katz JM, Naeve CW, Webster RG (1987): Host cell-mediated variation in H3N2 
influenza viruses. Virology 156: 386-95.  
Katz JM, Wang M, Webster RG (1990): Direct sequencing of the HA gene of 
influenza (H3N2) reveals sequence identity with mammalian cell-grown virus. 
J. Virol. 64: 1808-11. 
Keitel WA, Couch RB, Cate TR, Hess KR, Baxter B, Quarles JM, Atmar RL, Six HR 
(1994): High doses of purified influenza A virus hemagglutinin significantly 
augment serum and nasal secretion antibody responses in healthy young 
adults. J Clin Microbiol 32: 2468-73. 
Keitel WA, Cate TR, Atmar RL, Turner CS, Nino D, Dukes CM, Six HR, Couch RB 
(1996): Increasing doses of purified influenza virus hemagglutinin and 
subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab 
Immunol 3: 507-10. 
Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, Cox MM 
(2009): Comparative Immunogenicity of Recombinant Influenza 
Hemagglutinin (rHA) and Trivalent Inactivated Vaccines (TIV) Among 
Persons ≥65 Years Old. Accepted Vaccine, October 2009 
Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM (2004): Dose sparing with 
intradermal injection of influenza vaccine. N Engl J Med 351: 2295-301.  
Khan AS, Sears JF (2001): Pert analysis of endogenous retroviruses induced from K-
BALB mouse cells treated with 5-iododeoxyuridine: a potential strategy for 
detection of inducible retroviruses from vaccine cell substrates. Dev Biol 
(Basel) 106: 387-92. 
Khan AS, Muller J, Sears JF (2001): Early detection of endogenous retroviruses in 
chemically induced mouse cells. Virus Res 79:39-45. 
Kida H, Webster RG, Yanagawa R (1983): Inhibition of virus-induced hemolysis 
with monoclonal antibodies to different antigenic areas on the hemagglutinin 
molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virol 
76: 91-9. 
Kilbourne ED, Laver WG, Schulman JL and Webster RG (1968): Antiviral activity of 
antiserum specific for an influenza neuraminidase. 1. In vitro effects. J 
Virology 2: 281-8. 
Kilbourne ED (1980): Influenza: viral determinants of the pathogenicity and 
epidemicity of an invariant disease of variable occurrence. Phil Tran R Soc 
288: 291-7.  
Kilbourne ED (2006). Influenza pandemics of the 20th century. Emerg Infect Dis 
[serial on the Internet]. Available from 
http://www.cdc.gov/ncidod/EID/vol12no01/05-1254.htm. 
King Jr. JC, Cox MM, Reisinger K, Hedrick J, Gram I, Patriarca P (2009): Evaluation 
of the safety, reactogenicity and immunogenicity of FluBlok®  
trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine 
administered intramuscularly to healthy children aged 6 to 59 months. 
Vaccine, Aug 27 [Epub ahead of print] 
112
  References 
  
 
Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, 
Hayden FG, Sugaya N, Kawaoka Y (2004): Resistant influenza A viruses in 
children treated with oseltamivir: descriptive study. Lancet 364: 759–65.  
Kitts PA, Possee RD (1993): A method for producing recombinant baculovirus 
expression vectors at high frequency. BioTechniques 14: 810–6.  
Klenk HD, Wagner R, Heuer D, Wolff T (2002): Importance of hemagglutinin 
glycosylation for the biological functions of influenza virus. Virus Res 82: 73-
5.  
Knezevic I, Stacey G, Petricciani J (2008): WHO Study Group on cell substrates for 
production of biologicals, Geneva, Switzerland, 11-12 June 2007. Biologicals 
36: 203-11. 
Kool M, Voncken JW, van Lier FL, Tramper J, Vlak JM. (1991): Detection and 
analysis of Autographa californica nuclear polyhedrosis virus mutants with 
defective interfering properties. Virology 183:739-46. 
Kost TA, Condreay JP, Jarvis DL (2005): Baculovirus as versatile vectors for protein 
expression in insect and mammalian cells. Nat Biotechnol 23: 567-75. 
Review.  
Kucukosmanoglu E, Yazi D, Yesil O, Akkoc T, Gezer M, Bakirci N, Bahceciler NN, 
Barlan IB. (2008): Prevalence of egg sensitization in Turkish infants based on 
skin prick test. Allergol Immunopathol (Madr). 36: 141-4. 
Kuno G, Chang GJ (2005): Biological transmission of arboviruses: reexamination of 
and new insights into components, mechanisms, and unique traits as well as 
their evolutionary trends. Clin Microbiol Rev 18: 608-37. 
Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier 
R, Grimaldi R, Goudsmit J (2009): Immunogenicity and safety of low dose 
virosomal adjuvanted influenza vaccine administered intradermally compared 
to intramuscular full dose administration. Vaccine 27: 351-7.  
Kwon MS, Dojima T, Park EY (2005): Use of plant-derived protein hydrolysates for 
enhancing growth of Bombyx mori (silkworm) insect cells in suspension 
culture. Biotechnol Appl Biochem 42: 1-7 
Lakey DL, Treanor JJ, Betts RF, Smith GE, Thompson J, Sannella E, Reed G, 
Wilkinson BE, Wright PF. (1996): Recombinant baculovirus influenza A 
hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. 
J Infect Dis 174: 838–41.  
Lamb RA and Krug RM (2001): Orthomyxoviridae: The viruses and their replication. 
In Knipe DM, Howley PM, Griffin DE et al,. editors. Fields Virology, 4th 
edn. Lippincott Williams & Wilkins: pp. 1487-531. 
LaMontagne JR, Noble GR, Quinnan GV (1983): Summary of clinical trials of 
inactivated influenza vaccine-1978. Rev Inf Dis 5: 723-36.  
Latham T, Galarza JM (2001): Formation of wild-type and chimeric influenza virus-
like particles following simultaneous expression of only four structural 
proteins. J Virol 75: 6154-65. 
Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen 
HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, 
Suzuki Y, Kawaoka Y (2005): Avian flu: isolation of drug-resistant H5N1 
virus. Nature 437: 1108. Erratum in: Nature 438: 754. 
Li TC, Scotti PD, Miyamura T, Takeda N (2007): Latent infection of a new 
alphanodavirus in an insect cell line. J Virol 81: 10890-6. 
113
  References 
  
Luckow VA, Lee SC, Barry GF, Olini PO (1993): Efficient generation of infectious 
recombinant baculoviruses by site-specific transposon-mediated insertion of 
foreign genes into a baculovirus genome propagated in Escherichia coli. J 
Virol 67: 4566–79. 
Maley F, Trimble RB, Tarentino AL, Plummer TH Jr (1989): Characterization of 
glycoproteins and their associated oligosaccharides through the use of 
endoglycosidases. Anal Biochem 80: 195-204. 
Mancini G, Carbonara AO, Heremans JF (1965): Immunochemical quantitation of 
antigens by single radial immunodiffusion. Immunochemistry  2: 235-24. 
Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, 
Bautista OM, Jansen KU, Barr E (2006): Efficacy of human papillomavirus-
16 vaccine to prevent cervical intraepithelial neoplasia: a randomized 
controlled trial. Obstet Gynecol 107:18-27. Erratum in: Obstet Gynecol.107: 
1425. 
Matthews J (2000): Preclinical and clinical evaluation of a purified, baculovirus-
expressed influenza neuraminidase antigen. The Baculovirus & Insect Cell 
Culture Conference, San Antonio, TX. 
Al-Mazrou A, Scheifele DW, Soong T, Bjornson G (1991): Comparison of adverse 
reactions to whole-virion and split-virion influenza vaccines in hospital 
personnel. CMAJ 145: 213-8.  
McPherson, CE. (2008): Development of a novel recombinant influenza vaccine in 
insect cells. Biologicals 36: 350-3. 
Meghrous J, Mahmoud W, Jacob D, Chubet R, Cox M, Kamen A (2009): 
Development of a simple and high-yielding fed-batch process for the 
production of influenza vaccines.  Accepted Vaccine, October 2009. 
Meiklejohn G, Eickhoff TC, Graves P (1987): Antigen drift and efficacy of influenza 
virus vaccines. 1976-1977. J Infect Dis 138: 618-24.  
Menzel, T. and Rohrmann, G.F. (2008): Diversity of errantivirus (retrovirus) 
sequences in two cell lines used for baculovirus expression, Spodoptera 
frugiperda and Trichoplusia ni. Virus Genes 36, 583-6. 
Merten OW, Manuguerra JC, Hannoun C, van der Werf S (1999): Production of 
influenza virus in serum-free mammalian cell cultures. Dev Biol Stand 98: 23-
37.  
Miller LK (1981): A virus vector for genetic engineering in invertebrates in Genetic 
Engineering in the Plant Sciences. NJ. Panopaulus ed. (Praeger, NY): 203-22.  
Miller LK, Ball LA (editors) (1998): The Insect Viruses: Plenum Pub. Corp. 
Mir-Shekari SY, Ashford DA, Harvey DJ, Dwek RA, Schulze IT (1997): The 
glycosylation of the influenza A virus hemagglutinin by mammalian cells. A 
site-specific study. J Biol Chem 272: 4027-36. 
MMWR (1993): CDC. "Immunization Practices Advisory Committee [ACIP]. 
Prevention and control of influenza: Part 1,vaccines." Morb Mortal Wkly Rep 
42: 1–14.  
MMWR (2000): CDC. Updated Recommendations from the Advisory Committee on 
Immunization Practices in response to delays in supply of influenza vaccine 
for the 2000-01 season. Morb Mortal Wkly Rep 49: 888-92. 
MMWR (2004): CDC. Preliminary assessment of the effectiveness of the 2003-04 
inactivated influenza vaccine – Colorado, December 2003. Morb Mortal Wkly 
Rep 53: 8-11. 
114
  References 
  
MMWR (2005): CDC. Update: Influenza activity - United States and worldwide, 
2004-05 season. Morb Mortal Wkly Rep 54: 631-4. 
MMWR (2008): ACIP. Prevention and Control of Influenza, Recommendations of 
the Advisory Committee on Immunization Practices, Morb Mortal Wkly Rep 
57: 1-60  
MMWR (2009); Update: Swine Influenza A (H1N1) Infections California and Texas. 
Morb Mortal Wkly Rep 58, 585-89. 
Molowa DT, Mazanet R (2003): The state of biopharmaceutical manufacturing. 
Biotechnol Annu Rev 9: 285-302.  
Montagnon B, Vincent-Falquet JC, Fanget B (1983): Thousand litre scale 
microcarrier culture of Vero cells for killed polio virus vaccine. Promising 
results. Dev Biol Stand 55: 37-42. 
Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R 
(2004): Use of the inactivated intranasal influenza vaccine and the risk of 
Bell's palsy in Switzerland. N Engl J Med 350: 896-903. 
NCT00395174 (2007): Comparison of the immunogenicity, safety and reactogenicity 
of FluBlØk™, to a licensed vaccine in elderly adults. National Institutes of 
Health, Bethesda, MD, USA. 
NCT00539981 (2007): Immunogenicity, safety, reactogenicity, efficacy, 
effectiveness and lot consistency of FluBlok. National Institutes of Health, 
Bethesda, MD, USA. 
NCT00539864 (2007): Safety and reactogenicity of FluBlok and comparison of 
immunogenicity, efficacy and effectiveness against TIV. National Institutes of 
Health, Bethesda, MD, USA. 
NCT00519389 (2007): A phase I/IIa trial to evaluate the safety, reactogenicity, and 
immunogenicity of an H5N1 virus-like particle (VLP) influenza vaccine 
(recombinant). National Institutes of Health, Bethesda, MD, USA.  
Neidhart J, Allen KO, Barlow DL, Carpenter M, Shaw DR, Triozzi PL, Conry RM 
(2004): Immunization of colorectal cancer patients with recombinant 
baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid 
A in liposomal emulsion, with and without granulocyte-macrophage colony-
stimulating factor. Vaccine 22: 773-80. 
Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999): A 
universal influenza A vaccine based on the extracellular domain of the M2 
protein. Nat Med 5: 1157-63. 
Nichol KL, Margolis KL, Wuorenma J,Von Stenberg T (1994): The efficacy and cost 
effectiveness of vaccination against influenza among elderly persons living in 
the community. N Engl J Med 331: 778-84.  
Nichol KL, Margolis KL, Lind A, Murdoch M, McFadden R, Hauge M, Magnan S, 
Drake M (1996): Side effects associated with influenza vaccination in healthy 
working adults. A randomized, placebo-controlled trial. Arch Intern Med 156: 
1546-50. 
Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M (2003): Influenza 
Vaccination and Reduction in Hospitalizations for Cardiac Disease and Stroke 
among the Elderly. N Engl J Med 348: 1322-32.  
Nicholson KG, Tyrrell DAJ, Harrison P, Potter CW, Jennings R, Clark A, Schild GC, 
Wood JM, Yetts R, Seagroatt V, Huggins A, Anderson SG. (1979): Clinical 
studies of monovalent inactivated whole virus and subunit A/USSR/77 
115
  References 
  
(H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 7: 
123-36. 
Nims RW (2006). Detection of adventitious viruses in biologicals--a rare occurrence. 
Dev Biol (Basel) 123: 153-64; discussion 83-97. 
Nivitchanyong T, Tsai YC, Betenbaugh MJ, Oyler GA (2009): An improved in vitro 
and in vivo Sindbis virus expression system through host and virus 
engineering. Virus Res 141:1-12. 
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (2009): 
Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N 
Engl J Med 361: Published on-line (10.1056/NEJMoa0903810) 
Ogra PL, Chow T, Beutner KR, Rubi E, Strussenberg J, DeMello S, Rizzone C 
(1977): Clinical and immunologic evaluation of neuraminidase-specific 
influenza A virus vaccine in humans. J Infect Dis 135: 499-506.  
Ohmit SE, Victor JC, Rotthoff JR Teich ER, Truscon RK, Baum LL, Rangarajan B, 
Newton DW, Boulton ML, Monto AS (2006): Prevention of antigenically 
drifted influenza by inactivated and live attenuated influenza vaccines. N Engl 
J Med 355: 2513-22. 
Osterholm MT (2005): Preparing for the next pandemic. N Engl J Med 352: 1839-42. 
Palache AM, Scheepers HS, de Regt V, van Ewijk P, Baljet M, Brands R, van 
Scharrenburg GJ (1999): Safety, reactogenicity and immunogenicity of Madin 
Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A 
meta-analysis of clinical studies. Dev Biol Stand 98: 115-25.  
Palomares LA, Estrada-Mondaca S, Ramirez OT (2004): Production of recombinant 
proteins: challenges and solutions. Methods Mol Biol 267: 15-52.  
Patch CT, Chattopadhyay SK, Hauser J, Levine AS (1981): Regulation of viral 
transcription in cells infected with iododeoxyuridine-substituted simian virus 
40 as a model for the activation by iododeoxyuridine of latent viral genomes. 
Cancer Res 41: 2421-7. 
Patriarca PA, Weber JA, Parker RA, Hall WN, Kendal AP, Bregman DJ, Schonberger 
LB (1985): Efficacy of influenza vaccine in nursing homes. Reduction in 
illness and complications during influenza A (H3N2) epidemic. JAMA 253: 
1136-9.  
Percheson PB, Trepanier P, Dugre R, Mabrouk T (1999): A Phase I, randomized 
controlled clinical trial to study the reactogenicity and immunogenicity of a 
new split influenza vaccine derived from a non-tumorigenic cell line. Dev Biol 
Stand 98: 127-32.  
Pijlman GP, van den Born E, Martens DE, Vlak JM (2001): Autographa californica 
baculoviruses with large genomic deletions are rapidly generated in infected 
insect cells. Virology 283: 132-8. 
Pijlman GP, van Schijndel JE, Vlak JM (2003): Spontaneous excision of BAC vector 
sequences from bacmid-derived baculovirus expression vectors upon passage 
in insect cells. J Gen Virol 84: 2669-78. 
Powers DC and Belshe RB (1993): Effect of age on cytotoxic T lymphocyte memory 
as well as serum and local antibody responses elicited by inactivated influenza 
virus vaccine. J Infect Dis 167: 584-92.  
Powers DC, Smith GE, Anderson EL, Kennedy DJ, Hackett CS, Wilkinson BE, 
Volvovitz F, Belshe RB, Treanor JJ (1995):  Influenza A virus vaccines 
containing purified recombinant H3 hemagglutinin are well tolerated and 
induce protective immune responses in healthy adults. J Infect Dis 171: 1595-
9. 
116
  References 
  
Powers DC, McElhaney JE, Florendo OAJ, Manning MC, Upshaw CM, Bentley DW, 
Wilkinson BE (1997): Humoral and Cellular Immune Responses following 
vaccination with purified recombinant hemagglutinin from influenza A 
(H3N2) virus. J Infect Dis 175: 342-51. 
Quan FS, Huang C, Compans RW, Kang SM (2007): Virus-like particle vaccine 
induces protective immunity against homologous and heterologous strains of 
influenza virus. J Virol 81: 3514-24. 
Quinnan GV, Schooley RS, Dolin R, Ennis FA, Gross P, Gwaltney JM (1983): 
Serologic responses and systemic reactions in adults after vaccination with 
monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong 
Kong/72 influenza vaccines. Rev Infect Dis 5: 748-57.  
Rajakumar A, Swierkosz EM, Schulze IT (1990): Sequence of an influenza virus 
hemagglutinin determined directly from a clinical sample. Proc Natl Acad Sci 
87: 4154-8.  
Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A, Illum L, Jennings R 
(2005): Effective nasal influenza vaccine delivery using chitosan Vaccine 23: 
4367-74 
Renfrey S, Watts A (1994): Morphological and biochemical characterization of 
influenza vaccines commercially available in the United Kingdom. Vaccine 
12: 747-52. 
Rohwer RG (1996). Analysis of risk to biomedical products developed from animal 
sources (with special emphasis on the spongiform encephalopathy agents, 
scrapie and BSE). Dev Biol Stand 88: 247-56. 
Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC (1985): 
Alterations in the hemagglutinin associated with adaptation of influenza B 
virus to growth in eggs. Virology 143: 166-74. 
Robertson JS, Bootman NR, Oxford JS, Daniels RS, Webster RG (1987): Structural 
changes in the haemagglutinin which accompany egg adaptation of an 
influenza A (H1N1) virus. Virology 160: 31-7. 
Rose TM, Schultz ER, Henikoff JG, Pietrokovski S, McCallum CM, Henikoff S 
(1998): Consensus-degenerate hybrid oligonucleotide primers for 
amplification of distantly related sequences. Nucleic Acids Res 26: 1628-35. 
Rose TM (2005). CODEHOP-mediated PCR - a powerful technique for the 
identification and characterization of viral genomes. Virol J 2: 20. 
Ruben FL (1987): Prevention and control of influenza: role of vaccine. Am J Med  82: 
31-3.  
Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, 
Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad, II, 
Couch RB (2006): Dose-related safety and immunogenicity of baculovirus-
expressed trivalent influenza vaccine: a double-blind, controlled trial in adult 
patients with non-Hodgkin B cell lymphoma. J Infect Dis 194: 1394-7. 
Sato SB, Kawasaki K, Ohnishi S (1983): Hemolytic activity of influenza virus 
hemagglutinin glycoproteins activated in mildly acidic environments. Proc 
Natl Acad Sci 80: 3153–57.  
Schild GC, Oxford JS, de Jong JC, Webster RG (1983): Evidence for host-cell 
selection of influenza virus antigenic variants. Nature 303: 706-9. 
Schroder E Jonsson T, Poole L (2003): Hydroxyapatite chromatography: altering the 
phosphate-dependent elution profile of protein as a function of pH. Anal 
Biochem 313:176-8.  
117
  References 
  
Schulze IT (1997): Effects of glycosylation on the properties and functions of 
influenza virus hemagglutinin. J Infect Dis 176 (Suppl 1): S24-28. 
Sheridan C (2004): Next generation flu vaccine boosted by Chiron debacle. Nat 
Biotechnol 22: 1487-8. 
Skehel JJ, Wiley DC (2000): Receptor binding and membrane fusion in virus entry: 
The influenza hemagglutinin. Annu Rev Biochem 69: 531–69.  
Skowronski DM, de Serres G, Dickinson J, Petric M, Mak A, Fonseca K, Kwindt TL, 
Chan T, Bastien N, Charest H, Li Y (2009): Component-specific effectiveness 
of trivalent influenza vaccine as monitored through a sentinel surveillance 
network in Canada, 2006-2007. J Infect Dis 199: 168-79. 
Smith GE, Summer MD, Fraser MJ (1983): Production of human beta interferon in 
insect cells infected with a baculovirus expression vector. Mol and Cell Biol 
3: 2156-65.  
Smith GE, Volvovitz F, Wilkinson BE, Hackett CS (1993): Method for producing 
influenza hemagglutinin multivalent vaccines. United States Patent 5,762,939 
and foreign counterparts. 
Smith GE, Volvovitz F, Wilkinson BE, Voznesensky AI, Hackett CS (1995): Vaccine 
comprising a baculovirus produced influenza hemagglutinin protein fused to a 
second protein. United States Patent 5,858,368 and foreign counterparts. 
Smith GE, Volvovitz F, Wilkinson BE, Voznesensky AI, Hackett CS (1998): Method 
for producing influenza hemagglutinin multivalent vaccines. United States 
Patent 6,245,532 and foreign counterparts. 
Smith GE, Foellmer HG, Knell J, Debartolomeis J, Voznesensky AI (2000): 
Spodoptera frugiperda: Single cell suspension cell line in serum-free media, 
methods of producing and using. United States Patent 6,103,526 and foreign 
counterparts. 
Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G, Wilschut J 
(1987): Functional reconstitution of influenza virus envelopes. EMBO J 6: 
2651-9. 
Stephenson I Nicholson KG, Wood JM, Zambon MC, Katz JM (2004): Confronting 
the avian influenza threat: vaccine development for a potential pandemic. 
Lancet Infect Dis 4: 499-509. 
Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice 
G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG (2006): 
Phase I evaluation of intranasal trivalent inactivated influenza vaccine with 
nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal 
adjuvants, using adult volunteers. J Virol 80: 4962-70.  
Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, Ellis J, 
Bermingham A, Nicholson K, Zambon M (2009): Neuraminidase inhibitor 
resistance after oseltamivir treatment of acute influenza A and B in children. 
Clin Infect Dis 48: 389-96. 
Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, 
Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, 
Donis RO, Liddington RC, Marasco WA. (2009): Structural and functional 
bases for broad-spectrum neutralization of avian and human influenza A 
viruses. Nature Structural & Molecular Biology 16: 265-73. 
Sun X, Wang H, Sun X, Chen X, Peng C,Pan D, Jehle JJ, van der Werf W, Vlak JM, 
Hu ZH (2004): Biological activity and field efficacy of a genetically modified 
Helicoverpa armigera SNPV expressing an insect-specific toxin from a 
chimaeric promoter. Biol Control 29: 124-37 
118
  References 
  
Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG (2005): 
Characterization of the 1918 influenza virus polymerase genes. Nature 
437:889-93. 
Terzian C, Pelisson A, Bucheton A (2001): Evolution and phylogeny of insect 
endogenous retroviruses. BMC Evol Biol 1:3. 
Thompson WW, Shay DK, Weintraub E, et al. (2003): Mortality associated with 
influenza and respiratory syncytial virus in the United States. JAMA 289: 179-
86.  
Thompson WW, Shay DK, Weintraub E, et al. (2004): Influenza-associated 
hospitalizations in the United States. JAMA 292: 1333-40.  
Tinsley TW and Harrap KA (1978): Viruses of Invertebrates. In”Comprehensive 
Virology 12”, p. 1-101, Fraenkel-Conrat H., Wagner R.R. (ed), Plenum,NY. 
Treanor JJ, Betts RF, Smith GE, Anderson EL, Hackett CS, Wilkinson BE, Belshe 
RB, Powers DC. (1996): Evaluation of a recombinant hemagglutinin 
expressed in insect cells as an influenza vaccine in young and elderly adults. 
J. Infect. Dis. 173: 1467–70.  
Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff 
M, Rabinovich G, Blackwelder W, Katz JMJ  (2001): Safety and 
immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in 
humans vaccine. Vaccine 19: 1732-37.  
Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, 
Cox MM (2006): Dose-related safety and immunogenicity of a trivalent 
baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly 
adults. J Infect Dis 193:1223-8. 
Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, Innis BL 
(2005): Rapid licensure of a new, inactivated influenza vaccine in the United 
States. Human Vaccines 1: 239-244 
Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M: Safety and 
immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine 
(2006). N Engl J Med 354: 1343-51. 
Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L (2006): 
Intranasal administration of a proteosome-influenza vaccine is well-tolerated 
and induces serum and nasal secretion influenza antibodies in healthy human 
subjects. Vaccine 24: 254-62. 
Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, 
Liang H, Gilbert A, Cox M. (2007): Safety and immunogenicity of a 
baculovirus-expressed hemagglutinin influenza vaccine: a randomized 
controlled trial. JAMA 297: 1577-82. 
Tumpey, TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE and Basler 
CF (2004): Pathogenicity and immunogenicity of influenza viruses with genes 
from the 1918 pandemic virus. Proc Natl Acad Sci 101: 3166-71.  
Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, 
Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, 
Thawatsupha P, Chittaganpitch M, Khontong R, Simmerman JM, 
Chunsutthiwat S (2005): Probable person-to-person transmission of avian 
influenza A (H5N1). N. Engl. J Med 352: 333-40. 
Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD (1982): Synthesis and 
assembly of hepatitis B virus surface antigen particles in yeast. Nature 298: 
347-50. 
119
  References 
  
van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, 
Tang DC (2005): Safety and immunogenicity of adenovirus-vectored nasal 
and epicutaneous influenza vaccines in humans. Vaccine 23: 1029-36. 
van Lier FLJ, van den Hombergh, JPTW, de Gooijer CD, den Boer MM, Vlak JM and 
Tramper J (1996): Long-term semi-continuous production of recombinant 
baculovirus protein in a repeated (fed-)batch two-stage reactor system. Enzyme 
Microb Technol 18: 460-66. 
van Oers MM (2006): Vaccines for viral and parasitic diseases produced with 
baculovirus vectors. Adv Virus Res 68: 193- 253.  
van Oers MM and Vlak, JM (2008): Baculovirus Insect Cell Expression System. In: 
“Encyclopedia of Life Sciences”, John Wiley & Sons Ltd, Chichester. Online 
Publication 
(http://www.els.net/[doi: 10.1002/9780470015902.a0002660.pub2]. 
Vaughn JL, Goodwin RH, Tompkins GJ, McCawley P (1977): The establishment of 
two cell lines from the insect Spodoptera frugiperda (Lepidoptera; Noctuidae). 
In Vitro 13: 213-7.  
Vierk KA, Koehler KM, Fein SB, Street DA (2007): Prevalence of self-reported food 
allergy in American adults and use of food labels. J Allergy Clin Immunol 
119: 1504-10. 
Wang K, Spector A (1994): The chaperone activity of bovine alpha crystallin. 
Interaction with other lens crystallins in native and denatured states. J Biol 
Chem 269: 13601-8. 
Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM (2006): 
Expression and purification of an influenza hemagglutinin--one step closer to 
a recombinant protein-based influenza vaccine. Vaccine 24: 2176-85. 
Wang M, Katz JM, Webster RG (1989): Extensive heterogeneity in the 
hemagglutinin of egg-grown influenza viruses from different patients. 
Virology 171: 275-9.  
Wang Z, Tobler S, Roayaei J, Eick A (2009): Live attenuated or inactivated influenza 
vaccines and medical encounters for respiratory illnesses among US military 
personnel. JAMA 301: 945-51. 
Web link 1-1: http://www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm updated 
with WHO information, July 2009 
Web link 1-2: http://www.cdc.gov/flu/weekly/fluactivity.htm 
Web link 1-3: 
http://www.fda.gov/ohrms/dockets/ac/cber09.html#VaccinesandRelated 
Biological 
Web link 3-1: http://www.cbs.dtu.dk/services/NetNGlyc/ 
Web link 5-1: http://www.flu.lanl.gov/vaccine 
Web link 5-2: http://www.ncbi.nlm.nih.gov 
Web link 6-1: http://blocks.fhcrc.org/blocks/process_blocks.html 
Web link 6-2: http://blocks.fhcrc.org/codehop.html 
Web link 7-1: http://www.hhs.gov/news/press/2005pres/20050401.html 
Web link 7-2: http://www.torontosun.com/news/canada/2009/02/27/ 8560781.html 
Web link 7-3: http://en.wikipedia.org/wiki/Mexican_flu 
Web link 7-4: http://www.economist.com/displaystory.cfm?story_id=13576483 
Web link 7-5: http://www.uq.edu.au/news/index.html?article=18698 
Web link 7-6: http://www.who.int/csr/disease/swineflu/notes/h1n1antiviral_ 
resistance20090708/en/index.html 
Web link 7-7: http://www.hhs.gov/news/press/2009pres/06/20090623c.html 
120
  References 
  
Webster RG (2005): Research Issues in Animal Surveillance and Pandemic Planning. 
In: Meeting Proceedings of the John R. La Montagne Memorial Symposium 
on Pandemic Influenza Research. Inst. of Medicine: 128-31.  
WHO report (2005): Influenza vaccines: Prospects for production from viruses grown 
in cell culture, Geneva, Switzerland 1995. 
WHO (2005): Recommended composition of influenza virus vaccines for use in the 
2005-2006 influenza season. Weekly Epidemiologic Record 80: 71-6. 
Williams MS (1993): Single-radial-immunodiffusion as an in vitro potency assay for 
human inactivated viral vaccines. Veterinary Microbiology 37: 253–62.  
Wuethrich B (2003): An avian flu jumps to people. Science 299: 1504.  
Wood JM (1998): Standardization of inactivated influenza vaccine. In: Nicholson KG, 
Webster RG, Hay AJ, eds. Textbook of Influenza. London: Blackwell Science. 
pp. 333-45. 
Wood JM, Major D, Newman RW, Dunleavy U, Nicolson C, Robertson JS, Schild 
GC (2002): Preparation of vaccines against H5N1 influenza. Vaccine 20: 
S84–S87. 
Wood JM and Robertson JS (2004): From lethal virus to life-saving vaccine: 
developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2: 
842-7.  
Wright PF, Webster RG (2001). Orthomyxoviridae: In Knipe DM, Howley PM, 
Griffin DE et al,. editors. Field Virology, 4th edn. Lippincott Williams & 
Wilkins: 1533-79. 
Yoden S, Kida H, Kuwabara M, Yanagawa R, Webster RG (1986): Spin-labeling of 
influenza virus hemagglutinin permits analysis of the conformational change 
at low pH and its inhibition by antibody. Virus Research 4: 251-64.  
Zambon MC (1999): Epidemiology and pathogenesis of influenza. J. Antimicrob. 
Chemotherapy 44 (Topic B): 3-9. 
Zambon MC (2001): The pathogenesis of influenza in humans. Rev. Med. Virol. 11: 
227- 241 
Zeddam JL, Rodriguez JL, Ravallec M., Lagnaoui A (1999): A noda-like virus 
isolated from the sweetpotato pest Spodoptera eridania (Cramer) (Lep.; 
noctuidae). J. Invertebr Pathol 74: 267-74.  
Zhang PF, Klutch M, Muller J, Marcus-Sekura CJ (1994): Susceptibility of the Sf9 
insect cell line to infection with adventitious viruses. Biologicals 22: 205-13. 
Zhou Z, Post P, Chubet R, Holtz K, Mc Pherson C, Petric M, Cox M (2006): A 
recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers 
of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. 
Vaccine 24: 3624-31.  
121
 122
  Abbreviations 
  
Abbreviations and definitions of terms 
 
Abbreviation Definition 
  
µg microgram 
ACIP Advisory Committee on Immunization Practices; (refer to 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5306a1.htm).
AcMNPV Autographa californica multiple nucleocapsid (multicapsid) 
nucleopolyhedrovirus 
AE Adverse event 
BCA Bicinchoninic acid 
BLA Biologics license application 
BEVS Baculovirus expression vector system 
BV Budded virus 
oC Degrees Celsius (Centigrade) 
oF Degrees Fahrenheit 
CBER  Center for Biologics Evaluation and Research 
CDC Centers for Disease Control and Prevention 
CDC-ILI Influenza-like illness as defined by the Centers for  Disease 
Control and Prevention: fever (temperature ≥100ºF oral) plus 
either cough or sore throat on the same day or on consecutive 
days 
cGMP  current Good Manufacturing Practices 
CI Confidence interval 
CODEHOP Consensus-degenerate hybrid oligonucleotide primers 
CV Column volume 
DHHS Department of Health and Human Services 
DO2 Dissolved oxygen 
EM Electron microscopy 
Endo H Endoglycosidase H 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
FluBlok® rHA trivalent recombinant hemagglutinin influenza vaccine 
GMT Geometric mean titer 
GSK GlaxoSmithKline 
HA Hemagglutinin  
HAI Hemagglutination inhibition 
hpi Hours post infection 
IgA Immunoglobulin A (most important mucosal [secretory] 
immunoglobulin) 
IgG Immunoglobulin G (most abundant serum [circulating] 
immunoglobulin) 
ICH International Conference on Harmonization  
IdU Pyrimidine analog 5-iododeoxyuridine  
kDa kilo Dalton 
LAIV Live attenuated influenza vaccine 
M Matrix protein (M1 en M2) 
MCB Master cell bank 
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MDCK Madin Darby canine kidney (cells) 
MDCO Molecular weight cut-off 
mL Milliliter 
MOI Multiplicity of infection 
MW Molecular weight markers 
NA Neuraminidase 
NIAID National Institute of Allergy & Infectious Diseases 
NP Nucleoprotein 
NS Nonstructural proteins 
nt Nucleotides 
ODV Occlusion-derived virus 
ORF Open reading frame  
P Viral polymerase proteins (PB1, PB2 and PA) 
P1, P2, etc Passage 1, Passage 2, etc. 
PBS Phosphate buffered saline  
PCR Polymerase chain reaction 
PNGase F Peptide-N-glycosidase F 
Per.C6 Human retina cell line 
PERT Fluorescent- PCR based reverse transcription 
PSC  Protein Sciences Corporation 
PSFM Protein Sciences fortified medium 
OE-PCR Overlap-extension polymerase chain reaction 
RBC Red blood cells 
rHA Recombinant hemagglutinin  
RR Relative risk 
RNA Ribonucleic acid 
SAE Serious adverse event / Serious adverse experience 
RT-PCR Reverse-transcriptase polymerase chain reaction 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SF Spodoptera frugiperda 
SRID Single radial immunodiffusion assay 
TEM Transmission electron microscopy  
TIV Trivalent inactivated influenza vaccine 
TPCK L-(tosylamido-2-phenyl) ethyl chloromethyl ketone 
T. ni Trichoplusia ni 
TNCL Trichoplusia ni cell line 
VERO African green monkey kidney (cells) 
VRBPAC Vaccine and Related Biological Products Advisory Committee
vRNA Viral RNA 
WCB Working cell bank 
WHO World Health Organization 
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Influenza (or flu) is a highly contagious, acute viral respiratory disease that occurs 
seasonally in most parts of the world and is caused by influenza viruses. Epidemics 
are seen annually and cause significant morbidity and mortality worldwide. The 
symptoms of the flu are similar to those of the common cold but tend to be more 
severe. Fever, headache, fatigue, muscle weakness and pain, sore throat, dry cough, 
and a runny or stuffy nose are common and may develop rapidly. A number of 
complications, such as the onset of bronchitis and pneumonia, can occur in 
association with influenza and are especially common among the elderly, young 
children, and anyone with a suppressed immune system. Influenza affects all age 
groups and in the United States (U.S.) alone, 25 to 50 million people contract 
influenza each year, and an annual average of 36,000 deaths and 226,000 
hospitalizations has been associated with influenza epidemics. Over 90% of the deaths 
related to annual influenza epidemics occur in people over age 65. Epidemics on a 
global scale are called pandemics and may occur when a new influenza virus capable 
of causing severe disease transmits easily among humans. Since there is no or little 
residual immunity in the human population to such a newly emerging influenza virus, 
it may spread quickly world wide.  
 
Influenza vaccination is an effective way to reduce the complications and the 
mortality rate following influenza infections. For example, studies have shown that 
influenza vaccination can reduce hospitalization rates by about 50% and the risk of 
death in the elderly by about 75%. The available inactivated and live attenuated virus 
influenza vaccines, that stimulate humoral and (to a lesser extent) cellular immunity, 
are cost-effective. Influenza vaccines currently licensed in the U.S. are manufactured 
in embryonated chicken eggs. The manufacture is therefore limited to influenza virus 
strains that replicate well in eggs but requires a large supply of eggs is required each 
year. Influenza viruses that are highly pathogenic to birds would therefore create a 
manufacturing problem since it could jeopardize the egg supply required for vaccine 
production. In addition, the current vaccines can not be administered to people with a 
severe allergy to eggs. Thus, a high priority in vaccine research is the development of 
novel influenza vaccines that do not use embryonated eggs as the substrate for 
production.  
 
The research in this thesis was aimed at the design, validation and development of a 
production process for a recombinant hemagglutinin (rHA) influenza vaccine for the 
prevention of seasonal influenza. The viral surface protein HA has been recognized as 
a key antigen in the host response to influenza virus in both natural infection and 
vaccination since neutralizing antibodies directed against HA can mitigate or prevent 
infection. In the design, the baculovirus-insect cell system is used for the synthesis of 
rHA molecules. This expression system is generally considered as safe with unlikely 
growth potential for human pathogens. Extensive characterization of the novel cell 
substrate was performed, none of which revealed the presence of adventitious agents. 
In insect cells, full-length properly folded biologically active rHA was produced as 
concluded from its ability to efficiently agglutinate red blood cells, its resistance to 
trypsin, and the rosette-like structures revealed with electron microscopy. Hence the 
rHA produced in the baculovirus expression system could potentially be used in a 
seasonal influenza vaccine. 
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Influenza vaccines are adjusted annually and geographically based on surveillance 
data generated around the globe. This annual adjustment poses challenges for vaccine 
manufacturing as the time available to make adjustments is extremely short, a matter 
of months. Therefore, it is important that a versatile, robust manufacturing process is 
established that guarantees timely delivery of the new antigens. With the traditional 
egg-based approach a minimum of 3-6 months is needed to develop an influenza 
vaccine. As such, it is not feasible to surge capacity rapidly in case of a pandemic 
outbreak. The cloning of the HA from the influenza virus into a baculovirus vector 
and the expression of rHA in insect cell bioreactors, however, can readily be 
accomplished within the short time available. In addition, considerable progress was 
made towards establishing a scalable general purification processes for diverse rHA 
molecules within the available time frame. 
 
The developed process was used to manufacture a candidate recombinant trivalent 
HA vaccine, which was tested in a randomized, double-blind, placebo-controlled 
clinical trial during the 2004-2005 influenza season among 460 healthy adults to 
determine the dose-related safety, immunogenicity, and protective efficacy. The study 
demonstrated that the vaccine was safe, well-tolerated and immunogenic. The fact 
that none of the recipients of the high dose vaccine, containing 45 µg of each rHA 
antigen, developed cell culture confirmed influenza whereas in unvaccinated 
individuals 4.6% developed influenza suggests that absence of the influenza 
neuraminidase (NA) in the vaccine and differences in glycosylation in insect versus 
vertebrate cells does not interfere with vaccine performance. Based on the success of 
this study a dose selection was made for the “45 µg” vaccine, which has a 3-fold 
greater rHA content than the licensed inactivated influenza HA vaccine. 
Subsequently, three additional clinical studies were performed in a total of more than 
3000 human subjects to support licensure of FluBlok under the “Accelerated 
Approval” procedure in the United States (U.S.). These studies demonstrated that the 
highly purified rHA protein was well tolerated and resulted in a strong and long 
lasting immune response. In addition, the novel vaccine provided cross protection 
against drifted influenza viruses. 
 
A pandemic was officially declared on June 11, 2009 when the World Health 
Organization (WHO) raised its influenza alert to the highest level – phase 6 – for the 
first time in over 40 years. The first initiative for a vaccine against the new H1N1 
A/California /04/2009 strain, based on the design outlined in this thesis, was taken on 
April 29, 2009 and by mid June, merely 6 weeks later, the first batches of vaccine 
were produced, ready for clinical testing in human subjects. The commercial 
production of this novel vaccine could start as early as 45 days after receipt of the 
influenza virus. In principle, many millions of doses of vaccine can be produced 
within months if only a portion of the global bioreactor capacity were to be allocated 
to baculovirus-based rHA vaccine production. 
 
The baculovirus-insect cell system tackles the need for new influenza vaccine 
production technology as it can be used for the expedited production of a safe and 
efficacious vaccine. Using this technology, influenza vaccines can be made available 
worldwide within a very short time, which is an absolute requirement in combating 
newly emerging influenza strains and in particular in the case of pandemics. As a 
result, it should be feasible to provide a worldwide solution to pandemic preparedness 
within the next five years using this technology.  
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De griep is een zeer besmettelijke, acute virale ziekte, die jaarlijks heerst in grote 
delen van de wereld en veroorzaakt wordt door griepvirussen. Influenza-epidemieën 
zijn een jaarlijks voorkomend verschijnsel en leiden wereldwijd tot veel ernstig zieke 
patiënten en  dodelijke slachtoffers. De symptomen van de griep zijn vergelijkbaar 
met die van een normale verkoudheid, echter meestal ernstiger van aard. Koorts, 
hoofdpijn, vermoeidheid, spierpijn en spierzwakte, keelpijn, droge hoest en een 
lopende of verstopte neus zijn normale griepverschijnselen, die zich snel kunnen 
ontwikkelen. Complicaties, zoals de ontwikkeling van bronchitis of longontsteking, 
komen vooral voor bij ouderen, jonge kinderen en andere mensen met een zwak 
immuunsysteem. De griep komt voor in alle leeftijdsgroepen en alleen al in de 
Verenigde Staten (VS) worden jaarlijks 25-50 miljoen mensen door de griep 
getroffen, met een jaarlijks gemiddelde van 36.000 doden en 226.000 
ziekenhuisopnames. Meer dan 90% van de mensen die jaarlijks ten gevolge van een 
griepgerelateerde aandoening overlijden, is ouder dan 65 jaar. Een wereldwijde 
epidemie wordt een pandemie genoemd en kan ontstaan wanneer een nieuw 
griepvirus, dat in staat is ernstige ziekteverschijnselen te veroorzaken, gemakkelijk 
van persoon tot persoon overdraagbaar is. Omdat het immuunsysteem in dit geval 
grotendeels onbekend is met het nieuwe type influenzavirus, kan het virus zich snel 
over de hele wereld verspreiden.  
 
Vaccinatie is een effectieve methode om de kans op complicaties te verkleinen en het 
dodental ten gevolge van griepinfecties te reduceren. Studies hebben bijvoorbeeld 
aangetoond dat antigriepvaccinatie het aantal ziekenhuisverblijven tot 50% kan 
terugbrengen en het overlijdensrisico met ongeveer 75% kan beperken. De 
beschikbare geïnactiveerde influenzavaccins en het verzwakte, levende vaccin zijn 
kosteneffectief en stimuleren antilichaamproductie en (in mindere mate) cellulaire 
immuniteit. Alle influenzavaccins, die op dit moment in de VS beschikbaar zijn, 
worden geproduceerd in bevruchte kippeneieren. Dit betekent dat de productie 
beperkt is tot griepvirussen die zich goed kunnen vermeerderen in kippenembryo’s en 
dat er jaarlijks veel eieren nodig zijn voor vaccinproductie. Griepvirussen die (ook) 
ziekteverwekkend zijn voor vogels zorgen dus voor een probleem, daar zij de 
voorraad eieren die nodig is voor vaccinproductie in gevaar kunnen brengen. 
Bovendien moeten de virussen eerst nog verzwakt worden alvorens ze in 
kippenembryo’s kunnen worden vermeerderd. Daarbij komt ook nog dat de huidige 
vaccins niet toegediend kunnen worden aan mensen, die allergisch zijn voor eieren. 
Dus de ontwikkeling van nieuwe griepvaccins, waarbij de productiemethode 
onafhankelijk is van eieren, heeft een hoge prioriteit.  
 
Het beschreven promotieonderzoek was gericht op de ontwikkeling van een 
recombinant hemagglutinine (rHA) influenzavaccin ter preventie van de jaarlijkse 
griep. Het virale oppervlakte-eiwit HA is het sleutelantigeen voor het opwekken van 
antilichamen in de gastheer, zowel tijdens een natuurlijke infectie als na vaccinatie. 
De neutraliserende antilichamen, gericht tegen HA, kunnen infectie voorkomen. In 
het gepresenteerde procesontwerp worden de rHA-eiwitten gemaakt in het 
baculovirus-insectencelsysteem. Dit expressiesysteem wordt algemeen als veilig 
beschouwd, daar de groeimogelijkheden van ziekteverwekkers bij de mens zeer 
beperkt zijn. Omdat in het ontwerp een nieuwe cellijn gebruikt is, werd een 
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uitgebreide karakterisering van de cellijn uitgevoerd, waarbij geen pathogenen 
aangetoond konden worden. In de insectencellen wordt een volledig, goed gevouwen 
en biologisch actief HA-eiwit geproduceerd, wat geconcludeerd kan worden uit de 
eigenschappen van het rHA, dat rode bloedcellen laat samenklonteren,  bestand is 
tegen trypsinebehandeling en dat roset-achtige structuren vormt, die met een 
elektronenmicroscoop waargenomen kunnen worden. Daarnaast wordt het rHA in 
grote hoeveelheden gemaakt in insectencellen. Dus het rHA, geproduceerd in het 
baculovirus-expressiesysteem, is een goede kandidaat voor een jaarlijks griepvaccin.  
 
Het griepvaccin moet jaarlijks worden aangepast op basis van gegevens, die in een 
wereldwijd surveillancesysteem (WHO) gegenereerd worden. Deze jaarlijkse 
aanpassing vormt een uitdaging voor vaccinproducenten, die slechts enkele maanden 
de tijd hebben om deze aanpassing in hun productieproces door te voeren. Het is 
daarom belangrijk dat een robuust en breed toepasbaar productieproces beschikbaar 
is, dat tijdig nieuwe antigenen kan leveren. Met de bestaande productiemethode in 
eieren zijn 3 tot 6 maanden vereist om een influenzavaccin te ontwikkelen. Als gevolg 
daarvan is het niet mogelijk om de productiecapaciteit snel uit te breiden in het geval 
van een pandemische uitbraak. De klonering van HA in een baculovirusvector en de 
productie van rHA in bioreactoren kunnen zonder problemen op grote schaal en op 
diverse (internationale) locaties uitgevoerd worden binnen dit korte tijdsbestek. 
Voorts is bij deze studie een aanzienlijke vooruitgang geboekt in het ontwikkelen van 
een opschaalbaar zuiveringsproces, dat algemeen toepasbaar is voor diverse 
influenza-HA-eiwitten en dat binnen de beschikbare tijd kan worden gerealiseerd.  
 
Het ontwikkelde proces werd vervolgens gebruikt voor de productie van een 
recombinant vaccin met rHA-eiwitten van drie verschillende griepstammen. Dit 
vaccin werd getest in een klinische studie gedurende het griepseizoen 2004-2005, 
waarbij zowel de 460 gezonde deelnemers als de onderzoekers, zolang de studie liep, 
niet wisten wie vaccin en wie fysiologisch zout toegediend had gekregen. Deze studie 
toonde aan dat het vaccin veilig en immunogeen was en goed getolereerd werd. Het 
feit dat geen enkele deelnemer, die de hoge antigendosering van 45 microgram van 
elk rHA-eiwit toegediend kreeg, aantoonbare griep ontwikkelde, suggereert dat de 
afwezigheid van neuraminidase in het vaccin en verschillen in eiwitglycosylering 
tussen insectencellen en cellen van gewervelde dieren de werking van het vaccin niet 
negatief beïnvloeden. In de controlegroep kreeg 4,6% van de proefpersonen griep. Op 
basis van het succes van deze studie werd de dosering vastgesteld op 45 microgram 
van elk rHA; driemaal meer dan de dosering van de op dit moment  beschikbare 
geïnactiveerde vaccins. Vervolgens werden drie additionele studies met in totaal meer 
dan 3000 deelnemers uitgevoerd ten behoeve van productregistratie. Hierbij werd 
gebruik gemaakt van het “versnelde goedkeuring”-protocol in de VS. Deze studies 
hebben aangetoond dat een gezuiverd rHA-eiwit goed getolereerd wordt en dat een 
hoge en langdurige antilichaamproductie geïnduceerd wordt. Tevens bleek dat het 
nieuwe vaccin bescherming kan bieden tegen griepvirussen, die genetische 
veranderingen hebben ondergaan. 
 
Op 11 juni 2009 verklaarde de Wereldgezondheidsorganisatie dat er een 
grieppandemie heerste en zij verhoogde voor het eerst in 40 jaar het alarmniveau naar 
fase 6.. Het eerste initiatief om een vaccin tegen dit nieuwe H1N1 A/California 
/04/2009-influenzavirus te ontwikkelen, gebaseerd op het ontwerp beschreven in dit 
proefschrift,  werd genomen op 29 april 2009. Half juni, slechts zes weken later, werd 
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het eerste vaccin geproduceerd en getest in klinische studies. Dus commerciële 
productie van dit nieuwe vaccin was mogelijk binnen 45 dagen na ontvangst van het 
nieuwe influenzavirus. In principe zouden er binnen enkele maanden vele miljoenen 
doseringen entstof geproduceerd kunnen worden, als slechts een deel van de 
wereldwijde bioreactorcapaciteit gebruikt zou worden voor de productie van 
baculovirus-rHA-vaccin.  
 
Het hier beschreven proces, dat gebruik maakt van het baculovirus-
insectencelsysteem vervult de behoefte aan nieuwe technologie om influenzavaccins 
te produceren en kan ingezet worden voor de versnelde productie van een veilig en 
effectief griepvaccin. Met de ontwikkelde technologie is het ook mogelijk om in zeer 
korte tijd een griepvaccin wereldwijd beschikbaar te hebben, hetgeen absoluut 
noodzakelijk is om bescherming te bieden tegen nieuwe influenzastammen en in het 
bijzonder bij pandemieën. Het zou dan ook mogelijk moeten zijn om uitgaande van 
het hier ontwikkelde proces binnen vijf jaar tot een wereldwijde aanpak te komen ter 
voorbereiding en bestrijding van influenzapandemieën.  
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